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ABSTRACT 
Although conventional systems of staging for patients with lung 
cancer rely almost exclusively on anatomic evidence, a symptomatic staging 
system proposed by Feinsteln was able to demonstrate distinctive prognostic 
gradients independent of anatomic stages. Because the s3rmptomatic staging 
system, however, was developed for patients with lung cancer treated 
during 1953-64, the current impact of the system was uncertain. The 
current study was planned to evaluate the prognostic role of clinical and 
morphologic staging features in "modern" circumstances. The analysis 
contains results for 131 lung cancer patients treated during 1977 in 
the era of improved anatomic imaging with radionuclide scans and 
computerized tomography. 
The results contain evidence to support the three main conclusions: 
1. Despite modern improvements in morphologic information, the 
symptomatic stages continue to produce distinctive prognostic gradients 
within each morphologic stage. 
2. Though differences in descriptive attributes exist between the 
patient populations of 1953-64 and 1977, the modern patients are found 
and treated in stages that are symptomatically and morphologically less 
severe and with shorter durations of symptoms than patients in the older 
era, suggesting a zero-time shift. 
3. The new diagnostic techniques afforded "modern" patients 
provide an improved accuracy of morphologic staging, which can lead to 
apparent improvements in the prognosis of Individual stages without 
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INTRODUCTION 
The purpose of this study was to evaluate the prognostic 
efficacy of a new staging system for patients with lung cancer. 
The new system, which had originally been developed and tested 
in a cohort of patients observed during 1953-6A, adds a series of 
clinical variables to the customary morphologic information used 
in cancer staging. Because of modern Improvements in imaging and 
methods for acquiring other morphologic data, the aim of this study 
was to determine whether survival rates for lung cancer have 
changed in patients with similar stages, and, if so, to appraise 
the contribution of new staging procedures to those changes. 
The study of prognostic staging for lung cancer is important 
because lung cancer is the leading cause of cancer-related deaths 
1 2 
in men , and appears to be reaching a similar stature among women . 
It has been estimated that lung cancer will develop in 135,000 
Americans during 1983, and that 117,000 will die from the disease 
during the year^. To use scientific methods to investigate the 
problems of treating lung cancer, a systematic approach is needed, 
beginning with a standardized assessment of the disease. 
Scientific assessments must fulfill at least three basic 
principles^: 
1. The materials prepared for the investigation and the 
methods of preparation must be clearly specified, 
2. The instruments for evaluating critical variables must be 
standardized for consistency and accuracy. 
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3. The experimental material must be divided in a manner 
producing similar groups for comparison. 
All three principles are essential to making results 
reproducible. The third principle, in particular, enables a 
valid assessment of the investigated therapy. If the division 
produced groups that varied in their susceptibility to the target 
event, then differences in outcome between the groups may be 
spuriously attributed to the treatment rather than this baseline 
inequality. 
Baseline inequality, sometimes called susceptibility bias, 
can be introduced to human investigation at any of the many places 
where people are transferred from the general population to the 
4 
therapeutic groups under comparison . Prognostic analysis allows 
accomodation of baseline differences in outcome susceptibility, 
provided that the analysis contains a taxonomy for cogent prognostic 
features^. One method of prognostic analysis is to compare 
identical strata which are created within each total group by 
differences in prognostic expectations. Division of the cohort by 
random allocation alone cannot always assure equal proportions of 
these strata^. Providing prognostlcally homogeneous strata for 
comparison, in order to fulfill the principle of division into 
similar groups, requires diligent attention to differences in 
susceptibility. 
The benefits of attention to differences in susceptibility 
through prognostic analysis include enabling valid assessment of 
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therapeutic interventions and facilitating the dissemination of 
scientific discoveries by helping to standardize experimental design^. 
This attention to differences in susceptibility also provides direct 
benefit to individual patients by more accurate quantification of 
prognosis and appropriate selection of therapy. 
The success of prognostic analysis, which usually appears as 
staging systems in studies of cancer, depends on the extent to which 
A 
all cogent prognostic variables are accounted for . The controversy 
about staging systems for human cancer arises in identifying 
appropriate prognostic features and in classifying their relative 
importance. 
The most common staging method for lung cancer in the United 
g 
States is an adaptation of the TNM system formulated by the American 
9 
Joint Committee for Cancer Staging and End-Results Reporting . In 
this system, the anatomic extent of the disease is categorized through 
morphologic descriptions of the primary tumor (T), regional lymph 
nodes (N), and distant metastases (M). The taxonomy provides criteria 
for categorizing the cancer, and attempts to standardize consistency 
and accuracy in observing stipulated variables. The composite stages 
of 1, II, and III are formed from the T, N, and M categories and have 
demonstrated a capacity to produce distinctive prognostic gradients, 
thus improving the homogeneity of prognostic classification^^’. 
When applied before or after therapy, the TNM staging system enhances 
the valid assessment of therapeutic interventions by comparing 
treatments in strata with relatively similar prognoses. 
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Despite these advantages, the TNM system and similar 
morphologic staging systems do not account for all cogent prognostic 
12 
variables . In particular, the TNM system does not deal with the 
biologic character of the tumor, the host, or the tumor-host 
interaction. Strict morphologic descriptions do not adequately 
account for the morbidity of tumor effects, the host susceptibility, 
and the biologic potential or aggressiveness of the cancer. A 
description of symptoms and other non-morphologic phenomena can 
13 16 
provide valuable Indices for each of these features 
The primary, systemic, and metastatic features of symptoms are 
used to provide an indication of the functional effects of the tumor. 
Variations in the host susceptibility to the functional effects of 
tumors, or to an outcome event such as mortality, give rise to 
distinctly different prognostic expectations despite similar 
morphologic extent of disease. Demographic features may provide 
indirect markers for some of these variations in susceptibility. 
Exceptionally severe tumor effects, such as when cerebral metastases 
result in coma as opposed to a mild hemiparesis, would also be 
suspected to portend a worse prognosis. Severe co-morbidity may have 
prognostic significance when capable of affecting the host 
susceptibility, or capable of affecting the outcome event on its own. 
Such co-morbidity may be evident when it is deemed life-threatening, 
or prevents optimal diagnostic and therapeutic maneuvers. This 
category may include intractable cardiovascular disease and end-stage 
disease of other major organs. 
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Variations in host susceptibility result from variations in 
competence of host defense mechanisms. As expressed by MacDonald^^ 
in his concept of 'biologic predeterminism', these host defense 
mechanisms interact with the inherent growth potential of the tumor 
to define the clinical course. Morphologic definitions of 'early' and 
'late' stages of cancer fail to address the rate of tumor growth which 
represents this interaction between inherent growth potential and host 
defense. Symptom chronometry (i.e. the duration of s3miptoms before 
treatment), may be unable to provide information concerning change in 
tumor size, but can potentially provide a temporal dimension defined 
18 
by the symptomatic course . Symptomatic staging may be less valuable 
in this regard than in providing a taxonomy for quantifying functional 
effects of tumors and prognostic co-morbidity. [The term "symptomatic 
staging" is used to refer to a system of prognostic stratification 
which utilizes clinical data, consisting of S3nnptoms and signs of 
disease recognized by the patient and the physician in routine bedside 
examination. The term "clinical staging" will be avoided because of its 
ambiguous application to morphologic staging systems.] 
Another shortcoming of a purely morphologic staging system is 
that the data needed for morphologic descriptions are not always 
available. One type of problem is the variation in the amount of 
evidence that can be reasonably collected in individual patients to 
define the anatomic extent of the cancer. One patient may have tumor 
grossly visualized on a pre-therapeutic diagnostic thoracotomy, while 
another may have only positive sputum cytology and an ill-defined 
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abnormality on chest film. Advances in technology have also created 
problems in data availability as new techniques have been developed to 
increase the accuracy, thoroughness, and convenience with which a 
tumor's anatomic extent can be defined. For different eras in time, 
different amounts and types of morphologic evidence will be available 
to describe anatomic extent. The problem of variation in data 
availability is particularly relevant for diseases such as cancer, 
where large studies may require collections of patients spanning many 
years or technologic eras. The variations in the available morphologic 
data can be a source of bias when comparisons are based on "historical 
controls". This problem of variation in technologic data does not occur 
with symptomatic staging, since s3nnptoms can always be identified. 
The disregard for analyzing symptoms in medical research often 
19 
arises from perceived deficiencies of so-called "soft data" 
Information is usually believed to be "hard" when it can be quantified 
on a dimensional scale, when its source can be preserved for 
retrospective analysis, and when it is standardized for objectivity and 
reproducibility. Although the "soft" decisions of clinical judgment may 
be considered an art, incapable of taxonomic improvements that might 
3 
provide quantification and standardization, Feinstein has argued that 
this belief need not be maintained: "If the clinical judgment used in 
therapeutic experimentation is so scientifically defective today, it is 
not because the clinician's human capacities impede science, but because 
he has failed to use his human capacities in a scientific manner." 
Since the study of clinical medicine is a study of human 
phenomena, the soft clinical data that are often the expression of these 
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phenomena play an irreplaceable role in understanding disease and its 
human responses. An important scientific challenge, therefore, is to 
find methods of hardening clinical data to improve dimensional 
quantification, preservation of data, and standardization, while 
utilizing the uniquely human qualities of soft data. 
Human symptoms and signs, discerned during the bedside examination 
of patients, have already demonstrated a value in lung cancer assessment. 
20 
Bignall showed that prognosis in lung cancer patients varied with the 
duration of symptoms before diagnosis. He remarked that the morphologic 
definitions of "early" and "late" were misleading and that the stage of 
disease could be referenced by the disorder of function manifest in 
symptoms. Most of the work in S3nnptomatic staging of lung cancer has 
. 13-16,21 
been done by Feinstein , with the value of the results confirmed 
22-25 
by others . S3miptomatic staging has also been able to produce 
.... . ,. ^ T j, , 26,27 
distinctive prognostic gradients for neoplasms of the prostate , 
28 29 30 31 
rectum , larynx , acute leukemia , and Hodgkin's disease 
Feinstein's symptomatic staging systems for lung cancer were 
developed, however, for a population of patients whose lung cancers 
were treated during 1953-1964. Since many new technologic procedures 
for both diagnosis and therapy have been developed since that time, the 
role of symptomatic staging needs re-examination. Does the staging 
of symptoms still have value in the era of computerized tomography and 
the various radionuclide imaging techniques? The purpose of the 
research reported here was to answer this question. The study was 
intended to investigate the consistency of symptoms as "scientific 

- 8 - 
instruments", and to check their prognostic value in the assessment 
of contemporary patients with cancer of the lung. 
MATERIALS AND METHODS 
Selection of Patient Population 
The inception cohort under study consists of all patients with 
a diagnosis of cancer of the lung and bronchus whose first anti¬ 
neoplastic therapy, or first therapeutic decision if no therapy was 
received, occurred at the Yale-New Haven Hospital (Y-NHH) or the West 
Haven Veterans Administration Hospital (WHVAH) during the calendar year 
of 1977. This year was chosen to allow five-year survival data to be 
available when the research was conducted in 1982. Eligible patients 
were identified through the diagnostic indices of medical records 
maintained at both institutions. The material of the tumor registry at 
the Y-NHH was also examined to check for patients treated as inpatients 
or outpatients at the Y-NHH during 1977. 
Each appropriate medical record was solicited and evaluated for 
fulfillment of the following eligibility criteria: (A) the zero-time 
event (as defined below) must have occurred at either of the two index 
hospitals between January 1, 1977 and December 31, 1977; (B) the disease 
must have had histologic or cytologic confirmation somewhere in the 
clinical course, up to, and including, post-mortem; (C) the cancer must 
have been suspected during life. 
After duplicate records were eliminated, the search yielded 340 
candidate cases. Of these, 2 were eliminated because their medical 
record could not be located. The remaining records were reviewed in 
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detail and 11 were eliminated because they carried an inappropriate 
diagnosis. Of the remaining 327 patients, 192 were eliminated for 
violation of at least one of the eligibility criteria: 137 cases had 
a zero time outside the designated secular period; 35 cases were first 
treated (for the lung cancer) at a hospital other than the Y-NHH or 
VJHVAH; 17 cases lacked microscopic evidence of cancer; and in 3 cases 
lung cancer was unsuspected and first discovered at necropsy. Of the 
remaining 135 cases, 3 were excluded because of a tissue diagnosis of 
carcinoid of the bronchus, leaving 132 cases available as the inception 
cohort for admission to this study. 
Selection of Zero Time 
In any study of this type, a datemark must be chosen as a temporal 
reference point for comparisons of clinical course. This reference point, 
also called zero time, was chosen as the date of the first anti-neoplastic 
therapy. The advantages of this date are that it is a clinically and 
temporally well-defined entity, even when checked in retrospect. It 
represents the onset of attempts to alter the clinical course, and 
provides a time at which all patients will be mutually comparable in 
their clinical course. It is also a time when the medical record tends 
to be most complete for clinical and paraclinical data. Details of 
32 
zero time selection for patients with lung cancer are shown in 
Appendix A of the coding criteria for card 2, found in Appendix IV of 
this report. 
Extraction of Data 
The primary source of information for this survey was each 
patient's medical record. When necessary, supplementary data were sought 
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from the tumor registry files, radiation therapy files, and surgical 
pathology files. There were 14 cases for whom a complete medical 
record was not available, and for whom data were extracted solely 
from supplementary sources. This group consists of 7 cases extracted 
from tumor registry files, 4 cases from radiation therapy files, and 
3 cases from abridged medical records for whom the actual record was 
not retrievable from storage. 
The available data extracted to characterize each patient's 
condition were demographic, clinical, paraclinical, co-morbid, and 
32 
therapeutic . Clinical data consist of symptoms and signs of disease 
recognized by the patient and the physician in routine bedside 
questioning and examination. Paraclinical data refer to evidence of 
disease obtained through methods other than routine clinical examination. 
Such data are derived from imaging procedures, microscopic specimens, 
and other laboratory techniques. Co-morbid data form a complex category 
of information which refers to any diseases, other than lung cancer, 
that occur during the clinical course and that might influence either the 
clinical course or its interpretation. 
The extraction process and the management of the occasionally 
imperfect data in medical records were performed according to methods 
32-34 
presented by Feinstein, et al. . To assure compliance with these 
methods, a researcher who was experienced in using them provided ongoing 
supervision by reviewing randomly selected extractions. An example of 
the extraction form used in the current study is shown in Appendix I. 
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Data Coding and Analysis 
The extracted data were categorized and coded according to 
35 36 
a taxonomy designed and described by Feinstein ’ . Symptoms were 
coded as primary, systemic, or metastatic. For lung cancer, primary 
symptoms refer to : the bronchial symptoms of cough, hemoptysis, and 
subjective wheezing; the parenchymal symptoms of infection and dyspnea; 
and the parietal symptom of thoracic pain. Systemic symptoms refer to 
remote tumor effects that do not necessarily indicate dissemination of 
tumor beyond the lung. Such s3miptoms include anorexia, weight loss as 
a chief complaint, weakness or fatigue, and such paraneoplastic 
syndromes as painful hypertrophic pulmonary osteoarthropathy. Metastatic 
symptoms include: mediastinal symptoms, such as dysphagia, hoarseness, 
and superior vena caval syndrome; and symptoms indicating extrathoracic 
tumor extension, such as bone pain, neurologic manifestations, cutaneous 
13-15 
masses, and s3miptoms of hepatic dysfunction . The criteria for 
coding these symptoms of lung cancer can be found in the coding criteria 
for card 2 under columns 12-22, in Appendix IV of this report. 
The coding criteria are detailed in order to minimize variability 
in coding S5anptoms. The parenchymal symptom of infection, for example, 
is described so as to indicate pulmonary parenchymal infections, not 
non-specific upper respiratory tract inflammation or extrapulmonary 
infection. Questions of attribution arise when a patient has a 
concurrent illness which produces a symptom similar to lung cancer, 
such as hemoptysis in a patient with active tuberculosis, or, an 
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infection In the contralateral lung in a patient with chronic lung 
disease. The coding criteria were designed to count primary and 
systemic symptoms as positive if there was at least questionable 
attribution to the lung cancer. The burden of proof in attribution 
of metastatic symptoms, however, was on the lung cancer. A metastatic 
symptom must be clearly attributable to the lung cancer to be coded as 
positive. For example, a patient with long-standing degenerative 
joint disease who complained of pain at a site of previous disease would 
not be coded in the metastatic clinical group. Symptoms with questionable 
attribution to lung cancer are discussed in depth in either column 22 
or the criteria for coding the specific symptom. 
The symptoms determined the classification of clinical group. 
The clinical groups were coded as: Asymptomatic; Long pulmonic (which 
included any of the primary symptoms with at least one having been present 
for 6 months or more, and no systemic or metastatic symptoms); Short 
pulmonic (primary symptoms as in long pulmonic except that all of the 
symptoms must have had a pre-zero time interval of less than 6 months); 
Systemic (must have one or more of the systemic symptoms already described 
and no metastatic sjmiptoms); and Metastatic (must have at least one 
metastatic symptom definitely attributable to the spread of the cancer). 
The criteria for coding these categories can be found in Appendix C of 
the coding criteria for card 2, located in Appendix IV of this report. 
The categories of anatomic extent of cancer were as in the TNM 
9 
classification of the American Joint Committee , as well as the anatomic 
groups: Ultrathoraclc (indicating involvement ouside the thorax or 
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involvement of an outer thoracic structure without contiguity to the 
chest wall); Contrathoracic (contralateral involvement within the 
thorax); Isothoracic ( non-contiguous ipsilateral involvement within 
the thorax to other parenchymal structures, mediastinal structures 
other than lymph nodes, or any peri-thoracic structure); Vicinal 
(lymph nodes of the hilum or mediastinum, or any ipsilateral peri- 
thoracic structure, when involvement is contiguous ); and Endopulmonic 
(none of the above). Details of coding for contiguity can be found in 
Appendix B of the coding criteria for card 2 and details of the 
anatomic groups can be found in Appendix F of the same. The coding 
criteria for card 2 can be found in Appendix IV of this report. 
These anatomic groups were devised from morphologic evidence 
provided by techniques such as diagnostic imaging, bronchoscopy, 
mediastinoscopy, biopsy, and physical examination. This information was 
coded in columns 26, 27, and 29-42 of card 2. For this study, 
"radiographic involvement" referred to all diagnostic imaging techniques. 
Those techniques included the conventional roentgenographic studies 
as well as relatively new procedures, such as radionuclide scans and 
computerized tomography. Special attention was given to liver-spleen 
scans, brain scans, bone scans, gallium scans, Acta scan of the head, 
and ultrasound of the abdomen. Coding criteria for these "new techniques" 
can be found in the coding criteria for card 3 in columns 10-23, in 
Appendix V of this report. 
New techniques in diagnostic imaging represent methods of 
defining tumor extent that were available in 1977 but not in 1953-1964. 
, ' ■ ■ ^ t ■ ■ '>'■■■ ^ f-tFiw-'i’JKAfcK ' ' «■■ 
t-- 
l^' ^ :PV ■■ ' -■vt'^.i. .•-'‘.^-'^T<Jo'^. 2.l';>i?-'j^' ' ^(4^£Tvifl3' 
'' . ■ ■■ ’"’' '■ • ■'/,, 
" 'R;.!,!.' '-. .r l:vr , x j'f .'uz U .■ a; ifaja x^^ )||f .■’'i m'<#3 
■ ■»} ?«.t: •<^^'‘/'tt'j / Yfty' " ■> , '‘<'•'3*'? - i ^i»ci-S0 
, ,v:7i.> i "utr i»1 u.M 'io : i>c--^ 
■ n,.., . .j,. w,. ;( ri>f*.4i)rt ;.T-ir, A.A a»«'.' 0..i^)4 ••-'ti. 
.. 
:J t.iV'.'^. I'.l ';v»o 'ro: .ffi'.r '.. •'i'il -iTJ 
" I ' 
wfv 1o I^f*.i '’■ bit', jj( #fc76^l‘^3 .-• ■•fi7 1'> tl Kl -r^j<tqA 
iJ 'to «*•■■ -ajq|03Kdo 
. t/. .»<>1‘1. ^^^|ll^| ^ X--I ' .r•^■/‘ i- t,'J na:u- - 'J V.'U 'rfit. ..li4 3iTf3 
■ .c,^- '.'JkiTO? ■«» -•■ .ilT 
' "'' *-■<' <v '" 
Ji«w f::.v jiMsno: ■ 'tT . or , .•<\Cf3*lMHl23etlfe>a 
,v''):Oa ' , J ' ■■'? vT />'*i4^'! vf!M . '1 , j£ '. I' j ni baf/o;^ 
. ,. j .p.i.'>^-Sfc ,I ' c' "4'' '• ‘' ’ I v 'i •'■ ■ ' 
««' ■* ". ••-'..iwj; ;-■ V.''- ,f:* 1 js - ••♦pi•»aorf'f 
■'-vr, .r'f .■ ■ rA il ‘Ibt ,-R.i «*-, ; > ;-livi 7 n I-i'T iw. iaa 
. . aR'07 st‘*: lAi’iit'.i'i .iOi->Ji*)*:.. t*'0al7Jv.l^^)t*v:u 
• » ...;, ~ 
• • If 
fi,i©pt ->*;.i' y;* ■ •5'«>A , o.a "vut.i (a.> ..ftoaAa 4Mi»# . 
'.1 ( >:(..'.jfljriT .•,v.t’ : n . /«- ^oi) «JKHI(el^-' '•<< f ''<>» huA 
'ir'V' 
•0. g.jijj.ilp-. c:r ' < >^ ^ ' r, ■, • ,'S-t:y:v ij tsiauc^l '.-js!: fiii.*> 
14 
Because new procedures to define morphologic extent of lung cancer 
have been developed since 1964, the data for the 1977 cohort were 
coded in a manner that would allow the "modern*' patients to be 
classified in two different ways. First, according to all of the 
information available in 1977; and secondly, according to only the 
information available from procedures that could have been used in 
1953-64. This classification process is described for columns 23-33 
of the coding criteria for card 3, in Appendix V of this report. 
The combined symptomatic-morphologic staging classification 
used in this study was derived from the above types of anatomic and 
37 
symptomatic evidence by Felnstein and Wells . In this classification 
system, the final composite stages A-E are created from a combination 
of functional severity stages and topon5mic stages. Functional severity 
is itself a combination of symptom severity and prognostic co-morbidity. 
The symptoms coded under functional severity were dyspnea, systemic 
symptoms, metastatic symptoms of questionable attribution, and tumor 
effects that were excessively severe (as defined for column 44 of the 
coding criteria for card 2, in Appendix IV of this report). Prognostic 
co-morbidity denotes a condition or associated ailment, other than the 
lung cancer, that is expected to have a more unfavorable effect on the 
outcome of the clinical course than is otherwise anticipated. This 
category includes intractable cardiovascular disease and end-stage 
disease of other major organs. 
toponymic stages were classified from a combination of 
morphologic and symptomatic evidence used to define the topographic 
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extent of the lung cancer. Toponymic stage is divided into 7 strata. 
In descending order of extensiveness the strata are: 
7 = Liver/Other: evidence of metastasis to deep, vital organs 
other than brain or bone, and beyond the thorax; 
6 = All other ultrathoracic sites; evidence of metastasis to CNS, 
bone, or surface nodules beyond the thorax; 
5 = Intrathoracic; implies massive spread within the thorax; 
4 = Isothoracic: non-contiguous spread within the thorax on the 
same side as the primary tumor; 
3 = Vicinal: spread limited to contiguous sites within the thorax; 
2 = Symptomatic or Central: includes primary symptoms other than 
dyspnea, or central location of the tumor; 
1 = Asymptomatic and Peripheral. 
The coding criteria for toponymic stages, as well as functional severity 
stages and composite stages, are located in the coding criteria for card 
3 under columns 34-36, in Appendix V of this report. 
The coding criteria for therapeutic decisions are presented under 
columns 47-48 of the coding criteria for card 2. Criteria for further 
description of surgery, if performed, and of the subsequent clinical 
course are also present in the coding criteria for card 2. As evidenced 
by the coding cards and coding criteria presented in the Appendix, a 
large amount of information was extracted and coded but not used in the 
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Except for the coding criteria concerning new diagnostic 
techniques, which were designed for this study, the coding criteria 
used for both cards 2 and 3 (Appendix IV and V respectively) were 
compiled by Dr. Feinstein and his clinimetric research group for a 
cohort of patients from 1953-64. The criteria were meticulously 
maintained; and again, an experienced researcher checked a random 
sample of the coded extractions to assure consistency. She also 
helped in decisions about difficult cases. After all of the extractions 
were coded and the coding problems addressed, each of the extractions 
was re-checked, blinded to the outcome event, to assure consistency in 
coding. Examples of the coding cards can be located in Appendix II 
(card 2) and Appendix III (card 3). 
Once coded, the data were keypunched onto Hollerith cards and 
the punched cards were doubly verified. Data analysis was then performed 
using an IBM 4341 computer with SAS program package. Because the 
gradients produced by the numbers were clearly evident, tests of 
statistical significance have been omitted. [I am grateful to Carolyn K. 
Wells for assistance in checking the extractions and the coding, as well 
as for performing the computer procedures.] 
Outcome Variable 
The data collected by the described methods were analyzed for 
prognosis according to survival rate. Six-month survival was chosen for 
most of this analysis because the median survival of the cohort was close 
to 6 months, and because follow-up Information was usually readily 
available at that point. The analysis was performed on 131 of the 132 cases 
admitted to the survey because no follow-up information was available for 
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one case after his zero-time admission. Nine other cases lacked 
follow-up data to either death or 5-year survival. They were accounted 
for in survival rates, for times beyond the available follow-up data, 
by being deleted from both the numerator and the denominator of the 
calculated survival rates. 
Previous Cohort for Comparison 
The results of the 1977 cohort were compared with those found 
in an analogous cohort of patients, studied with similar methods, whose 
zero times occurred at Yale-New Haven and West Haven VA Hospitals during 
21 37 
the years 1953-64, and whose results have been described previously ’ 
The data for that "old" cohort, which were computer coded in a manner 
similar to the techniques employed here, were made available for the 
contrasts under discussion. 
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RESULTS 
Descriptive Data 
The basic descriptive data for the 1977 and 1953-1964 cohorts 
are provided in the first 5 tables. These data describe the similarities 
and the differences in the composition of the two cohorts. The 
differences raise intriguing questions about the epidemiology of lung 
cancer in modern patients. Differences in prognosis for the new 
cohort may result simply from the changing composition of the lung 
cancer patient population. If the cause of prognostic change were to 
be concluded from a comparison of two cohorts then the prognostic 
analysis must correct for the differences in baseline composition 
of the two cohorts. The data from the 1953-1964 cohort are presented 
in this report to illustrate the different zero-time characteristics 
of a modern population of lung cancer patients and to evaluate the role 
of symptomatic staging for a new, albeit different population. Since 
this report will not make conclusions of cause and effect derived from 
a comparison of the two cohorts, an analysis which corrects for 
differences in composition according to descriptive attributes will not 
be reported here. 
The demographic data for the two cohorts are shown in Table 1. 
The gender composition of the modern cohort continues to be male 
dominated, but the proportion of females has increased substantially 
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since 1953-64. Though there is some redistribution in age category 
composition, the median age is similar for both patient populations. 
The hospital at which zero time occurred is more heavily weighted by 
Y-NHH in the 1977 survey. The race distribution remains predominately 
white, although there is an Increased proportion of blacks in the new 
group. 
Descriptive histologic data are shown in Table 2. Fewer 
well-differentiated neoplasms occur in the modern cohort, but the 
change may reflect differences in histologic criteria for pathologists. 
The coding criteria for histologic classification presented in this 
report can be found in Appendix D of the coding criteria for card 2, 
located in Appendix IV of this report. 
Description of aspects of the diagnostic work-up which were 
unique to the 1977 cohort are presented in Table 3. Positive and 
equivocal results are defined in Appendix V under coding criteria for 
card 3. The category of ’’other" under new diagnostic techniques 
refers to computerized tomography used at sites other than the head 
and to ultrasonic imaging used outside the abdomen. 
Table 4 shows the overall survival data up to 5 years. This 
information is also displayed in Figure 1 as survival curves. There 
is a notable improvement in survival rates at the various times after 
zero time for the new cohort up until 5 years. The median survival of 
the new cohort has increased more than 2 months beyond that of the 
1953-64 patient population. 
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Descriptive data for therapy are shown in Table 5. This 
table describes the initial therapy regardless of whether subsequent 
therapy was provided. Of interest is that fewer patients received 
thoracotomy without excision of the primary tumor in 1977 than in 
1953-64. While fewer people went without therapy of any kind in 1977, 
the only notably increased therapeutic maneuver was radiation therapy 
to the primary tumor. The use of thoracotomy and of chemotherapy as 
first therapy changed little. Zero-time therapy is evaluated according 
to six-month survival to give a sample of interesting trends. Of note 
is that the improvements in survival for the modern cohort have come in 
the traditional modes of therapy — thoracotomy and radiation therapy — 
and not in the evolving realm of chemotherapeutics. There are many 
potential explanations for results in this table, but the complex 
analysis required to draw substantial conclusions demands a larger 
cohort. Further appraisal of these issues in therapy will await 
enlargement of the patient sample. 
The remaining tables introduce the principal topics of the 
present study. They can be considered under three headings: 
1. Prognostic Effect of Symptomatic Staging 
2. Zero-time Shift ("Lead-Time Bias") 
3. Impact of New Technology 
Prognostic Effect of Symptomatic Staging 
Tables 6-8 present the 6-month survival rates for both 
13 
cohorts according to symptomatic stages. The clinical groups in 
Table 6 represent the zero-time symptomatic state. The functional 
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severity stages in Table 7 represent a combination of symptom 
37 
severity and prognostic co-morbidity. The composite stages in 
Table 8 represent the final staging categories resulting from a 
combination of morphology, symptoms, and functional severity. Survival 
gradients are produced by each of these symptomatic staging methods in 
both the 1953-64 and 1977 cohorts. The gradients between some of the 
stages have sharper definition in the 1953-64 cohort than in 1977. 
Survival gradients for s3miptomatic stages can also be defined 
within the morphologic stages of the conventional TNM staging system. 
Table 9 demonstrates this striking gradient-within-gradient effect by 
presenting clinical group staging concomitantly with TNM staging. 
The clinical groups are presented as Indolent (a combination of 
asymptomatic and long pulmonic). Obtrusive (a combination of short 
pulmonic and systemic symptoms), and Deleterious (metastatic symptoms). 
The clinical groups were combined in this manner because the combinations 
were used in a previous report^^ and because they increase the numbers 
available for statistical appraisal of each cell. As shown in Table 9, 
the clinical groups produce a distinct prognostic gradient within each 
TNM stage. Conversely, within any clinical group the TNM stages 
produce a distinct prognostic gradient. Table 10 contrasts the composite 
stages A-E with the TNM stages. This table does not show a good double 
gradient. TNM does not impact on the composite stages, as might be 
expected since the composite stages already account for morphology. The 
composite stages do show a prognostic gradient within TNM stages but the 
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The presence of sharper prognostic gradients using clinical 
features in 1953-64 versus 1977 prompts questioning of the amount 
that symptomatic staging benefits the new cohort relative to the old 
cohort. Since this report was not designed to address cause-effect 
comparisons between the two cohorts, the issue of the relative benefit 
of symptomatic staging in old versus new patient populations cannot be 
addressed here. However, a number of competing explanations for the 
less distinct prognostic gradients of the 1977 cohort can be considered: 
1. baseline differences between cohorts resulting from a changing 
lung cancer patient population may adversely affect the efficacy of the 
symptomatic staging system for the 1977 cohort; 
2. changes in primary or ancillary therapy may have altered 
survival rates of select groups of patients; 
3. since the prognostic gradients of 1953-64 were observed in the 
cohort which generated the prognostic system, the new population could 
not be expected to match the "best fit" gradient and, therefore, the 
prognostic system appears to be less discriminating in the new population 
used to test it; and 
4. variability in the prognostic gradients of the 1977 cohort may 
be attributable to the nearly 10-fold smaller sample size relative to the 
1953-64 cohort. 
However, the results confirm the expectation that clinical 
phenomena continue to show prognostic significance despite the more 
precise morphologic staging available in a modern cohort and despite 
possible baseline Inequalities between cohorts. The data for symptom 
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types, and symptom severity, and co-morbid severity provided 
distinctive prognostic gradients and the gradients were maintained 
in the unified categories of the composite stages. That these 
symptomatic stages were able to show gradients within TNM stages, and 
vice versa, indicates that each of the two types of staging 
independently yields prognostic discrimination not provided by the 
other. Thus, the current study reiterates the importance of 
classifying both morphologic and symptomatic features in prognostic 
analysis for the evaluation of lung cancer therapy. 
Zero-Time Shift 
Tables 11-14 display the composition of both the 1977 and 
1953-64 cohorts categorized by morphologic and symptomatic stages. 
Table 11 shows that the 1977 cohort contains a higher percentage of 
patients who are in the more favorable TNM morphologic stages at 
zero time. Clinical group, functional severity, and composite stage 
all show a shift to less severe stages in the 1977 cohort. 
The shift to less severe stages is demonstrated more graphically 
when the composition of the 1977 cohort is examined without the results 
from new diagnostic techniques. By comparing the cohorts in this way, 
a similar standard of diagnosis can be applied to both cohorts in 
categorizing morphologic extent of disease. Table 15 shows the 
composition of both cohorts according to TNM stages constructed without 
the use of data from new diagnostic tests. Table 16 has a similar 
comparison, according to composite stages. 
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A final aspect that bears on cohort composition at zero time 
is the "progression interval" in patients who had symptoms at zero time. 
The progression interval refers to the length of time from inception of 
18 
symptoms until zero time . The number of symptomatic patients in the 
1977 cohort was 112 (85%), and the median progression interval was 3.0 
months. The 1953-64 cohort contained 1173 (93%) symptomatic patients 
with a median progression interval of 5.4 months. 
This demonstrated shift in zero time is sometimes referred as 
lead time. The term is generally applied to increased survival time 
39 
provided by early diagnosis as a result of screening , which enables 
the disease to be found at an earlier time than would have occurred with 
conventional clinical diagnosis. This study does not address the impact 
of screening, since the population of patients was not derived from a 
screening program. There are strong suggestions, however, that members 
of the 1977 cohort appeared earlier for diagnosis and treatment of their 
lung cancer than the 1953-64 cohort. The evidence for this zero-time 
shift, or lead-time bias, is demonstrated in the zero-time data of the 
1977 cohort, from the smaller percentage of patients who had symptoms or 
were in severe morphologic or symptomatic stages, and also from the 
shorter progression interval for the symptomatic patients. 
At zero time, 15% of the 1977 cohort was without lung cancer 
symptoms, in contrast to only 7% of the 1953-64 cohort. Although the 
results suggest at least passive Improvements in screening for lung 
cancer since 1953-64, this study does not provide sufficient Information 
to draw further conclusions. 
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The results showing a smaller percentage of patients in both 
severe morphologic and symptomatic stages at zero time in 1977 
indicate that the improvement in the 1977 cohort is most striking when 
similar staging information is used for morphologic features. The 
lower percentage of severe clinical groups, and the notably higher 
percentage of the 1977 cohort lacking any functional severity, also 
demonstrate a clinically "earlier" composition of the modern population 
of patients. 
The modern population of patients possesses a shorter progression 
interval of symptoms than the 1953-64 cohort. This smaller time interval 
from onset of symptoms to zero time is also suggestive of a zero-time 
shift. Thus, it appears that, for whatever reasons, the modern population 
of patients comes to therapy in a more favorable clinical state than in 
1953-64. 
Impact of New Technology 
The "new technology" in this study consists of new techniques in 
diagnostic imaging that were available to the 1977 but not to the 
1953-64 cohort. In particular, the new techniques include the scans of 
nuclear imaging, computerized tomography, and ultrasonic imaging that 
were used to define tumor extent. Tables 17-20 present survival rates 
with special attention to the results of these techniques. The survival 
rates are reported for stages assigned by using three categories of 
data: (1) information that excludes results from the new techniques, 
i.e. the "old" results; (2) information that includes unequivocal 
results of new techniques; or, (3) information that includes both 
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unequivocal and equivocal results counted as "positive". The data 
reported earlier for the 1977 cohort includes only unequivocal results 
unless otherwise specified. Although equivocal results are often used 
38 
in staging , they are displayed separately for clarity. 
Table 17 shows the 6-month survival rates according to TNM 
stages for the three categories of data. It portrays a striking 
improvement in prognosis for each stage as the data are expanded from 
the "old" information, to include first the unequivocal and later the 
equivocal results of new techniques. These improvements in prognosis 
for each stage occur simply as acts of staging, without altering the 
cohort itself, or the overall survival rates in the cohort. Table 18 
shows the same for composite stages, and Table 19 and 20 show 5-year 
survival rates for TNM and composite stages respectively. 
DISCUSSION 
This study was concerned neither with the etiology of lung cancer 
nor with the results of its primary or ancillary therapy. The goal was 
to examine the methods that can be used for the prognostic assessment of 
lung cancer. Not all of the data acquired in the research were analyzed 
in this report. Some information will be used in future reports and 
other analyses await the enlarged numbers of an expanded cohort. 
The three major topics addressed in this report are: the impact of 
clinical phenomena on lung cancer staging; the effect of a zero-time 
shift between 1953-64 and 1977; and the impact of new diagnostic 
techniques on the staging of lung cancer. Since the first two topics 
were discussed when the results were presented, the rest of this discussion 
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will focus on the impact of improved diagnostic methods on the staging 
of lung cancer. 
The 1977 cohort investigated in this study has been contrasted 
with a cohort whose cancers occurred at least 12 years earlier, during 
1953-64. When contrasted with a newer population of patients, previous 
patients deemed to have the same clinical condition but managed 
differently are called "historical controls". "Historical controls" 
are often used to assess new treatment when comparisons with "concurrent 
controls" are unfeasible for ethical, financial, or logistical reasons. 
The major hazards of comparison with historical controls are the biases 
produced by unrecognized differences in pre-treatment clinical condition 
and by differences in ancillary therapy. 
Since new technology provides new standards of care in diagnosis 
and therapy, secular changes can occur in both baseline assessment and 
ancillary therapy. The observed improvement in survival rates for the 
1977 cohort versus the 1953-64 cohort may be attributable to improvements 
in therapy, to the "zero-time shift", or to baseline inequality between 
cohorts arising from the changing composition of the lung cancer cohort. 
A different source of improvement in survival rates, however, has been 
strikingly demonstrated in the third part of this study. Major improve¬ 
ments have occurred simply from changes in staging created by advances 
in diagnostic technology. 
While the data extraction was in progress during the research. 
it became apparent that the morphologic extent of lung cancer for patients 
in 1977 was defined with data that were not available for patients in 
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the earlier cohort. The new diagnostic techniques were particularly 
useful in demonstrating symptomless metastatic disease or in providing 
morphologic confirmation of symptomatic metastases. The improving 
capacity to identify metastatic disease would allow many patients who 
would previously have been classified without this evidence, to receive 
a "proper" categorization as metastatic. 
40 
Mintz, et al. , using many of the same new Imaging techniques 
examined in the current study, were able to demonstrate an increased 
capacity to detect otherwise unrecognized spread of lung cancer. The 
routine use of liver-spleen scans, bone scans, CT scans of the brain, 
and total-body gallium scans created significant changes in the TNM 
stage composition of the group when compared with the initial staging 
without these techniques. Similar results have been demonstrated using 
41 
CT scans of the abdomen and thorax. 
The cited studies, however, have not addressed the altered 
prognosis produced by changing the composition of pre-therapeutic stages. 
The current research demonstrates that prognosis itself, regardless of 
therapeutic effects, is improved by the contributions of the new diagnostic 
technology. 
Since increased morphologic extensiveness of lung cancer has been 
shown to portend a worse prognosis, a patient who had asymptomatic 
metastases that went undetected during pre-therapeutic staging would be 
expected to lower the overall survival of the "higher" stage to which 
he was originally assigned. Having fewer symptomatic manifestations of 
the disease, however, such a patient may have a better prognosis than 
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the other patients in the "lower" stage, to which he is assigned 
when better data are available. Because of the accurate staging, 
survival rates can be improved for the stage that the patient leaves 
and also for the stage that he joins. Nevertheless, prognosis will 
have changed for neither the individual nor the total cohort. 
This migratory shift, which seems to produce major changes in 
the surroundings without any changes in the shifted entity, is analogous 
to a phenomenon described in a quotation attributed to Will Rogers: 
"When the Okies left Oklahoma and moved to California, they raised the 
average IQ of both states". A graphic demonstration of this "Will 
Rogers Phenomenon" is provided in the survival rates found for the 1977 
cohort, staged with and without the application of new diagnostic 
techniques. Since the members of the cohort are being compared with 
themselves, nothing can change for the individual people or for the 
total survival rate in the cohort. Nevertheless, with the data from 
the new technology, the survival rate improves for each stage! 
The "Will Rogers Phenomenon" has important implications when 
the results of new treatments for cancer are compared with survival 
rates found in "historical controls". The new treatments may seem 
impressively better, but the superiority may arise from diagnostic 
rather than therapeutic improvements. An attention to all prognostic 
variables, rather than morphologic data alone, can help prevent this 
error and can Improve the validity of therapeutic assessments. 
Thus, the results of this study have three main concusions: 
1. The symptoms produced by lung cancer are still important. 
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although generally ignored variables for estimating prognosis and 
evaluating therapy in a modern population of patients. 
2. A shift in zero time has occurred for modern patients with 
lung cancer, whereby the patients receive treatment while in more 
favorable stages, and may contribute to the improved survival in the 
total cohort. 
3. Some (or much) of the improved survival in the morphologic 
stages of modern patients may be attributable to improvements in 
diagnostic technology, which can alter the staging classification of 
patients without truly affecting the results in the individuals or in 
the total group. 
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Table j_. COMPOSITION OF THE TWO COHORTS 









Men 96 (73%) 1118 (88%) 
Women 35 (27%) 148 (12%) 
Age (years) 
<40 4 (3%) 34 (3%) 
40 - 49 8 (6%) 134 (11%) 
50 - 59 37 (28%) 330 (26%) 
60 - 69 42 (32%) 527 (42%) 
70 - 79 33 (25%) 222 (18%) 
>79 7 (5%) 19 (2%) 
Median 63 63 
Range 34 - 83 25 - 91 
Hospital 
Y~NHH 99 (76%) 867 (68%) 
WHVAH 32 (24%) 399 (32%) 
Race 
White 119 (91%) *556 (96%) 
Black 12 (9%) 24 (4%) 
Oriental — 2 (<1%) 
*Race composition for the 1953-64 cohort was 
available only for patients seen during 
1960-64. N=582 
Note: Total proportions in composition of a 
cohort may not sum to 100% in this and 
subsequent tables, because of "rounding errors". 
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Table 2. COMPOSITION OF THE TWO COHORTS ACCORDING 







21 (16%) 338 (27%) 
Well-Differentiated 
Adenocarcinoma 
26 (20%) 227 (18%) 
Small Cell 9 (7%) 109 (9%) 
Anaplastic 60 (46%) 418 (33%) 
Metastatic 1 (1%) 15 (1%) 
Cytology Only 14 (11%) 159 (13%) 
TOTAL 131 (100%) 1266 (100%) 
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Table 3. FREQUENCY OF PERFORMANCE AND RESULTS OF NEW DIAGNOSTIC 
TECHNIQUES EMPLOYED IN THE 1977 COHORT 
N= 132 Result 








Brain Scan 79 8/79 4/79 








Head Acta Scan 12 7/12 0/12 
(9%) (58%) (0%) 
Abdominal Ultrasound 14 2/14 5/14 
(11%) (14%) (36%) 
Gallium Scan 32 10/32 10/32 








* "Other" was coded when a study performed to define tumor 
extent was not available during the 1953-64 survey, and 
is not listed above. In this study, the category was 
used for CT other than head, and for ultrasound outside 
the abdomen. 
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Table _4. SURVIVAL RATES FOR THE TWO COHORTS 






























Median Survival , 
s 6.65 4 .60 
* For the 1953-64 cohort, survival information 
is available for all 1266 patients. For the 
1977 cohort, certain patients seemed to be 
"lost to follow-up" when this research was 
done. The changing denominators in the 1977 
survival rates reflect these losses. 
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Table 5. DISTRIBUTION AND SIX-MONTH SURVIVAL RATES FOR THE TWO 
COHORTS ACCORDING TO THE FIRST COURSE OF THERAPY 
First Course of 
Therapy 
Cohort 6 Month Survival 
1977 1953 - 64 1977 1953 - 64 
Thoracotomy With 
Excision of Primary 





Excision of Primary 
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Table 6. SIX-MONTH SURVIVAL RATES FOR THE TWO COHORTS 
ACCORDING TO CLINICAL GROUPS 
Cohort 
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Table 7_. SIX-MONTH SURVIVAL RATES FOR THE TWO COHORTS 
ACCORDING TO FUNCTIONAL SEVERITY STAGES 
Functional Severity 
None 



























Table 8. SIX-MONTH SURVIVAL RATES FOR THE TWO COHORTS 
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Table 9. SIX-MONTH SURVIVAL RATES FOR THE 1977 COHORT 
PRESENTED BY CLINICAL GROUPS AND 
TNM STAGES CONCOMITANTLY 
TNM Stage 
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Table 10. SIX-MONTH SURVIVAL RATES FOR THE 1977 COHORT 
PRESENTED BY COMPOSITE AND TNM STAGES CONCOMITANTLY 
Composite Stage 
TNM Stage 










8/9 10/14 14/16 32/39 
(89%) (71%) (88%) (82%) 
n 0/1 2/3 10/34 12/38 
L 
(0%) (67%) (29%) (32%) 
D 
0/1 4/5 1/18 5/24 
(0%) (80%) (6%) (24%) 






30/34 17/23 25/74 72/131 
(88%) (74%) (34%) (55%) 
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Table 11. COMPOSITION OF THE TWO COHORTS 
ACCORDING TO TNM STAGES 
Cohort 
TNM Stage 1977 1953-64 
I 34 (26%) 281 (22%) 
II 23 (18%) 172 (14%) 
III 74 (56%) 813 (64%) 
TOTAL 131 (100%) 1266 (100%) 
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Table 12. COMPOSITION OF THE TWO COHORTS 
ACCORDING TO CLINICAL GROUPS 
Cohort 
Clinical Group 1977 1953-64 
Asymptomatic 19 (15%) 88 (7%) 
Long Pulmonic 17 (13%) 148 (12%) 
Short Pulmonic 44 (34%) 193 (15%) 
Systemic 22 (17%) 417 (33%) 
Metastatic 29 (22%) 420 (33%) 
TOTAL 131 (100%) 1266 (100%) 
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Table 13. COMPOSITION OF THE TWO COHORTS 
ACCORDING TO FUNCTIONAL SEVERITY STAGES 
Cohort 
Functional Severity 1977 1953-64 
None 72 (55%) 340 (27%) 
Systemic/Dyspnea 36 (27%) 607 (48%) 
Quasi-Metastatic 3 (2%) 94 (7%) 
Severe 20 (15%) 225 (18%) 
TOTAL 131 (100%) 1266 (100%) 
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Table _U. COMPOSITION OF THE TWO COHORTS 















(18%) 133 (11%) 
(30%) 393 (31%) 
(29%) 415 (33%) 
(18%) 238 (19%) 
(5%) 87 (7%) 




l.nu j. A# i / 
I.-OC/ v'T 
^-Jiti ) (ii ^ . .-'P'v) 1 ■■ 
Ttr > Hf-' > ,r<\i /W 
•' ■' -ii 
< a (x;) '3 » 








- 46 - 
Table 15. COMPOSITION OF THE TWO COHORTS 
ACCORDING TO TNM STAGES WITHOUT DATA 
FROM NEW DIAGNOSTIG TEGHNIQUES 
TNM Stage , 
"Old" Morphologic -—-— 
Data Only 1977 1953-64 
I 42 (32%) 281 (22%) 
II 25 (19%) 172 (14%) 
III 64 (49%) 813 (64%) 
TOTAL 131 (100%) 1266 (100%) 
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Table J_6. COMPOSITION OF THE TWO COHORTS 
ACCORDING TO COMPOSITE STAGES WITHOUT 












(20%) 133 (11%) 
(34%) 393 (31%) 
(28%) 415 (33%) 
(16%) 238 (19%) 
(2%) 87 (7%) 
(100%) 1266 (100%) 
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Table 17 . SIX-MONTH SURVIVAL RATES FOR THE 1977 COHORT 
PRESENTED FOR TNM STAGES DETERMINED WITH INCREASING 
AMOUNTS OF INFORMATION FROM NEW DIAGNOSTIC TECHNIQUES 
TNM Stage 
Information Used In Staging 
All Technologic All Technologic 
"Old" Data, With Only Data, With 
Technologic Unequivocal Results Equivocal Results 
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Table J_8, SIX-MONTH SURVIVAL RATES FOR THE 1977 COHORT 
PRESENTED FOR COMPOSITE STAGES DETERMINED WITH INCREASING 
AMOUNTS OF INFORMATION FROM NEW DIAGNOSTIC TECHNIQUES 
Composite Stage 
Information Used In Staging 
All Technologic All Technologic 
"Old" Data, With Only Data, With 
Technologic Unequivocal Results Equivocal Results 


















































Table 19. FIVE-YEAR SURVIVAL RATES FOR THE 1977 COHORT 
PRESENTED FOR TNM STAGES DETERMINED WITH INCREASING 






Information Used In Staging 
All Technologic All Technologic 
"Old" Data, With Only Data, With 
Technologic Unequivocal Results Equivocal Results 
Data Only Counted As Positive Counted As Positive 
7/35 7/28 6/19 
(20%) (25%) (32%) 
2/23 2/21 2/17 
(9%) (10%) (12%) 
1/64 1/73 2/86 
(2%) (1%) (2%) 
10/122 10/122 10/122 
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Table 20. FIVE-YEAR SURVIVAL RATES FOR THE 1977 COHORT 
PRESENTED FOR COMPOSITE STAGES DETERMINED WITH INCREASING 
AMOUNTS OF INFORMATION FROM NEW DIAGNOSTIC TECHNIQUES 
Composite Stage 
Information Used In Staging 
All Technologic All Technologic 
"Old" Data, With Only Data, With 
Technologic Unequivocal Results Equivocal Results 
Data Only Counted As Positive Counted As Positive 
6/21 6/19 5/15 
(29%) (32%) (33%) 
4/43 4/37 4/26 
(9%) (11%) (15%) 
0/36 0/37 1/41 
(0%) (0%) (2%) 
0/20 0/23 0/34 
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LUNG CANCER EXTRACTION FORM 
6. NECROPSY No._ 





lUNG: EXTBATHOSACIC STKUCTIRES: 
1. MEDICAL ITINERARY 
INDEX HOSP.... 
Oete Oeie 
Uni* * No. Adm:  Piich: 
ZERO TIME HOSP. 
Dete Date 
I**!' No. Adm: . Ditch: 
Dete Dele 





REASON(S) FOR TRANSFER(S): 
2. DEMOGRAPHIC DATA 
D.O.B. Age . Race 
M F 
Sox 
7. INTERVALS Don of Dooth: .. 
Soorco: ----Dote Un Alivo:  
* lo ADM; ... * to ZT: ... 
♦ to ADM; __-»to ZT:__ 
ADM to ZT: ... ZT to END; .. 
8. SPECIAL COMMENTS 
OTHER SOURCES TO CHECK PONE 
SMOKING HISTORY: CHANGE IN SMOKING HABITS: 
CUSTOMARY CIGAREnES; 
Unk. M Smoked Ami. Unk. 
0 1/2 1/2 to I 
I I to 2 » —-- 
Ymti: 
PIPE, CIGAR OR OTHER TOBACCO HABIT: 
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3. ZERO STATE DATA 
PRESENT lUNESS 








Cold ' Fowor Sinel* 
UR I Swoon Rocurroni 
Clin Db fn UnroooUod Fn 
DYSPNEA 
THORACIC Pi Non PI Unk 





WT. toss C«nololnt 
Symptom 
CLUBSING (Notod by Pi.) 
JOINT PAIN 
HOARSENESS: NMVC NEVC MVC 
SWEUING OF: Foco Ann Nock 
DYSPHAGIA 
PALPABLE MASS (Notod by Pi.) 
NEUROLCXIC SX: 
OTHH SXt 
PttTlNDIT StONS AW fTNOBOMD WOTH> BY BLD. 
MRACLINICM DATA 
BADtOOtAPMIC DATA 
Boe Um Anglo B'gront 


































OTHER BESP. FUNCTION TESTS: 
Uni 






Wl. Lou_ —. Wt. Uu _ . ..% 









GROSS PL. FLUID: 
‘ ‘I "*('« 
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ASSOCIATED EVENTS 4. THERAPEUTIC DATA ZERO TIME: 
mcBMNC AcnvniES 
HRST COURSE Of ANTINEOPLASTK RX 
. . C P ONK 
oil* Pr*-op lni«nt ftx Course No. 






Frozan Section: .. 
. . CP UNK 
*«=  Int.«* ln«nl 
ExcUien: I umc RUl RML RU I lUNC lUl Ul 
RHion No 
Rwoctlon:  
Imro^op Complix: Prognotlic Commontt: 
PATHOLOGY 
REPORT: Coll Type: . SP No. 
SHm: Node*: 
Other; 
MnAHATK SUROaV (During Pirtt Rx Coutm) 
hooidufo: . 
.-. Dele; 
Surgial Finding*: ....... 
CoH Type: .......SP No. 
■ADIOTHBUPY (During PlrM R> Coutm) 
She Ontet Ended Tumor Dose Medium 
CYTOTOXIC RX (During Fim Ri Cane) 
Drug: ___ Oniet: 
I', .v 
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(Tv. WMW^r) 
Canc*r of th« Lung 
Cord No. 2: GENERAL SUMMATION 
TEAR or 














OTHB TOftACCO HAtITS 
CiQ«rft 













Chronic Cough . 1 
Chronk Dyspnoo 2 I I 
Chronic Pulm. OnMM . 4 
01) 
PAtlETAL SX AND TIC 
Plovritic Chost Pain 1 
Non-Pkuritk Chost P#in . 2 
Activ TBC_ 4 I I 
(for • and 9 Criroria) 02) 
BtONCHlAi SX PABENCHYMAl SX PCATUBES OF INFECTION OTHEB EVENTS 




Butt. Blood Streaks, or 1 1 Singla infection 2 □ Pneumonia (Clinical Dx) 2 Trensient "Prifnary Sx Hemoptyiia 3 Lj Becurrerrt Infection 4 Cold or Flu 4 Parar>eopla»tic Syndrome 4 1-1 
Subfoctivt Whoozo 02) 04) 05) 00) 
OiNEtAl SX 
Anortxta 
Wt. Lou {•& Complaint) 







Clubbing Noted by Pt. 
Significant Clubbing 
Noted by 










tfOIONAl MSTAHATtC SX 
Homer'i Syndrome 
irachial or Peripheral 
Arm Nerve SSx . . 
Sx in Outer Thoracic 
Sfrvctwfti . 
OtnAKT ISnAnATtC SX 
Non-Thorack Bone Pain . 1 
Peripheral Neurologic SSx 
or Other. 
Cerebral Neurologic SSx . 
2 
4 □ 
PtOBLEMS IN ArrtlBin'ION 
Primary Sx of ?-Attfib. 
Sytiemic Sx of ?-Attrib, 





fVIOENCE Of ANCILLARY DATA SPUTUM CYTOLOGY; 
SYEIOHT LOSS Anemia .. .. I •LEDIASTINOSCOPY 
□ Elevated VP  Hyparcalcemia or Other . . -u □ 















M LUNO MOPSY 
□ 
m 
CUNICAL ANATOMIC EVIDENCE 
P«lp«bl« Thoracic MaUitatis 
Palpable Surface Metaitaiii 
Liver or Other . 
1 
01) 
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59 II 
EXTIAPUUWONIC MOtPHOtOSIC EVIDENCE 
fie9«nal Node 1 
Pleura. Pleural Fluid. 
Chen Wall or Thoracic Bone 2 
Contiguous Involvement 4 
Pericardial 
Involvement . 1 
Contralateral Site 2 















Definite Hilar Nodes 
Definite Mediastinal Nodes 
Mediastiriai "Viscera" 
lAOtOGtAPHIC MVOIVEMENT 
IPSILATEIAL THOtACIC CONTtALATEIAt THOKACIC 
Pancoast Tumor or 
Pleural Effusion 








or Pleural Effusion 
Hilum or Mediastinum 
Other Contralateral Structures 
IRTKATMOftACIC 
Extrathorecic Bone . 1 
Liver or Other . 2 r* 








Severity of Tumor Effects 
Signif. Cardiovascular Disease 





Juxta-Carinal or Cell Type 
Metastasis of Tumor 
Functional Severity of 
Tumor Effects . 
NON-ONCOGENIC 







THBtAPEUTIC OTHER THERAPEUTIC SURGICAL PROCEDURE FURTHER SURGICAL DESCRIPTION 
AaiON CONSIDERATIONS AND INTENT Other Structures Excised, or 
Involved but 1* not Excised 1 □ □ □ Post-op. Complications . 2 1 I Op. or Post-op Death 4 
(471 (4SI (4P1 (50) 
SUICICAL EUieiCAl 
HISTOIOGY PATHOLOGY 
□ □ □ 
(SI) (S2) (S3} 
SUBSEQUENT TREATMENT 
Surgery to Primary Site 1 
Radiation to Primary Site 2 
Systemic or Metastatic 
Treatment . 4 (44) 
SUBSEQUENT CUNtCAL EVIDENCE Of METASTASIS OR RECURRENCE 
ATTRIBUTION CERTAIN ATTRIBUTION UNCERTAIN 
New Endopulmonic or Systemic 
Manifestations of Tumor 
New Evid. of Thoracic involverrtent 
New Evid. of Ultrathoracic involvement 
;□ 
4 (55) 
New Endopulmonic or Systemic 
Manifestations of Tumor 
New Evid of Thoracic involvement 
New Evid of Ultrathoracic involvement 
O 
4 (S61 
SUBSEQUENT NEW SUBSEQUENT MODE OF DEATH 
MORPHOLOGIC EVIDENCE BUCBOSCOPIC Circumstances Unknown 1 
Uothoracic 1 EVIDENCE Sudden or Unexpected 2 
Contrathoracic 2 I | 
Ultrathoracic 4 □□ Definitely or Probably net Due to CA Lung ■D 
(57) (SBl (SPl (601 
ASSOCIATED DISEASES 
Ce*xiitcni Of her Cancer 
Ceaxitteni Tubarccrloxis 
Nccropiv Oatection . 
WCiOPSY mCtOPSY 
TUSUE 




( • to rn □□□. 




(ZT to Ertd) 





ADDinONAl DATA □ 0I2] Reveraibte Co>Morbid Wt. Lots Additional Card . ;□ = □□□□ 
(731 V4) (751 Pre-Zero Morph. Evid. (761 (77) (76) (79) (K| 
of Brain Involvatnanf . 4 
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- 60 - Appendix III 
Cancer of the Lung 
Card Number 3 : General Summation Ft. Number 
Race T Evidence TNM Stage 
□ 
T3 T2 Tj 
□ □□D 
T N M 1 
□ □□ 
(1) (2) (3) (4) (5) (6) (7) (8) 
Study 
New Techniques in Imaging : 
Result Associated Clinical 
Liver/Spleen Scan B B 
Brain Scan B B 
Bone Scan B B 
Acta Scan B B 
Ultrasound B B 
Gallium Scan B B 
Other B B 
(9) 
Toponymic Stage Toponymic Stage With TNM Stage TNM Stage With 
Without Results From Equivocal Results From Without Results From Equivocal Results From 
New Techniques New Techniques New Techniques New Techniques 
N M Stage TNM Stage 
25) 
TNM  
□ □□ P PPP 
(26) (27) (JF) (29) (30) (JT) (32) (33) 
Functional Severity 
Q 




Patient ID Number 
□ □ □□ 
(77) (78) (79) (80) 
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Appendix IV 
CRITERIA FOR CODING 
Cancer of the Lung 
Card No. 2: GENERAL SUMMATION 
This revision was completed in March, 1972. It supplants the previous 
criteria, used for coding the analogous format marked Card No. 1: 
GENERAL SUMMATION. 
These criteria were compiled by Dr. Feinstein and his Clinimetric 
research group. 
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(1). (2); YEAR OF ZERO Tllffi 
The criteria for determining zero time, the inception event (”*" event), and 
zero state in a patient's clinical course are stated in Appendix A. The year of 
zero time is directly coded as '53, '54, ..., '59, '60, ..., etc. in columns 1 and 2. 
(3). (4); AGE 
Code in years as of last birthday before zero time. 
(5) ; SEX 
1: Male 
2: Female 
3: Male; stopped cigarette smoking, definitely before inception event 
4s Female; stopped cigarette smoking, definitely before inception event 
5s Male; decreased cigarette smoking, definitely before inception event, 
but patient continued smoking 
6: Female; as in 5 
(6) s HOSPITAL STATUS 
Code the status and the hospital at which zero time occurred. An exception 
to this rule is the situation la which the diagnostic work-up and therapeutic 
decision occurred during an admission to one of our index hospitals, but the chosen 
zero-time treatment was administered elsewhere. In this circumstance, the patient's 
status at our index hospital is acceptable for the coding here. (The numbers and 
letters in parentheses refer to the coding citations used by the Admission Office 
at Yale-New Haven Hospital.) 
1; Yale Private (LA, IB, 1C, ID, or IE) 
2: Yale Semiprivate (SP-2, P-2, SP-3, P-3, SP-4, or P-4) 
3s Yale Ward (SP-6, S-6, SP-5, S-5, or SP-4-T) 
4: Other [non-VA] hospital 
5s West Haven VAH 
6s Other VA hospital or Federal hospital (e.g., U.S.P.H.S. hospital) 
7s Yale Out-Patient Department 
8s Office of private doctor 
95 Referred only for necropsy 
(7) s CUSTOMARY CIGARETTES 
Code the amount (in packs per day) that represents the patient's most common 
mode of cigarette smoking before the event. 
Os None 
Is Rare or < 1/2 
2s 1/2 
3s 1/2 to 1 
45 1 
55 1 to 2 
6s 2 
7s >2 
8s Smoked, but amount DOTC (used for descriptive terms such as "heavy", 
"chain", "moderate", or "light" smoker) 
UNK re cigarette smoking 9s 
__ 
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2 - 
(8) ; OTHER TOBACCO HABITS 
Code as cited if patient ever engaged In these habits, even If he has stopped. 
Code as 0 if UNK. 
(9) - (10): lATROTROPY 
The coding of columns 9 and 10 depends on the types of symptoms in the 
"present illness", on the iatrotropic stimulus, and on the dlagnostropic stimulus. 
The iatrotropic stimulus (I.S.) is the event or chain of events that evoked 
the clinical work-up that led to the occurrence of zero time. The dlagnostropic 
stimulus (D.S.) is the event or manifestation(s) that made the doctorCs) decide to 
look for evidence of lung cancer. Going backwards from zero time, we first ask 
the question, "What event provoked the doctor(B) to search for evidence of lung 
cancer in this patient?". The answer to this question is the dlagnostropic 
stimulus. We then ask the question, "What event provoked the patient to consult 
the doctor(s) who did the work-up (or who referred the patient for the work-up) 
that contained that diagnostic search?". The answer to this question is the 
iatrotropic stimulus. 
The iatrotropic stimulus is often, but not always, the same as the "chief 
complaint" (C.C.) of the "present Illness" that preceded zero time. The I.S. will 
usually differ from the C.C. in patients who are asymptomatic (so that there may 
be no C.C.), in patients whose C.C. has had a long duration, or in patients with 
a plethora of complaints. The dlagnostropic stimulus is usually the same as the 
iatrotropic stimulus, but may differ in circumstances in which the Initial 
complaints do not suggest lung cancer, or in irfiich the diagnostically provocative 
events occur in a patient who has been chronically hospitalized for a temporally 
distant iatrotropic stimulus. If the D.S. occurs as the direct result of the 
work-up begun in response to the original I.S., that original event is regarded 
as the I.S. If the D.S. occurs as the result of new events that began after the 
work-up for the original I.S. was completed without a diagnosis of lung cancer, 
then the new D.S. is regarded as the I.S. for that patient. 
These principles are Illustrated in the cases that follow: 
(a) The initial I.S. is the fever, cough and chest pain of a 
pneumonia that is at first not suspected as related to neoplasia. When the 
patient's X-ray fails to improve, the "unresolved pneumonia" then leads to a 
work-up for lung cancer. In this situation, the unresolved pneumonia is the D.S., 
having been provoked by events noted during the infectious episode. For such 
"intra-episodic" discoveries, the original clinical symptoms of the Infection are 
coded as the I.S. 
(b) Psychotic behavior is the I.S. for a patient who then receives 
long-term hospitalization for a "chronic brain syndrome". After five years in the 
hospital, this patient develops hemoptysis as the D.S. that leads to the 
identification of lung cancer. In this situation, the D.S. would be coded as the 
I.S. 
(c) After completion of a clinical episode diagnosed and treated 
as infectious pneumonia (i.e., viral, tuberculous, or other bacterial), the patient 
is left with a pulmonary shadow that is re-examined periodically with X-ray. On 
one of the periodic X-rays, the shadow is found to be larger, and a work-up is 
instituted that leads to a diagnosis of lung cancer. In this case, the routinely 
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scheduled X-ray examination is the D.S., having occurred as a "post-episodic" event, 
at some time after completion of the original clinical episode 2md after the 
persistent shadow had not acted as a D.S. In such temporally remote "post-episodic" 
discoveries, the D.S. is coded as the I.S. 
(d) A patient with psychotic behavior is committed to a state 
hospital and shortly afterward is transferred to another hospital for long-term 
care. At the second hospital, a routine admission X-ray film shows the pulmonary 
lesion for which the patient is then referred to an index hospital where he receives 
the diagnostic work-up that shows lung cancer. The psychotic behavior is the I.S., 
and the admission X-ray at the second hospital is the D.S. Since this D.S. was a 
routine procedure, presumably performed on all patients regardless of their clinical 
state, the psychotic behavior is coded as the I.S. 
(9): COMPLAINANT STATUS 
This coding depends on many variations in the data available in a patient's 
medical record. The identity of the I.S. may or may not be clearly determined, and 
its attribution may be certain or uncertain. "Suspicious" symptoms (i.e., those 
that can be attributed or ?-attributed to lung cancer) may also be present, 
questionably present, or absent. 
The following flow chart shows how these different variations are managed 
for choosing the coding numbers for the I.S. in this column: 
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With these conventions, the coding for column 9 can be simply listed as 
follows: 
0: Not applicable, "necropsy surprise" 
1: l.S. due to Sx attrlb. to CA lung 
2: l.S, of uncertain attribution. Pt. has other Sx attrlb. or ?-attrlb. 
to CA lung 
3: l.S. due to cause other than CA lung. Pt. has Sx attrlb. to CA lung 
A: l.S. due to cause other than CA lung. Pt. has Sx ?-attrlb. to CA lung 
5: No "Sx suspicious" of CA lung 
6: l.S. due to cause other than CA lung. Pt. has suspicious Sx of 
?-existence 
7: l.S. not clearly determined or identified 
8: l.S. of uncertain attribution. Pt. has no other Sx attrib. to CA lung 
For patients who are "necropsy identification" cases — l.e., tumor suspected 
in life, but primary source not identified until necropsy — this column should be 
coded with the l.S. selected on basis of the examinations that led to the diagnosis 
and/or treatment of cancer. 
For patients whose l.S. is due to "cause other than CA lung" (l.e., patients 
coded with _3, _4, _5, or _6), a positive response must be entered in column 10. 
(10); EXTRANEOUS lATROTROPIC STIMULUS 
0; Not applicable 1^, 2^, 2» or ^ lii column 9] 
1: Sx of other disease; probably not related to CA lung 
e.g. Hernia (without cough); hemorrhoidal bleeding; urinary retention 
2: Sx of other disease; relation to CA lung unclear 
e.g. Newly developed diabetes mellltus; Sx of peptic ulcer 
3: Sx of other disease; probably related to CA lung 
e.g. Hernia (with cough) 
4: Regular follow-up of a chest disease 
e.g. TBC; chronic lung disease; previous shadow 
5: "Routine" test: not further specified 
e.g. "Mobile unit"; "routine check-up" 
6: "Routine" test Imposed on patient or pre-scheduled 
e.g. Factory survey; employment film; annual exam; veteran's 
benefits; son’s TBC skin test positive In school 
(11): PULMONARY CO-MORBIDITY 
The cited entitles are coded here regardless of their prognostic or contra- 
therapeutic significance. Cough or dyspnea should be persistent to be coded; do 
not code these entities if they disappeared well before zero time, or if they 
occurred only in isolated past episodes. The only pulmonary co-morbid conditions 
not cited here are "Active TBC", which is coded in column 12, and low "Respiratory 
Reserve", which is coded in column 28. 
Only chronic entitles may be coded in this column; recent cough and dyspnea 
are coded in columns 13 and 14. A manifestation such as cough or dyspnea is 
clearly chronic if the patient says it has been present for an unquantified but 
definitely long period of time, such as "all my life" or "for many years". On the 
other hand, the cough or dyspnea is clearly recent if the patient assigns to it a 
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specific duration that is shorter than the duration of tine from the Inception event. 
For the cases In which the cough or dyspnea may Itself be a candidate for 
inception event, we have adopted the following convention for consistency in 
classification. Cough or dyspnea that has persisted for 10 years or less without 
an apparent cause other than lung cancer Is considered recent and may therefore be 
assigned to the The symptom Is then coded appropriately in column 13 or 14; if 
the duration Is more than 10 years, the entity is considered chronic and is coded 
in column 11. 
Chronic Cough; A past diagnosis of "chronic bronchitis" should 
not be coded here unless a cough is specifically mentioned. See previous 
comments for definition of "chronic". 
Chronic Dyspnea; In elderly patients, "2-flight dyspnea" is not 
designated as dyspnea unless accompanied by a statement that the exertion 
was interrupted by the need to rest. "Three-flight dyspnea" is ignored 
unless specified as a significant worsening in respiratory capacity. 
"Two-pillow orthopnea" is not regarded as orthopnea unless there is 
reasonable evidence or presumption that the pillows are used to elevate 
the upper torso, rather than the head alone. An M.D. statement of low 
respiratory reserve is coded in column 28, not here. 
Chronic Pulm. Disease; This entity is coded when a definite 
co-pulmonary disease is diagnosed clinically. An X-ray diagnosis alone 
does not suffice. This category includes such citations on the extraction 
form as "significant emphysema", "CPD", "silicosis", and "pulmonary 
fibrosis". Do not code "asthma" or "bronchitis" unless they are medically 
documented. 
(12) - (15); PRIMARY SYMPTOMS 
The primary symptoms coded in columns 12-15 need not be present at zero time 
and can be coded as long as they have had a distinct existence during the "present 
illness". The TBC entry in column 12 is not a primary symptom, and is included 
here only for convenience in the coding format. 
(12); PARIETAL SX AND TBC 
The term "parietal symptoms" refers to chest pain that is definitely or 
possibly attributable to the lung cancer or to surrounding inflammation. Excluded 
from this coding are a thoracic pain that lasts no more than several hours or a 
pain that occurs uniquely with exertion and subsides with rest. 
The object here is to describe the totality of "suspicious" chest pain 
regardless of whether the totality included one, two or more different types and 
locations of pain. Mote that the 1^, 2 and ^ parts of this coding are used 
addltlvely. Thus, pleuritic and non-pleurltlc pain in a single location would be 
a ^ and two different pains (one pleuritic and one non-pleurltlc) in two separate 
locations would also be When the pleural characteristic of one chest pain is 
known but the pleural aspect of a second pain is unknown, code only the known 
pain. Use the ^ or ^ codes (as described later) only when the pleuritic aspect 
of all existing chest pain is unknown. Note that a chest pain can be coded here 
and also in column 20 when appropriate. 
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When TBC Is coded here, category 2. of column 61 should also be coded unless 
subsequent evidence was obtained to demonstrate that the pre-zero diagnosis of TBC 
was fallacious. The refutational evidence can come from surgery or necropsy. If 
the evidence of TBC occurred only after zero time, or before the "present illness", 
code the 2^ in column 61 and do not code here. Thus, if ^ is coded here and 2^ is 
not coded in column 61, the implication is that the pre-zero diagnosis of TBC was 
erroneous. If TBC is coded here and in column 61, we are left unsure of whether it 
occurred before or during the "present illness". 
1: Pleuritic Chest Pain; A pleuritic pain is one that is noted as 
pleuritic" or "inspiratory (increased with deep breathing, inspiration, 
yawning or straining). A pain that occurred or increased only with 
coughing is not coded as pleuritic if the pain appeared to be due only 
to tracheal irritation (i.e., midline location). 
2: Won-Pleuritic Chest Pain; A non-pleurltic pain is one that was 
cited as "non-pleuritic", or that is specifically stated to have none 
of the characteristics just noted for "pleuritic" pain. 
4: Active TBC; Code this category if tubercle bacilli were demonstrated 
and/or if the patient received deliberately chosen anti-tuberculous 
treatment during the interval between the inception symptom and zero time. 
"Demonstration" of tubercle bacilli includes a positive smear or culture, 
or intra-animal growth. Anti-tuberculous therapy includes treatment with 
INH, PAS, streptomycin or other preparations specified as anti-tuberculous; 
or treatment in a TBC sanitorium with bed rest or other "nutritive" or 
salubrious procedures. 
8: Type of Chest Pain Unknown: Code when the pleuritic aspect of all 
chest pain is iinknown, and there is no evidence of "Active TBC". 
9: Active TBC and Type of Chest Pain Unknown; Code when the pleuritic 
aspect of all chest pain is unknown and the patient has evidence of 
"Active TBC". 
(13) ; BRONCHIAL SX 
Recent Cough: See the earlier comments about "chronic” and "recent" 
in column 11. The term "recent" can refer to an entirely new cough, or 
to a change in pattern of a chronic cough. 
Rust, Blood Streaks, or Hemoptysis: This category can be used for 
any of the various ways in vrtiich a patient can cough blood, such as 
liquid blood, clots, flecks, streaks, or "rusty" sputum. 
Sublective Wheeze; The wheeze should be recent, and subjectively 
noted and reported by the patient, regardless of whether or not a wheeze 
is noted on physical examination. 
(14) ; PARENCHYMAL SX; 
Recent Dyspnea: Before coding, verify that the S3niiptom is both 
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"recent" and "dyspnea" as cited earlier in column 11. In a patient with 
pleuritic chest pain, beware that "dyspnea" has not been reported 
erroneously as a description for shallow breathing or "short-windedness", 
and look for an exertional or positional distinction that can help clarify 
the situation. 
Single Infection; A "single infection" is one that qualifies as 
an infection, as cited in column 15, and that occurred as a continuous 
episode of Illness — even though the manifestations may have fluctuated 
during that episode. The episode is regarded as ended when the patient 
has entirely recovered, i.e., out of hospital, or back to the usual state 
that existed before the episode; after this time, new infectious 
manifestations would be regarded as a "recurrent infection". A reappearance 
of infectious symptoms while therapy is being discontinued or during the 
convalescent period is not regarded as a new episode of infection. 
Recurrent Infection; The patient should have had two or more 
distinct episodes of an illness qualified in column 15 as an infection. 
The episodes should have been separated by a time interval during which 
the patient was not receiving anti-infectious treatment and was in his 
usual state of previous health. If no distinct decision can be made between 
"single" or "recurrent", code the infectious events as "single". 
Note: If _2 or ^ is coded in column lA, a "feature of infection" must 
be coded in column 15. 
(15): FEATURES OF INFECTION 
The object here is to indicate pulmonary infections, not non-specific 
inflammations of the upper respiratory tract. These two topographic entities may 
easily be confused, because after a patient is discovered to have an abnormal 
shadow on chest X-ray, retrospective history-taking may evoke a story of infectious 
symptoms that were not particularly prominent or diagnostropic, and that may have 
been due to upper rather than lower respiratory ailments. The symptoms most likely 
to be truly in the lower respiratory tract are those that evoked the chest X-ray, 
rather than those whose existence was first described after the X-ray was noted 
to contain a lesion. 
Chills, Fever of Sweats: No inherent characteristics of these 
entitles can distinguish their source as a lower or upper respiratory 
infection. These symptoms are likely to be associated with a lower 
infection, however, if accompanied by hemoptysis or significant physical 
findings in the chest, or if they evoked a chest X-ray. Fever occurring 
after the patient was admitted to the hospital should be coded here only 
if cogent. A "cogent" fever is persistent (i.e., more than a single 
isolated reading), high (i.e., more than a minor "spike" above normal range), 
and has sufficient impact on the doctor to evoke specific diagnostic or 
therapeutic measures for it. 
Pneumonia (Clinical Dx): This entity is coded in at least two 
kinds of situation: 
(a) A hospitalized patient has been treated with antibiotics 
for a pulmonary shadow, or the diagnosis of pneumonia has been stated in a 
progress note or on the diagnostic sheet. This definition of "pneumonia" 
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does not pertain to a roentgenographic shadow and/or antibiotic therapy 
associated with unequivocal pulmonary tuberculosis. 
(b) At some time in the past, but still within the time 
boundaries of the "present illness", a non-hospitalized patient was told 
he had "pneumonia". 
Cold or Flu: This is the weakest type of evidence for denoting 
pulmonary infection, and this entry should be coded only in the following 
circumstances: 
(a) In the absence of chills, fever, or sweats, the coryzal 
symptoms acted as a diagnostropic stimulus for the chest X-ray, although 
a diagnosis of cancer rather than pneumonia was made at X-ray. (If the 
X-ray diagnosis was "pneumonia", mark the preceding entry as well as this 
one). 
(b) The patient's symptoms appear related to the lung cancer, 
but are described>no more specifically than "cold" or "flu". 
This entry should not be coded if the patient has only the following: 
(a) A recent cough of the same duration as the "cold" or 
"flu", and no other cited "infectious symptoms". 
(b) One of the cited "infectious S3nnptoms", and/or a clinical 
diagnosis of pneimonia, that has the same duration as the "cold" or "flu". 
An algorithm for coding this entity is shown as a "flow chart" on the 
next page. 
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Flow Chart for Coding "Cold" or "Flu" in Column 15 
Note: Throughout this flow chart, the term "cold" represents either 
"cold" or "flu". 
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(16); OTHER EVENTS 
The entities cited here are assembled in one column solely for convenience 
in the coding format. The category marked _1 (Unresolved Pneumonia) can be "added" 
to either the _2, ^ or _8 category to create a 2. .2. coding; but all other 
categories are mutually exclusive. 
1; Unresolved Pneumonia; Code when a presumptively inflammatory 
lesion (TBC, pneumonia, etc.) fails to resolve on X-ray and the absence 
of radiographic resolution acts as the diagnostropic stimulus for the 
work-up for cancer of the lung. In this clinical situation, the patient 
is initially regarded as having an acute infectious pneumonia, which may 
be viral, bacterial, or tuberculous, and which is confirmed by X-ray. 
After a period of appropriate therapy for the pneumonia, the chest X-ray 
fails to clear, or the lesion may even enlarge. At this point, the 
physician begins to suspect lung cancer and orders a further work-up to 
confirm his suspicion. 
The unresolved pneumonia coding should not be used for the fijllowing 
circumstances; 
(a) The initial X-ray provided a diagnostropic stimulus. 
Such a situation is exemplified by a patient who was treated at home for 
symptoms of infection without roentgenography, and who later shows an 
abnormal shadow on X-ray. 
(b) The diagnostropic stimulus was provided by a positive 
result in the initial sputum pap smear, ordered routinely at the time the 
patient was admitted with pneumonia. 
(c) A change in a long-standing lung shadow. Initially found 
In a routine screening examination or during an episode of pulmonary 
disease, is noted on routine follow-up examination. The change elicits 
a work-up for lung cancer. Because of the temporal remoteness from the 
original discovery of the shadow, its change is not regarded as "unresolved 
pneumonia", and will usually be coded in category ^ of column 10. 
2; Transient Primary Sx; In some patients with primary symptoms only, 
all of the symptoms may have disappeared before zero time. Such a 
circumstance is particularly likely when the symptoms have consisted 
exclusively of hemoptytic, infectious, or pleuritic manifestations or 
various combinations of these. In such situations, the disappearance of 
all previous symptoms, rendering the patient essentially asymptomatic at 
zero time, can be cited here. "Transient Primary Symptoms" is intended 
to deal with such situations as; 
(a) A patient with a single episode of cough and fever six 
weeks ago, and none since then; or 
(b) A patient whose only symptom is recurrent episodes of 
hemoptysis that stopped well before zero time. 
4: Paraneoplastic Syndrome; This category refers to a clinical 
"systemic" syndrome, other than HPO, attributed to products of the tumor. 
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Such syndromes can Include gynecomastia (when attributed to a "hormonal 
effect" of the lung tumor); carcinoid syndrome; Inappropriate secretion 
of antl-dluretlc hormone (vasopressin or ADH); and hypercalcemia. To be 
coded here, the syndrome must have produced distinct clinical symptoms 
or overt signs. If these clinical manifestations were not present, and 
the syndrome was Identified by laboratory evidence alone, the laboratory 
findings should be coded In column 25. The latter situation Is particularly 
likely to occur with h3rpercalcemla or the ADH abnormality. Note that 
"hormonal" neuropathy or neuromyopathy Is not coded In this category. 
6: "Metastatic" Paraneoplastic Syndrome: Certain neurologic 
manifestations are suggestive of a "hormonal" neuropathy or neuromyopathy. 
(E.G. Ataxia and gait disorder without hemlparesls or hemiplegia would 
Imply a cerebellar disorder of uncertain source.) Although a specific 
anatomic metastasis usually cannot be ruled out, such neurologic 
manifestations may be coded here when a "hormonal" cause Is suspected. 
(Do not also code the neurologic entity separately In column 21.) 
Although "distant" sites can be affected In a paraneoplastic syndrome, 
the "systemic" (rather than "metastatic") character of the manifestations 
Is usually denoted by paracllnlcal evidence (e.g., Cushing's syndrome) 
and or by the absence of X-ray or other anatomic evidence of metastasis 
(e.g., hypercalcemia without bone lesions). Such "systemic" manifestations 
are coded In category not here. 
8: Systemic and "Metastatic" Paraneoplastic Syndrome Code this 
category if the patient qualifies for both the ^ and ^ categories of 
coding. 
(17) - (18); SYSTEMIC SYMPTOMS 
In addition to the entitles cited In columns 17 and 18, this class of 
symptoms includes the paraneoplastic clinical syndromes cited in category or ^ of 
column 16. 
(17); GENERAL SX 
Anorexia: This symptom should have been persistent and not just 
a brief period of loss of appetite associated with Infectious symptoms. 
Wt. Loss (as Complaint); To be coded here, weight loss must be a 
chief complaint, or one of the main complaints. It should not have been 
merely a "symptom" noted during routine questioning about the Present 
Illness or Review of Systems. 
Weight loss, particularly when regarded only as a symptom, cannot 
ordinarily have its cited duration used as a significant chronometrlc 
entity for determining such Items as timing of the inception event or 
latrotropic stimulus. For weight loss to have chronometrlc "dignity" 
there must exist evidence to substantiate the duration during which the 
weight loss occurred. Such evidence can consist of one or both of the 
following: (a) regular weight examinations at frequent intervals, showing 
a declining value of weight; (b) an observed change In fit of an appropriate 
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assessed during the alleged period of weight loss. These requirements 
would pertain only when the weight loss Is said to have occurred over a 
long period of time, such as more than six months. A span of less than 
six months requires Individual decisions. If weight loss Is a chief 
complaint, Its chronometric validity Is more acceptable than if It is 
merely a symptom. 
Weakness. Fatigue, or Significant Malaise: "Weakness" here refers 
to general muscular weakness. It does not refer to any localized weakness 
In a single extremity or to the weakness associated with focal Involvement 
of the spinal cord or nerve roots. To be cited here, any one of these 
three symptoms should have been persistent, and not just a transient event 
associated with Infectious symptoms. 
(18) ; HPO [Hypertrophic Pulmonary Osteoarthropathy; sometimes also 
called "Periostopathy"] 
Clubbing Noted by Pt.: Coded here only when the patient reported 
It as a recent (datable) appropriate change in the shape of his fingertips 
or toes. 
Significant Clubbing Noted by M.D.: In an effort to avoid coding 
the many minor variations of fingertips that are cited as clubbing by over- 
eager examiners, clubbing Is coded here only when It Is unanimously agreed 
upon by all examiners or If It has been cited as "4+", "significant", 
"marked", or "unequivocal". 
Joint Pain Due to HPO; The object here Is to restrict the citation 
to an HPO type of joint pain, and to avoid coding joint pains due to 
various arthritides or to neoplastic metastases in bone. Consequently, the 
requirements for coding are; (a) pain in the articular segment of a long 
bone, (b) absence of some other form of joint disease at that site, and 
(c) no X-ray evidence of tumor at the affected site. Note that specific 
X-ray evidence of HPO is not required If the other three requirements are 
fulfilled. If X-ray evidence of HPO is present, requirement (b) can be 
Ignored, but X-ray evidence alone Is not satisfactory for coding in this 
column, i.e., appropriate pain must be present. If X-ray evidence of HPO 
exists without clinical signs or s3niiptoms, code this evidence in column 23. 
(19) - (21); METASTATIC SYMPTOMS 
To be coded in columns 19 through 21, metastatic symptoms must be definitely 
attributable to the cancer. The eligible regions are described In greater detail 
in Appendix B. 
(19) ; MEDIASTINAL SX 
Dysphagia; This entity refers to difficulty after the act of 
swallowing Is initiated. The symptom may also be expressed as "food getting 
stuck", "trouble in swallowing", etc. The coding citation requires that 
the dysphagia be a prominent and persistent symptom, but a positive barium 
esophagram Is not required. 
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Hoarseness (NMVC or NEVC); NMVC refers to "non-moving vocal cord"; 
but a report of "incomplete movement" is acceptable for this designation. 
NEVC refers to "non-examined vocal cord". Do not code this entity if the 
cord is examined and moves; in such a situation, the patient should have 
some other explanation for his "hoarseness", but if none is present, check 
for individual decisions about the coding. Do not code this entity if the 
cord is reported as non-moving but the patient is not reported to have 
"hoarseness" or some other difficulty in phonatlon. 
SVC Syndrome; Refers to svellings of the upper torso (neck and/or 
arms) designated as the "Superior Vena Cava Syndrome". In the absence 
of such swelling, unequivocal or massive distention of visible veins on 
the upper thorax is acceptable evidence. In the absence of the cited 
evidence, an elevated venous pressure alone is not acceptable for this 
coding, and is indicated in column 23. 
(20): REGIONAL METASTATIC SX 
Horner’s Syndrome: This coding requires the diagnostic statement 
of "Homer's Syndrome" o£ such acceptable constituents as unilateral ptosis, 
enophthalmos, miosis, or loss of sweating on the affected side of the face. 
Brachial or Peripheral Arm Nerve SSx; These are manifested in such 
symptoms or observable signs as pain, numbness, tingling, or paresthesias 
in the arm or fingers, or difficulty in moving muscles of the arm or 
fingers. This coding requires simultaneous evidence of tumor in the apex 
of the lung or mediastinum of the affected side. 
Sx in Outer Thoracic Structures; The eligible topographic regions 
are endothoraclc bones (ribs, sternum, thoracic vertebrae), parathoracic 
bones (clavicle and scapula), parathoracic nodes, and chest wall 
constituents (muscles, thoracic nerves, subcutaneous tissue, and skin). 
For a more complete discussion of topography, see Appendix B. To be coded 
here, an Involved bone must be painful, and must have either X-ray 
substantiation of Involvement or a clinical decision to treat it with focal 
anti-neoplastic therapy. X-ray evidence is not required if pain is 
attributed to a non-bony structure in the chest wall. If appropriate, a 
symptom coded here may also be coded in column 12. 
If the patient has reported a palpable thoracic mass, this "symptom" 
is coded here unless it is a non-contlguous subcutaneous mass, in which 
case it is coded as ^ in column 21. A "symptomatic" parathoracic node is 
always coded here, regardless of its contiguity. A thoracic mass noted on 
physical examination is coded appropriately in column 31, regardless of 
whether or not it was coded as a symptom in columns 20-21. When symptoms 
of the spine or spinal vertebrae are not specifically cited as ultrathoracic 
(i.e., cervical, lumbar or sacral) they are assumed to be thoracic (dorsal) 
and are also coded here. 
(21); DISTANT METASTATIC SX 
Non-Thoraclc Bone Pain; The acceptable topographic sites are any 
bones other than those described in column 20 as "endothoraclc" or 
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"parathoracic". In addition to pain, the required evidence Is either X-ray 
demonstration of metastasis (with or without fracture) or a clinical 
decision to treat the affected site with focal anti-neoplastic therapy. 
Peripheral Neuroloelc SSx or Other; The peripheral signs and 
symptoms should not be In the arm, whose manifestations are coded In column 
20. The most common peripheral manifestations to be coded here will be In 
the lower extremities, and can be caused either by direct metastatic 
Involvement of nerves, or by bony or other metastases pressing on nerve 
roots or spinal cord. If the peripheral manifestations are exclusively 
muscular, a "hormonal neuromyopathy" should be considered. 
The "other" part of this category refers to various ultrathoraclc 
manifestations that have been reported as symptoms by the patient, such as 
ultrathoraclc cutaneous or subcutaneous nodules. Manifestations such as 
jaundice (when attributable to hepatic or perl-hepatic metastases), 
pigmentation (when attributable to Addison's disease, presumably caused by 
metastases to the adrenals), or esoteric types of metastatic phenomena, 
are coded here if they are symptomatic or noted as overt signs by the 
examining physician. 
Cerebral Neurologic SSx; The manlfestaticns of cerebral metastases 
should be distinguished from those due to peripheral causes or co-morbld 
cerebral disease. The manifestations that suggest a cerebral lesion 
(in contrast to peripheral causes of neurologic S3nnptoms) are 
lateralization of symptoms to one side of the face, arm, or leg; the 
absence of pain or paresthesia at the affected site; and evidence of 
spasticity (e.g. hemiplegia) in an affected extremity. Manifestations 
regarded as "cerebellar", such as ataxia, are acceptable. Such non- 
lateralized neurologic manifestations as headache, convulsions, 
disorientation, and obtundlty are acceptable as significant cerebral 
phenomena provided they are persistent, and do not occur as terminal events 
In a moribund patient, or In association with other conditions 
simultaneously producing high fever, shock, etc. The attribution of 
cerebral lesions to metastases, rather than other causes, depends on the 
available evidence and on the decisions made by the attending physicians. 
(22); PROBLEMS IN ATTRIBUTION 
This column can be used in two different ways In reference to symptoms of 
tincertaln attribution: (a) to Indicate situations In which such symptoms, having 
been coded in columns 12-18, then served as major determinants of the "staging" 
decision for the clinical group coded in column 23; and (b) to Indicate certain 
"metastatic" symptoms, of uncertain attribution, that were not coded In columns 
19-21. 
If the assignment of clinical grouping depends solely upon the inclusion of 
primary or systemic symptoms of uncertain attribution, category 1^ or ^ is coded 
here. 
1; Primary Sx of ?-Attrlb.; The inclusion of primary symptom(s) of 
uncertain attribution In columns 12-15 may affect the chronometry or 
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circumstances are cited in this category. The coding of this category Is 
Illustrated by the following cases: 
(a) Example of chronometric distinction: In a patient with 
chronic lung disease, the reported Inception event Is a change two years 
ago In his chronic cough. Three months before the admission during which 
zero time occurred, he noted the onset of hemoptysis which has been 
definitely attributed to the lung cancer. The patient has no "systemic" or 
"metastatic" 63rmptoms. Both cough and hemoptysis are coded In column 13. 
The patient will be classified in Clinical Group "Long Pulmonic", solely 
on the basis of the cough, which Is only questionably attributed to cancer 
of the lung; but If the cough were not regarded as a neoplastic symptom, 
the Clinical Group would be _3, "Short Pulmonic". Code 1 in column 22 to 
indicate the chronometric influence of the cough. 
Note; Without the Inclusion of this symptom of questionable 
attribution, the patient's clinical stage would have been higher. 
(b) Example of toponymlc distinction: A patient admitted 
with hemoptysis, chills, fever, and cough is found to have active 
tuberculosis and lung cancer. The symptoms are all coded in columns 12-13, 
but none can be definitely attributed to his lung cancer. He has no 
"systemic" or "metastatic" symptoms, and his clinical group will be 
designated in column 23 as 2^ or according to the duration of the symptoms. 
Code 1^ In column 22 to indicate that all of the "primary" symptoms are only 
questionably attributable to cancer. (The 1^ would not be entered if any 
one of the "primary" S3nnptoms were distinctly attributable to the cancer.) 
Note; Without the Inclusion of the symptomCs) of questionable 
attribution, the patient's Clinical Group would have been lover, since 
he would be asymptomatic with respect to his lung cancer. 
Category 1^ should not be coded if the patient has any "systemic" or 
"metastatic" sjnnptoms that are definitely attributed to the cancer. The 
category should also not be used In the absence of a problem In prlmary- 
S3nnptom attribution, merely to indicate that the coding of Clinical Group has 
been affected by chronometric uncertainty. An example of imcertalnty In 
chronometry but not In symptom attribution Is as follows: 
(c) A patient is admitted with a history of fever, hemoptysis 
and chest pain for three months, according to two observers. One observer 
reports that the patient also has had a cough for three months, while the 
other states that the cough began one year ago. Since the patient has no 
co-pulmonary ailments, all of the primary symptoms are considered definitely 
due to his lung cancer, but according to the first observer, the coding for 
Clinical Group would be "Short Pulmonic" imd according to the second, "Long 
Pulmonic". This chronometric ambiguity, arising solely from observer 
variability. Is indicated only In columns 65-68 
Systemic Sx of ?-Attrlb.; Code here if all symptoms In columns 17, 
18 and category ^ of column 16 are of uncertain attribution, and If no 
metastatic symptoms are coded In columns 19-21. For example, if a patient 
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hemoptysis, and generalized weakness — all of questionable attribution — 
and If be had no other symptoms, he would fall Into the "systemic" category 
In column 23) for clinical grouping. Code 2_ In column 22 to Indicate 
that his "systemic" grouping Is based exclusively on a s3nnptom of uncertain 
attribution. In addition, code In this column, since the attribution of 
all his primary symptoms Is also in question. 
The ^ category In this column Is coded when a "metastatic" symptom of the 
type cited In columns 19-21 was not coded In those columns because It had uncertain 
attribution. 
Metastatic Sx of ?-Attrlb.: If no other metastatic symptom has been 
coded In columns 19-21, an entry here will Imply that a symptom of possible 
metastasis has been excluded from consideration for the clinical group coded 
In column 23. For example. In a patient who has no other metastatic 
manifestations, the symptom of "back pain" may not have been coded In column 
21 because the X-ray was negative and the site was not considered for local 
antl-neoplastlc therapy. A ^ Is entered here to Indicate that this back 
pain, although possibly due to metastasis, was not Included among the 
symptoms used In coding column 23. If another metastatic symptom has been 
coded In columns 19-21, this category may be coded to Indicate that a 
metastatic symptom of uncertain attribution has occurred In a region different 
from that of the entries coded In columns 19, 20, or 21. Thus, In a patient 
who has the t3rpe of back pain just described, and who also has the SVC 
syndrome, a ^ would be coded in column 19, a ^ In column 22, and a ^ In 
column 23. As another example, consider the development of jaundice In a 
patient with cirrhosis who Is also paraplegic secondary to a lower vertebral 
metastasis demonstrable on X-ray. Because It is uncertain whether the 
jaundice Is due to the patient's cirrhosis or to metastatic cancer. It Is 
coded as a ^ In column 22, whereas the paraplegia Is coded as a _2 In 
column 21. 
(23) ; CLINICAL GROUP 
The categories used here were developed arbitrarily for this research. They 
are based on the topon37mlc and chronometrlc spectrum of symptoms during the "present 
illness". The criteria for the categories listed below are found In Appendix C. 
1: "Asymptomatic" 
2; "Long Pulmonic" 
3; "Short Pulmonic" 
4; "Systemic" 
5: "Metastatic" 
(24) : DOCUMENTED WEIGHT LOSS 
Weight loss is not coded here if it Is deliberate (i.e., part of a reducing 
program) or If it is attributable to a reversible co-morbid ailment (such as an 
active peptic ulcer, uncontrolled diabetes mellltus, an Incarcerated hernia, etc.). 
Weight loss that appears to have "stabilized" for a substantial period of time is 
probably not due to the cancer and may have been associated with a reversible 
co-morbld ailment. Significant weight loss associated with a reversible, co-morbid 
ailment Is coded as a 1^ in column 76; minor weight loss associated with such an 
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Significant weight loss (l.e., ^lOZ or >-201bs. If Z not calculatable) that Is 
non-deliberate and "non-reversible" can be attributed definitely or probably to the 
cancer, definitely or probably to a co-morbld disease, or to uncertain attribution. 
Among the co-morbld diseases that can cause non-reverslble weight loss are chronic 
debilitating conditions (severe rheumatoid arthritis, cardiac decompensation, poor 
pulmonary function) or another cancer (chronic leukemia). The co-morbld disease is 
particularly likely to be the cause of a non-reverslble weight loss if the duration 
of the weight loss Is quite long (years) or exceeds the duration of other symptoms 
attributable to the cancer. Conversely, In the presence of a chronic co-morbid 
disease whose condition has shown relatively little recent change, a recent weight 
loss Is probably due to the cancer. If the weight loss Is attributable to a 
"metastatic" manifestation (e.g. cerebral symptoms) that is Itself of uncertain 
attribution, code the weight loss as though It were of co-morbld attribution. 
In coding the categories of minor weight loss (7, and 8 below), distinctions 
of attribution are unnecessary and the appropriate amount can be coded directly. 
In coding the other categories, note that the term "cachexia" (or its congeners as 
listed below) takes precedence over any quantitative categories. If the cachexia is 
due to a non-reverslble co-morbld disease, code 5. 
Weight loss that is coded in categories 1-4 is eligible for usage in coding 
latrotropy (column 9) and Clinical Stage (column 23). Unless the timing of the 
weight loss is precisely docimented (with repetitive weights, etc.), it is not 
eligible for coding in pre-zero chronometry (columns 65-68). 
A complete documentation of weight loss requires three items of information: 
the patient's average ordinary weight, the reported amount of weight lost at zero 
time, and the weight at zero time. (The weight and weight loss noted at the 
admission during which zero time occurred can be used instead of the values at 
zero time). If two of the cited values are kno\m but not the third, the coder may 
calculate the third, if the extractor has not done so already. If all three values 
are known, but do not add up correctly, an individual decision must be made about 
which value to reject. For example, a patient with an average weight of 170 lbs. 
may report a weight loss of 25 lbs., but may weigh 160 lbs. on admission. If the 
sequence of daily weights in the hospital seems consistent, the admission weight 
should be retained, and either the weight loss statement or the average weight 
statement should be rejected. 
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The percentage of wt. loss » 100 x (amt. of wt. loss)/(average usual wt.). 
The coding is: 
0: No wt. loss, voluntary deliberate wt. loss, or wt. loss 
associated with "reversible" co-morbid disease 
In categories 1-4, the weight loss is attributable or probably attributable to the 
lung cancer: 
1: M.D. statement of "cachexia", "emaciated", or "Inanition" 
Code such a statement here, regardless of the quantity of 
weight loss 
2: Wt. loss of > 20% In a relatively short period of time (usually 
6 mos. or less) 
3: Wt. loss of > 20% In a relatively long period of time (usually 
more than 6 mos.) 
4: Wt. loss 10%-<20% or 20 lbs. or more [% not calculatable] 
In categories 5-6, the weight loss Is attributable or probably attributable to a 
non-reversible co-morbid ailment: 
5: Super weight loss (l.e., cachexia or ^ 20%) 
6: Major weight loss (l.e., 10%-<20% or ^ 20 lbs. If % not calculatable) 
In categories 7-8, the weight loss is attributable to either the lung cancer, or to a 
non-reverslble, co-morbid ailment: 
7: Wt. loss 5%-<10% or 10-19 lbs. if % not calculatable 
8: Some wt. loss but not as much as any of the above 
9: Amt. of wt. loss (if any) is UNK 
(25): ANCILLARY DATA 
Certain significant para-cllnlcal findings are coded here: 
Anemia: Criteria are as follows: 
Men: Hct. 37 or less; Hgb. 11.9 or less 
Women: Hct. 34 or less; Hgb. 11.4 or less 
If values for both hematocrit and hemoglobin are given, and only 
one is normal, use the hematocrit value for making the decision. 
Elevated VP: Elevated venous pressure is coded when it is regarded 
as evidence of the SVC S3mdrome, particularly when this VP Is the only 
significant evidence to Indicate SVC. The measurement may have been performed 
in an arm vein or neck vein, and the criteria for coding or not coding it 
will depend on whether a therapeutic decision (radiotherapy, chemotherapy, 
or deliberately no therapy for SVC) was evoked by the result. If no clinical 
evidence of the SVC syndrome is coded in category £ of column 19, and if 
the venous pressure evokes a therapeutic decision for SVC, then the elevated 
VP should be coded here. If no therapeutic decision Is made about SVC, do 
not code here. If clinical evidence of SVC is present, and the syndromes 
receives a therapeutic decision, record the elevated VP if it is abnormal 
according to ad hoc criteria. 
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Hypercalcemia or Other; This category is used to denote unusual 
or striking para-clinical evidence of tumor effects in the absence of 
associated codable clinical signs and symptoms. In addition to 
hypercalcemia, the findings to be coded here include: X-ray evidence of 
HPO; laboratory data suggesting abnormal ADH secretion; para-clinical 
tests suggesting metastasis, such as strikingly abnormal liver fxmctlon 
studies; and a laryngoscoplc finding of "poorly moving vocal cord" in a 
patient who is not hoarse. By convention, thrombophlebitis believed due 
to cancer is also coded here. 
(26): SPUTUM CYTOLOGY; MEDIASTINOSCOPY 
These two unrelated entities are cited together here solely for purposes of 
compactness in coding. A sputum cytology reading of "saliva. Inadequate specimen" 
is regarded as "unknown" for this coding. 
If no mediastinoscopy was performed or if no tumor was grossly visualized at 
mediastinoscopy, code sputum cytology as: 
0: None positive 
1: None positive; at least one equivocal 
(includes "atypical" and "dyskeratotlc") 
2: Only one positive 
3: Two or more positive 
4: UNK or not done 
If tumor was grossly visualized at mediastinoscopy, code sputum cytology as: 
5: None positive 
6: None positive; at least one equivocal 
(includes "atypical" and "dyskeratotlc") 
7: Only one positive 
8: Two or more positive 
9: UNK or not done 
Note: If tumor was grossly visualized at mediastinoscopy, and microscopic 
specimens were not obtained or were read as negative for tumor, code gross 
visualization as ^ in columns 34-35. (See Microscopic Classifications, Appendix D.) 
(27): GROSS PLEURAL FLUID 
Categories _3, _5, and _9 of this column are significant in coding the Anatomic 
Group (Appendix F). Categories 1. - £ refer to ipsllateral effusions; if a- lateral 
primary site of the cancer is not specified, or if the extractor failed to note the 
side of the effusion, assume that the effusion is ipsllateral. If one specimen 
is bloody and another is sero-sangulnous or pink, code the one that was removed 
earliest. If one specimen is normal In appearance and another contains blood, code 
the bloody specimen. 
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0: None noted or no thoracentesis performed 
1: Pleural fluid was noted at physical examination, or was of "major 
proportions" (see criteria for "major proportions" in column 40) 
In the pre-zero X-ray, but no thoracentesis was performed. This 
designation can be used to separate patients with Pancoast tumor 
alone (coded as _! In column 40) from patients with pleural 
effusion (also coded as 1^ In column 40), If the existence of 
pleural fluid Is not coded elsewhere In this column 
2: "Amber", "serous", or "normal" In appearance 
3: First specimen sero-sangulnous or pink 
4: Subsequent pre-zero specimen sero-sangulnous or pink 
5: First specimen bloody 
6: Subsequent pre-zero specimen bloody 
7: Specimen removed but not described 
6: Pleural fluid attributed to cause other than lung cancer. Fluid 
may or may not have been bloody 
9: Contralateral first specimen pink, sero-sangulnous, or bloody 
(28); RESPIRATORY RESERVE 
Test Abnormal; The "test" used for most of the 1953-1964 case 
series Is the MBC (Maximum Breathing Capacity), which Is also called the 
MW (Maximum Voluntary Ventilation). An abnormal MBC value Is <50, 
expressed in liters per minute or in percentage. If MBC is recorded in 
both liters per minute and percentage, choose the value of liters per 
minute for coding this category. If the MBC was not recorded or was not 
used as the critical test of respiratory reserve, use values of "normal" 
and "abnormal" appropriate for the alternative test. 
M.D. Statement re Poor Ventilation; This entity must be cited in 
the record by such phrases as "low respiratory reserve" or "poor 
ventilatory capacity". 
Severe Dyspnea; This category is used for indicating unusually 
severe instances of dyspnea in which the dyspnea itself is life-threatening 
or has highly adverse prognostic connotations. The citations below Indicate 
some, but not necessarily all, of the situations In which this category may 
be coded: 
(a) The magnitude of the dyspnea Is described In such phrases 
as: "extreme", "at rest", "on minimal effort", "marked respiratory distress", 
"sit up all night", "air hunger" or "choking". The term "severe", if not 
further specified, does not alone suffice for coding the category. In 
addition, the cited degree of severity should be present In the absence of 
pleuritic chest pain. 
(b) Orthopnea, progressively worsening, within one month 
before admission, in the absence of pleuritic pain, CHF, or the SVC syndrome. 
(c) A rapidly progressive worsening of dyspnea. Examples 
(not exhaustive) of such a rapid progression are at least two distinct 
transition points in the previous three months; or at least one transition 
point in the previous 3 weeks with continued worsening thereafter. 
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Note; These categories are additive. A normal "test” (MBC > 50 liters per 
minute or percent) or the absence of data from such a test Is coded as making a ^ 
contribution to this column. 
(29) - (30); BRONCHOSCOPY REPORT 
(29); BRONCHOSCOPY FINDINGS 
0; Negative findings for mass 
1; Mass In or above carlna 
2; Mass In carlna and at least one main bronchus 
3; Mass In main bronchus, close to carlna 
4; Mass In main bronchus, not otherwise specified 
5; Mass In main bronchus, at distance from carlna 
6; Mass in a lobar bronchus, not In main bronchus, i.e., RULB, LLLB, etc. 
7; Not done or UNK 
Note; If tumor was grossly visualized at endoscopy, and microscopic specimens 
were not obtained, or were read as negative for tumor, code gross visualization as 
81 In columns 34-35. (See Microscopic Classifications, Appendix D.) 
(30); BRONCHOPATHOLOGY OR LUNG BIOPSY 
0; Test(s) done; none positive 
1: Positive biopsy and cytology 
2; Positive biopsy; cytology not positive, but done 
3; Positive biopsy; cytology not done 
4; Biopsy not done; cytology positive 
5; Biopsy not positive; cytology positive 
6; Positive lung biopsy 
7; No tests done or tests unsatisfactory 
(31); CLINICAL ANATOMIC EVIDENCE 
This section Is used for unequivocal anatomic evidence of metastasis, noted 
as physical signs by the examining physicians. If the manifestations wei'e also 
noted by the patient, they are coded In column 20 or 21 as appropriate. 
Palpable Thoracic Metastasis; This category refers to metastases 
that are palpable In the outer thoracic coverings of bones and chest wall. 
Intracutaneous or subcutaneous nodules in the thoracic region may be coded 
here If contiguously attached to underlying structures such as rib, or 
thoracic muscle; If not contiguous, these are coded as ultrathoraclc In 
the next category below. Parathoracic nodes are coded here if they are 
considered to be Involved with cancer, regardless of their contiguity. 
When a palpable thoracic metastasis Is considered contiguous with the 
underlying primary. Its contiguity Is coded In column 32. When such a 
palpable metastasis Is contralateral to the primary. Its contralaterallty Is 
Indicated In column 33. 
Palpable Surface Metastasis; The acceptable topographic sites are 
those noted In Appendix B as ultrathoraclc, and the acceptable manifestations 
are Intracutaneous, subcutaneous, and/or large lymph node masses, nodules. 
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or lumps regarded as CA metastases. For palpable masses in the thoracic 
region to be coded here, such masses must be described as "cutaneous" or 
"subcutaneous", and evidence of non-contlgulty must be present. 
Liver or Other; A palpated liver can be regarded as Involved with 
tumor if, in the absence of alternative explanations for hepatomegaly, 
one or more of the following conditions are fulfilled: (a) the liver is 
found to be "markedly enlarged" by X-ray; (b) the liver is palpated to be 
"hard" and "nodular", with distinct "large" nodules outlined; or (c) the 
liver is palpated as "hard" or "firm", and at least 10 cm. (5 finger- 
breadths) below the costal margin. The term "other" refers to non-hepatlc 
anatomic evidence of metastasis, such as large masses observed by the 
physician on deep palpation of the abdomen or pelvis. 
(32) - (33); EXTRAPULMONIC MORPHOLOGIC EVIDENCE 
These two columns are used primarily to record visible morphologic evidence 
obtained from sites other than the bronchus or pulmonary parenchyma. The evidence 
can be microscopic (histologic or cytologic) or a gross anatomic description of 
tumor observed during endoscopy or surgical exploration. The categories are 
arranged to record site, contiguity, and laterality of the evidence. The categories 
for contiguity and laterality are used to describe the morphologic evidence coded 
in this column, and also any palpable thoracic metastases coded in column 31. 
Criteria for contiguity and laterality are described in Appendix B. 
If "metastatic surgery" was performed before or at zero time, consult 
Appendix G for decisions about coding it in these columns. 
(32); .... 
Regional Node; Record positive morphologic evidence from a 
parathoracic node, regardless of its location, and/or positive morphologic 
evidence from mediastinal nodes. 
Pleura. Pleural Fluid. Chest Wall or Thoracic Bone; Includes 
positive evidence from any of these sites. Skin or subcutaneous tissue 
is considered as "chest wall" if contiguous to an underlying lesion, and 
as ultrathoraclc if not contiguous. "Thoracic bone" Includes both the 
endothoraclc and perlthoraclc bones. 
Contiguous Involvement; This category is used to "reduce" the 
extensiveness of perlpulmonic and perlthoraclc involvement when Involved 
structures are contiguous with the underlying primary lesion. (See 
Appendix B for a complete discussion of contiguity, and enumeration of 
perlthoraclc and perlpulmonic structures.) This category refers to all 
morphologic evidence (except pleural fluid cytology), coded in categories 
^ and 2^ of column 32, and to the clinical anatomic evidence cited as 
"palpable thoracic metastases" In column 31). Code ^ in column 32 if 
all of the positive entitles cited in category 1^ of column 31 and 
categories ^ and 2^ of column 32 are contiguous with the underlying primary 
lesion. If any of the positive entitles is not contiguous, do not a>de 
category^. Mediastinal nodes, by convention (see Appendix B), are always 
considered contiguous unless the primary is clearly shown to be located in 
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the periphery and to be contiguously involved vith peripheral structures, 
A pleural or parathoracic node biopsy vould not be considered contiguous 
unless the primary were clearly peripheral, and adjacent to the biopsy site. 
(33): .... 
Pericardial Involvement; This category refers to microscopic evidence 
from the pericardium or from pericardial fluid. Its contiguity need not be 
determined. 
Contralateral Site; Code this category for contralateral involvement 
of any one of the entities coded in category ^ of column 31 or categories 
^ or 2_ of column 32. Mediastinal nodes are considered ipsilateral unless 
they are specifically noted to be contralateral. 
Ultrathoracic Site: This category refers to all extrathoracic 
locations. Brain and extrathoracic spinal cord, when involved, are cited 
in column 76 as well as here. In addition to CNS structures, the sites 
to be coded here include; skull, liver, cervical node, non-thoracic 
bone, extrathoracic cutaneous mass, and non-contiguous subcutaneous thoracic 
masses. 
(3^) - (35): PRE-TREATMERT MICROSCOPY 
Use the Designation of Ce3J. Types listed in Appendix D. If the same slide 
has received several positive histologic readings, choose the one closest to, but 
before, zero time, or the one that was regarded as the cell type at zero time. 
If Histologic Discrepancy exists among the readings at several sites, or if 
Histologic Disparity exists among several readings of same slide, code in column 
73. Use Appendix D to determine when two histologic readings are inconsistent 
enough to be called a discrepancy or disparity. 
(36) - (lt2): RADIOGRAPHIC INTERPRETATIONS 
(36); RADIOGRAPHIC DESCRIPTION 
The object of this category is to indicate situations in which the X-ray 
dia^osis at zero time was erroneous, either by omission or commission. 
In categories 2^, and 3 the gross X-ray at zero time was originally read 
as negative. In category the "error" was never rectified, and the film, if later 
reviewed, was still regarded as negative. In category £, the film was later 
reviewed after zero time (when a lung cancer had been Identified at thoracotomy, 
necropsy, or by other means) and the positive finding was noted retrospectively. 
In category 3, a positive pre-zero diagnosis was established only by laminography 
or by radiographic methods other than the standard X-ray. 
In categories 5., and 7., the error was one of commission: a lesion was 
noted at roentgenography, but was regarded and initially managed as something other 
than lung cancer. In all three of these situations, the discovery of the error 
took place after zero time, i.e., at thoracotomy, necropsy, or during the extraction 
and coding procedures. 
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The codes are: 
0: Ko chest X-ray taken [may occur in our "necropsy detection" cases] 
1: Negative X-ray. Even in retrospect, no abnormalities were noted 
2: X-ray positive, in retrospect; diagnosis of 1° CA lung not made 
before zero time 
3: Gross X-ray negative or equivocal; laminograms or other radiographic 
methods positive 
4: X-ray definitely positive, by exclusion 
5: X-ray positive; read, until after zero time, as TBC 
6: X-ray positive; read, until after zero time, as primary intra- 
thoraclc lesion, such as non-tuberculous Inflammatory disease, 
degenerative disease, benign neoplasm, or Hodgkin's disease 
7: X-ray positive; read, until after zero time, as metastatic to lung, 
not 1“ 
(37) - (38): RADIOGRAPHIC LOCALIZATION 
These columns are used for indicating the site of the primary tumor. There 
are two locations to be cited: a lateral side and a vertical site. The vertical 
site should be decided upon first, because its description determines the digit 
used for coding the lateral side. 
If Intrathoraclc metastases exist, their sites are coded in column 40 or 
41. Examples and further comments about X-ray coding are presented in Appendix E. 
Note: If chest X-ray was not taken or was negative for cancer (i.e., no 
lesion seen before zero time), use columns 37-38 to code location of the tumor 
according to the site subsequently discovered in other ways. Order of choice: 
(a) pre-zero bronchoscopy; (b) any other pre-zero reading; (c) surgery; (d) 
post-zero X-ray; (e) necropsy. 
(37): PRIMARY SIDE 
0: Not applicable [X-ray negative or not taken, and no other suitable 
data available] 
1: R. lung, next digit is Lobe 
2: L. lung, next digit is Lobe 
3: R. lung, next digit is Field 
4: L. lung, next digit is Field 
5: Mediastinum only. The next digit should be jO 
7: Both sides involved; or primary side not specifiable. 
The next digit should be ^ 
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(38); VERTICAL LOCATION 
Lobe Code Field Code 
0; Not applicable or UNK§ 
1; Uppert 
2: Middle (or Linguist) 
3: Upper and Middle 
4; Lower 
5: Upper and Lower 
6: Middle and Lower 
7; All 3 lobes 
0: Not applicable or IMKi 
1: Upper 
2: Middle 
3: Hllua or Mediastinum^ 
4: Lower 
5: Vertical site not specified; 
or not specifiable for reasons 
other than those cited in ^ 
and 7 
6; Lung obscured by massive 
opacity 
7: Atelectasis of all 3 lobes 
8: Main bronchus 
(39): MEDIASTINAL INVOLVEMENT 
Definite Hilar Nodes; This refers to involvement of the hllum or 
hilar nodes on the same side as the primary lateral side. If no primary 
lateral side has been identified, and a lateral hllum is Involved, code 
here. If hllum is involved on the other side, code in column 41. If the 
patient has "bilateral hilar involvement", code here and also in column 
41. Do not code if the Involvement is marked minimal, questionable, 
dubious, or uncertain. 
Anatomically, the hllum is a part of the mediastinum, but in the 
designation here and in most X-ray reports, the term "mediastinum" refers 
either to central mediastinal regions that cannot be lateralized to a 
particular hilum, or to superior mediastinal regions located above the 
hilum. Accordingly, the category hilar nodes is not coded if the report 
is only "mediastinal involvement", nor is the latter category coded only 
on the basis of "hilar Involvement". 
If a tumor is marked as arising in a hllum and as Involving an 
adjacent lobe or field of the lung, code that lobe or field in columns 
37-38, and code the hilum here. See Appendix E for examples of this type 
of situation. 
i “ Neg. X-ray, or 5^, or ]_ in column 37. 
t > According to the anatomic circumstances described by the radiologist, the lingula 
can be coded separately as a type of "middle" lobe, or it can be,included as part 
of the left upper lobe. 
f “ To avoid losing information, use this entry only when no other vertical site 
appears Involved. If the tumor "arises in hilum" and appears to Involve a 
distinct vertical site on one side, code that vertical site in column 38, and 
code the hilar "origin" in column 39. 
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The following terms indicate the topographic location of the hilum: 
hilum, hilus, hilar, or any of these terms prefixed by peri- or para-. The 
following terms will indicate Involvement at this topographic site; 
originates, arises, extends from, prominent. Involved, enlarged, widened, 
adenopathy. 
Definite Mediastinal Nodes: The following terms indicate the 
topographic location of "mediastinum'': mediastinum; mediastinal; or any 
of these two terms prefixed by, or associated with, para-, perl-, near 
supra- or superior; para-tracheal; peri-tracheal; tracheal. The following 
terms Indicate Involvement of lymph nodes in this topographic location; 
Involvement, enlarged, widened, adenopathy. Do not code if the involvement 
is cited as minimal, questionable, dubious, or uncertain, or if the 
"widening of the mediastinum" is attributed to vascular or other non- 
neoplastlc causes. 
Do not code this category if the mediastinum is reported as "shifted" 
or "displaced" without a specific statement of involvement by tumor. In 
these situations, there should be a pleural effusion, atelectasis, or other 
explanation for the shift of the mediastinum. 
Mediastinal "Viscera": This designation refers to the specific 
structures topographically designated by the terms: pericardium; esophagus; 
trachea; diaphragm; and the large mediastinal blood vessels — aorta, 
pulmonary artery, and pulmonary veins. Do not code any structure whose 
involvement is minimal, questionable, uncertain, or dubious. The following 
descriptions will indicate Involvement of these topographic sites: 
Pericardium: Involved or effusion, without evidence of 
non-neoplastlc cause. 
Esophagus: Involved, displaced, impinged upon, or narrowed, 
without evidence of non-neoplastlc cause. 
Trachea: Involved or displaced; and not attributed to atelectasis, 
pleural effusion, or causes other than neoplastic nodes or 
direct neoplastic Involvement. 
Diaphragm: Involved, paralyzed, or elevated. The word "paralyzed" 
requires appropriate evidence either from fluoroscopy or 
from films taken in inspiration and expiration. The word 
"elevated" requires a significant amount of elevation, and 
not just "slight". In any of these situations, the 
diaphragmatic Involvement should be caused by an intrathoracic 
cause (rather than an intra-abdominal cause, such as ascites 
or a large liver); and the intrathoracic cause should not be 
attributable to atelectasis, or old inflammatory adhesions 
(often cited as "tenting"). 
Mediastinal Vessels: The involvement will usually be demonstrated 
by angiography. 
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(AO); IPSILATERAL THORACIC INVOLVEMENT 
Do not code questionable involvement of any of the structures cited here. If 
any of the structures in this section is involved by a tumor that caimot be 
lateralized, the Involvement should be coded here. (See Appendixes 6 and E for 
further discussion and examples of coding.) 
Pancoast Tumor or Pleural Effusion; Although coded here when 
appropriate, neither of these entitles is used for the "staging" of Anatomic 
Groups. "Pancoast tumor" is omitted because the term is not applied with 
topographic specificity in radiographic reports. (The involvement of bone 
or chest wall by such a lesion, however, is considered for anatomic staging, 
and is cited in categories 2^ and ^ of this column.) "Pleural effusion" is 
omitted from anatomic staging because this roentgenographlc designation 
cannot alone provide adequate evidence that the effusion is neoplastic. A 
pleural effusion is considered in anatomic staging, however, if it is bloody 
(cited in column 27), or if microscopic evidence shows it to be neoplastic 
(cited in column 32). The following specifications are used for these two 
entitles; 
Pancoast Tumor; Sometimes called "superior sulcus tumor". 
This tumor is located at the apex of the lung, and is characterized by its 
anatomic invasion of bone, chest wall, or neural structures. The Invasion 
is manifested by roentgenographlc evidence, or by clinical evidence of the 
types cited in column 20, and must be cited by name to be coded here. 
Pleural Effusion; Code when the effusion is of major 
proportions. A "major proportion" is of magnitude great enough to obscure 
the lung roentgenographically; or to create respiratory distress; or to 
evoke a therapeutic (rather than purely diagnostic) thoracentesis; or that 
yields 1000 ml. or more on thoracentesis; or that is cited as "large" or 
"moderately large". Do not code if the effusion is reported as "small", 
"minimal", or "confined to the costo-phrenic sulcus". Whenever an effusion 
is coded here, an appropriate positive entry should be made in column 27, 
so that Pancoast tumors can be separated from pleural effusions during 
data retrieval. 
Peripheral Primary or Contiguous Involvement; This category can be 
used for two different purposes. It can denote that a localized tumor has 
a peripheral location or "coin"-llke appearance; alternatively, this 
category can be used to "diminish" the "Isothoraclc" category, below, by 
indicating that the cited Involvement there was contiguous to an underlying 
parench]^! tumor. Radiographic reports should usually state "peripheral" 
or "coin" lesion for "peripheral primary" to be coded here. 
If "isothoracic 8tructure(s)" is coded in the next category below, a 
code here will mean that all of those structures were Involved contiguously. 
If any one of them was Involved non-contlguously, do not code here. This 
"peripheral primary" category will denote a peripheral primary or coin lesion 
only if the "Isothoraclc structure" category is not coded. (A brief 
recapitulation of the use of these two categories appears after the discussion 
of the "isothoraclc" category.) 
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Isothoraclc Structures! The topographic sites to be coded here are 
any one or more of the following: 
Pleura: When reported as "Involved", usually because nodules are 
seen after removal of a pleural effusion. The effusion 
Itself is not coded here. 
Chest Bones: These Include the scapula, clavicle, sternum, ribs, 
and thoracic vertebrae. Code only when one or more of these 
were reported as definitely, not questionably. Involved on 
the X-ray. 
Chest Wall: When soft tissue Involvement is shown on X-ray; clinical 
evidence is coded elsewhere in columns 20 and 31. 
Spinal Cord: Myelographlc demonstration of a mass in the thoracic 
region. 
Distant Parts of Liang: When two different parts of the lung are 
involved on the same side and the involvement is anatomically 
disconnected. This citation will be uncommon, because the 
involvement of several lobes is ordinarily contiguous, and 
%d.ll be cited appropriately in column 38. 
Thus, if "peripheral" is marked present, and "isothoraclc" is not, the result 
means that the patient has a localized peripheral or "coin lesion" tumor. If 
"isothoraclc" is marked present and "peripheral" is not, the result means that the 
patient has non-contiguous involvement of one or more of these isothoraclc 
structures. If "peripheral" and "isothoraclc" are both marked present, the result 
means that one or more "isothoraclc" structures are involved, and that all of them 
are Involved contiguously. 
(Al): CONTRALATERAL THORACIC INVOLVEMENT 
Questionable Involvement or Pleural Effusion: Use this code when 
a primary side has been identified, and when any contralateral structure 
has been cited as having questionable Involvement. This category is also 
coded when a contralateral pleural effusion has been reported. Except for 
topography, the pleural effusion is cited here according to the same 
criteria noted in category 2, of column 40. 
Hilum or Mediastinum: Code when there is bilateral Involvement 
of these structures, or specific Involvement of the contralateral hilum 
or mediastinum. 
Other Contralateral Structures: Code when there is involvement, 
other than hilar or mediastinal nodes, of any definite structure on the 
other side. The candidate structures are lung, pleura (when cited as 
"Involved"), bones, chest wall, and thoracic cutaneous tissue that is 
contiguous to an underlying lesion. 
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(i;2): ULTRATBORACIC IBVOLVEMENT 
Extratboracic Bone; Skull, pelvis, long bone, non-thoracic vertebra. 
Liver or Abdominal Mass; Large liver, abdominal mass, other non-CNS 
extratboracic evidence. 
Other; This category really refers to CNS lesions, such as mass 
on ventriculography or extratboracic myelography; pineal shift. Other 
non-thoracic but non-CNS sites should be coded in either of the two 
foregoing categories. 
(i<3): ANATOMIC GROUP 
This is an arbitrary coding system developed for this research, andlased 
on the topographic extent of the radiographic, microscopic, and gross anatomic 
evidence of cancer available at zero time. Criteria for topographic classification 








ADDITIONAL PROGNOSTIC CO-MORBIDITY 
This column is used to cite prognostically significant conditions not indicated 
in the preceding columns. A condition or associated ailment is regarded as 
prognostically significant if it is expected to have a more unfavorable effect on 
the outcome of the clinical course than is otherwise anticipated. The "associated 
phenomena" considered here can be unusually severe functional effects of the cancer 
itself, or the effects of separate co-morbid diseases. Since prognosis is 
customarily based on length of survival, the designation of "prognostic co-morbidity" 
is used mainly for conditions that can be expected to impair life expectancy. 
The cancer itself may be regarded as having severe functional effects when it 
has caused the patient's actual clinical state to be substantially worse than that 
of other patients with comparable anatomic dissemination and with the same general 
clinical phenomena. For example, consider two patients who both have the same 
primary symptoms and who both have weight loss and fatigue as the only systemic 
symptoms. One of these patients may be ambulatory and otherwise in good health, 
whereas the other patient may be cachectic and bed-ridden. As another example, two 
patients may both have clinical evidence of cerebral metastasis, but one patient 
may have hemiplegia as his only manifestation, whereas the other may be obtunded 
or comatose. In both of these examples, the pairs of patients are classified in 
the same general clinical and anatomic groups, but the second patient in each pair 
was more severely ill and had a significantly worse prognosis than the first. 
Regardless of whether an "associated ailment" is attributed to functional 
effects of the cancer, or to a co-morbid disease (or to both), decisions about 
prognostic co-morbidity are difficult. Research of the type described in this 
coder's manual is intended to quantify the prognosis of lung cancer, but such 
research has not yet been performed for the many co-morbid ailments encountered in 
patients with lung cancer. Consequently, decisions about prognostic co-morbidity 
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must be made as a matter of careful clinical judgment. The Judgment entails 
consideration of both the prognostic Import and the diagnostic attribution of each 
of the candidate phenomena. To establish precedents, maintain consistency, and 
develop specific criteria for making these decisions, a "running log" should be 
kept of all auch decisions, recording the salient data and reasons for each decision. 
Certain situations encountered In medical records can be Immediately regarded 
as evidence of prognostic co-morbldity. Such situations Include the following: 
(a) Statement by the attending M.D. that the patient had a 
llfe-threatenlng co-morbld disease or that the cancer In this particular case 
carried an exceptionally poor prognosis. 
(b) The patient's condition was bad enough to prevent a suitable 
diagnostic work-up for the cancer. 
(c) The "associated ailment" was severe enough to prevent a decision 
about antl-neoplastlc therapy. The absence of an antl-neoplastlc therapeutic 
decision need not be due, however, to overt co-morbidity. The patient may have 
died suddenly or unexpectedly (category ^ In column 60), or a therapeutic decision 
may not have been made only because the primary site of the cancer was unknown; 
such Instances are not coded as prognostic co-morbldity. 
Other situations encountered In medical records can often be Interpreted as 
evidence of prognostic co-morbidity. In such situations, a co-morbid condition has 
been cited as the M.D.'s reason for rejecting a therapeutic agent (such as surgery) 
that might otherwise be desirable. The clinical judgment about such conditions Is 
subtle. For example, multiple previous myocardial Infarctions would be regarded as 
prognostlcally significant, although a single, temporally distant myocardial 
Infarction would not. Congestive heart failure. If manifested by peripheral edema. 
Is almost always prognostlcally significant, but may not be, if manifested only by 
dyspnea. 
In many cases, a definite diagnostic attribution cannot be made for a 
prognostlcally significant condition. The condition may have been due to the cancer, 
to a co-morbld disease, or to both. We ascribe prognostic significance to a co-morbld 
disease only when the disease was diagnosed as definitely present and when the 
prognostlcally significant condition was attributable to the co-morbld disease. Thus, 
If the problem In attribution Is that the condition might equally be due either to 
the cancer or to the co-morbld disease, the co-morbld disease would not be coded 
here. However, In the Instances where the particular prognostic condition Is 
regarded as caused by both the cancer and the co-morbid disease, then the co-morbid 
disease should be coded as well. Thus, If a condition is considered to be 
prognostlcally significant, the following principles may be used to decide the 
category for its coding here: 
(a) If prognostlcally significant manifestations — other than 
extreme weight loss or severe dyspnea — have been coded In any of columns 12 
through 21, code jL In column 44. If any of these manifestations are conjunctively 
attributed to a definitely identified co-morbld disease(s) code ^ and/or ^ as 
appropriate In coltimn 44. 
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Bease(s), code the dlsease(s) appropriately as 2 and/or ± In column U. 
Categories i., 2, and ^ are further defined as follows; 
looR . °5 Effects; Do not use for re-coding extreme weight 
Use fo7’c7dine Inv“oth dyspnea (4, 5, 6, or 7 in colu^ 28). 
thro..!h “y other symptom that has already been coded tn columns 12 
iTfeTs IrL r.T,Tl " "" prognostically significant? suL 
«uHi L“:r rdJLf'?M ^ 
thrchest: discernible on the initial (pre-thoracentesis) X-ray of 
j-^goi^ioent. Cardiovascular Disease: With the prognostic and 
en?ItJ?? a^.'^^st^i^^'o^r «^rlier, this category may include such 
f other types of cerebrovascular accident, malignant 
^^d m???;n??’n congestive he^t f^^^^re. 
and multiple past episodes of myocardial infarction. 
Other Co-Morbid Conditions; With the prognostic and attribution 
a?^adv^'^^''H°°^ earlier, this category is coded for such conditions 
disease, it is coded accordingly a^^ror^A?*^ conjunctively attributed to a co-morbid 
(A5) - (46); CONTRA-THERAPY REASONS 
s srS;:2 
some?imS? be InfL^d as ^ ^ "metastasis of tumor" can 
v„ pdrtoSd!“iur«.fd^unrn^lTl'lMtIri’"““T ‘ rdsdctlod 
”SSiSE££EJ£ 
Tniic^ Ka u ^ m tn€ ]r63Sons fo]r dcfcrnifint of sinrfifiirv 
L^LLlo?" ir:;ea“?L"?" a r TiTcol±^l'^^,^ « 
coded in one of these two columns! “if a patient is 
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The contra-therapy reasons are divided into "oncogenic" ones that are directly 
or probably related to cancer, and "non-oncogenic" ones that have other origins. 
This separation is somewhat arbitrary, and used mainly for convenience in 
classification. 
Of the oncogenic categories cited in column 45, the first two are clearly 
associated with the cancer. The third can be coded if imusually severe symptoms, 
coded in columns 12-21, were cited as a contra-therapy reason. 
Note: Entries coded in columns 43 and 46 need not always be prognostlcally 
"significant". Such situations can occur when a patient appears to be in relatively 
good condition despite an anatomic metastasis or a co-morbld disease (such as recent 
myocardial infarction) that may be regarded as contra-indication to therapy. 
(45); ONCOGENIC 
Juxta-Carlnal or Cell Type: These two unrelated entitles are coded 
together here solely for convenience in format. 
Juxta-Carlnal! Refers to circumstances in which pulmonary 
resection is regarded as technically unfeasible because the tumor is located 
in or near the carina, or because the main bronchi are involved by adjacent 
hilar or mediastinal nodes. 
Cell Type: Refers to circumstances in which surgery was 
rejected because the "tumor is too anaplastic" or when "insensitive cell 
type" was cited as a contra-radiation reason. This category may also 
be coded if a mode of treatment was contra-indicated by lack of microscopic 
evidence of cancer. 
Metastasis of Tumor: Refers to any clinical or anatomic manifestation 
indicating metastasis or spread of the cancer, or M.D. statement that 
suspicion of metastasis prevented therapy. 
Functional Severity of Tumor Effects: To be coded when the unusually 
severe effect of a particular eymptom(s) or the adverse systemic effect of 
the tumor is cited as the contra-therapy reason. This entry may also be 
used when a local anatomic effect, such as a pulmonary abscess, is used as 
a surgical contra-indication. 
(46)! NON-ONCOGENIC 
Low Respiratory Reserve: Code whenever this condition has been cited 
as a contra-therapy reason. The condition may have been described by a 
suitable entry in column 28, or in such alternate phrases as "poor 
ventilatory capacity", "Impaired pulmonary function", or "severe dyspnea". 
If the condition is due to an associated pulmonary disease, the functional 
effect of that disease will be adequately noted here and the disease should 
not be coded as "co-morbld disease" in the next category of this column. 
Co-Morbid Disease: Code whenever a co-morbld disease has been cited 
as a contra-therapy reason, with the exception of solitary dyspnea, as just 
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noted. "Poor nutrition", if not due to effects of the cancer, is regarded 
as a co-morbld disease. 
Other; This category Includes such "non-disease" entities as age 
and obesity. The category may also denote a situation in which the cancer 
was untreated because the primary site was unknown or a definitive diagnosis 
was not established. Whenever this category is used, the coder should 
record the specific reason on the coding form Itself. 
(A7) - (48): THERAPEUTIC PROCEDURAL DECISIONS 
The coding here depends on the sequence in which treatment was actually given, 
regardless of the therapeutic event chosen to be zero time, as described in 
Appendix A. Conventions for coding metastatic surgery are provided in Appendix G. 
Another coding convention deals with "paired treatment", which refers to two 
(or more) different therapeutic agents chosen on the basis of evidence describing 
a single cllnlco-anatomlc state. The agents are planned to be delivered 
sequentially or concomitantly without any intervening change in the patient's 
condition. Examples: 
(a) At thoracotomy, decision is made to follow the surgery with 
radiation to the primary site. In this pair, surgery is the first element and 
radiation, the second. If the thoracotomy were followed by both radiation and 
nitrogen mustard, the second element of the pair is the doublet of primary 
radiation and cytotoxic. 
(b) At bronchoscopy, tumor is judged too close to carina. Decision 
is made to irradiate and then do surgery. If the surgery is performed regardless 
of post-irradiation effects, it is the second element of the pair. If the 
mediastinal nodes or other manifestations must regress in order for the surgery to 
be done, it is a separate second course of therapy, not a paired part of the first 
course. 
(47); FIRST THERAPEUTIC ACTION 
If the first antl-neoplastlc treatment cited in column 47 was an alternative 
to a previously refused agent, the patient's previous refusal is coded with ^ in 
column 48; if the previously offered treatment was thoracotomy, it is also coded 
as ^ in column 49. If a paired treatment was planned to follow the treatment coded 
in column 47 but was not given, code _3 in column 48 and, if appropriate, ^ in 
column 49. If ^-9^ is coded in column 47, a in column 48 indicates paired 
therapy. If ^ or _3 is coded in column 47, a in column 48 indicates the 
treatment that was planned or offered, but not given. 
In a patient who has received no antl-neoplastlc treatment, the medical 
record may not contain a specific statement that clearly indicates whether £ or 1^ 
should be coded in this column. The type of decision is often implied, however, 
by clues in the pattern of events. Thus, if microscopic evidence of cancer was 
obtained at a time when the patient was not obviously moribund, the doctors probably 
decided not to treat. On the other hand, if the diagnosis of cancer was never 
established, or if microscopic evidence had not been obtained, it is likely that 
no therapeutic decision was made by the doctors. 
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0: No treatment. No decision made by M.D. re treatment (patient died 
too soon, or was a necropsy surprise, or work-up was Incomplete) 
1: No treatment. M.D. made decision to give no antl-neoplastlc treatment 
2: No treatment. Patient refused to accept antl-neoplastlc treatment 
offered by M.D. [Code the offered treatment In column 48] 
3: No treatment. M.D. planned to give antl-neoplastlc treatment but the 
plan was not carried out for reasons other than patient refusal. 
[Code the planned treatment In column 48] 
4: Thoracotomy 
5: Primary radiation (to lung and/or mediastinum) 
6: Cytotoxic (Includes HN2, systemic radlo-lsotopes, TEM, 5 FU, etc. 
Does not Include antibiotics, narcotics, sedatives, etc.) 
7; Primary radiation and cytotoxic 
6: Radiation to metastatic site (Includes Intrapleural radiotherapy) 
9: Local treatment of metastatic site, with surgery or cytotoxic 
therapy (for the coding of metastatic surgery as opposed to 
metastatic biopsy as zero time events, see Appendix A) 
(48); OTHER THERAPEUTIC CONSIDERATIONS 
0: None (no paired treatment, or not applicable) 
1: Patient refused diagnostic work-up 
2; Patient refused M.D.’s first therapeutic offer, but accepted and 
received the alternative treatment coded In column 47 
3: A paired treatment was planned to follow the treatment coded In 
column 47, but was not given because patient refused, his 
condition changed, or he died too soon. If the planned paired 
agent was thoracotomy, code ^ In column 49 
4: Thoracotomy 
5: Primary radiation (as specified In column 47) 
6: Cytotoxic (as specified In column 47) 
7: Primary radiation and cytotoxic 
8: Radiation to metastatic site (as specified In column 47) 
9: Local treatment of metastatic site (as specified In column 47) 
(49) - (53): SURGERY 
Columns 49-53 are coded whenever thoracotomy Is performed, regardless of 
when It occurred In the sequence of therapy. If two thoracotomies were performed, 
use these columns for the thoracotomy that first removed the main tumor. If 
thoracotomy was not performed, category ^ of column 50 and columns 51-52 may be 
used to describe metastatic surgery. 
(49)! SURGICAL PROCEDURE AND INTENT 
If the patient previously refused thoracotomy but later accepted It, disregard 
the earlier refusal In coding column 49. 
"Palliative" Is used here If this purpose was evident before or during the 
operation. Removal of the lingula alone Is coded as a lobectomy. Removal of lingula 
and another lobe Is coded as bllobectomy. 
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0: Not applicable (no surgery to lung) 
1: Thoracotomy; no excision of main tumor 
2: "Palliative"; lobectomy or less 
3: "Palliative"; bllobectomy 
4: "Palliative"; pneumonectomy 
5: No statement that surgery was "palliative"; lobectomy or less 
6: No statement that surgery was "palliative"; bllobectomy 
7: No statement that surgery was "palliative"; pneumonectomy 
8: Patient was offered thoracotomy, but refused; or planned 
thoracotomy was not performed for reasons other than 
patient refusal 
(50) : FURTHER SURGICAL DESCRIPTION 
Except for category which might be based on surgery to a metastatic site, 
this column is coded for the surgical procedure noted in column 49. 
Other Structures Excised, or Involved but 1** not Excised; The 
topographic sites coded as "other structures" are: pericardium, major 
vessels, and such chest wall structures as parietal pleura, ribs, and 
muscle. Mediastinal or hilar lymph nodes, and visceral pleura are not 
"other structures". Code as 1^ if any of these structures were exised, 
or if any of these structures were noted to be grossly involved in a 
patient who had no excision of the main tumor. Do not code if these 
structures were Involved but not excised in a patient whose main tumor 
was excised. 
Post-op. Complications; A "complication" consists of dehiscence, 
wound Infection, or major surgical difficulties. A major intra-operative 
problem, such as a period of cardiac arrest, can also be coded here. 
Op. or Post-op. Death; The "post-operative" period ends when the 
patient is either discharged or transferred, for care of some other 
problem, to another service in the hospital. (E.G. Two days after surgery, 
patient becomes comatose; he dies after remaining in this state for two 
months. This situation is coded as a post-operative death.) If thoracotomy 
is not performed, this category can be used to code post-operative death 
after surgery to a metastasis. An "intra-operative" death (during 
operation or in the operating room) is coded as "sudden" in category 2^ of 
column 60. Post-operative deaths may or may not be "sudden", according to 
the sequence of events. See further remarks in column (60). 
If surgery has not been performed, this category may be used to code 
a "diagnostic death", occurring after bronchoscopy, liver biopsy, or some 
other procedure in the diagnostic work-up. 
(51) - (52); SURGICAL HISTOLOGY 
Use Designation of Cell T3rpe6 listed in Appendix D. 
Ignore readings of frozen sections, unless they provide the only positive 
histologic evidence. 
If several readings are available for a slide, choose the initial reading for 
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the slide, or the one on which a post-therapeutic decision was based. If subsequent 
review produced a disparate reading, code ^ In column 73. 
(53); SURGICAL PAniOLOGY 
This column contains a combination of the surgeon's report of gross neoplastic 
"spread" to lymph nodes or other structures beyond the pulmonary parenchyma, and 
the pathologist's microscopic findings of tumor extent. For the purposes of this 
column, the term "spread" Is not applied to a surgical report of metastasis to 
another part of the same lung, or a microscopic reading of lymphatic or blood vessel 
Invasion within an excised lobe. If no thoracotomy was performed, code for all 
other situations except category we assume that the surgeon either saw or 
palpated primary tumor. The codes are; 
0; Not applicable, no thoracotomy performed; or surgeon reports 
no spread to lymph nodes or other structures; pathology report 
is unknown (nodes and other structures not removed or removed 
but not reported). 
1; No tumor of any t3rpe (primary or beyond primary) noted at surgery. 
2; Surgeon reports no spread to lymph nodes or other structures. 
Pathologist reports nodes negative, other structures negative 
or not examined. 
3; Surgeon reports spread to lymph nodes and/or other structures. 
Pathology report Is unknown (nodes and other structures not 
removed, or removed but not reported). 
A; Surgeon reports spread to lymph nodes and/or other structures. 
Pathologist reports nodes negative, other structures negative 
or not examined. 
5: Surgeon reports spread to lymph nodes only, no spread to other 
structures. Pathologist reports only one node positive, other 
structures negative or not examined. 
6; Surgeon reports spread to other structures; lymph nodes may be 
grossly positive, negative or not mentioned. Pathologist 
reports only one node positive, other structures negative or 
not examined. 
7: Surgeon reports spread to lymph nodes only, no spread to other 
structures. Pathologist reports more than one lymph node 
positive (or imspecified number positive), other structures 
negative or not examined. 
8; Surgeon reports spread to other structures; lymph nodes may be 
grossly positive, negative or not mentioned. Pathologist 
reports more than one node positive, other structures negative 
or not mentioned. 
9; Surgeon's report re spread may be positive or negative. Pathologist 
reports spread to other structures. l3nnph nodes may be positive, 
negative or not reported. 
(54); SUBSEQUENT TREATMENT 
This column is intended to record all of the modes of anti-neoplastic treatment 
that were given after the first course of treatment, regardless of the sequence In 
which these agents were given. 
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Surgery to Primary Site; This category refers to an exploratory 
thoracotomy, with or without resection. In the therapeutic sequence of 
primary radiotherapy followed by thoracotomy, note the distinction, listed 
in column 47, that demarcates a "paired" sequence from two individual 
courses of treatment. If primary surgery occurs as a "subsequent" 
treatment, mark this category; then code the surgical procedure in column 
49, its further description in column 50, and its histologic findings and 
pathology in columns 51-53. 
Radiation to Primary Site; "Primary" radiation refers to treatment 
directed at the pulmonary parench3mia or mediastinum, not pleura or ribs. 
Systemic or Metastatic Treatment; This category Includes: systemic 
or focal cytotoxic agents; radiation directed at ribs, pleura, or 
ultrathoracic structures; and such exploratory or excising surgical 
procedures as cr£mlotomy and laminectomy, if a significant amount of tumor 
was removed. 
(55) - (56): SUBSEQUENT CLINICAL EVIDENCE OF METASTASIS OR RECURRENCE 
The three main categories in these two columns are Identical in contents. 
They differ only in their attribution as being "certain" in column 55 and "uncertain" 
in column 56. 
The distinction between a "certain" and "uncertain" diagnostic attribution 
for post-zero events requires the same type of diagnostic judgments used for 
appraising the attribution of pre-zero events, except that the post-zero judgments 
are further complicated by the following: (a) side effects of anti-neoplastic 
therapy (e.g., radiation esophagitis); (b) occurrence of events outside the index 
hospital; and (c) problems of differentiating events due to debilitated or terminal 
state from those due more directly to cancer or to an associated disease. No 
specific set of rules for these judgments can be stated briefly, and many of the 
decisions will be made on an ^ hoc basis. A "running log" should be kept of these 
decisions so that precedents can be established, and consistency maintained in 
subsequent codings. 
The remainder of this discussion will deal with toponymic distinctions in 
the three categories. 
New Endopulmonlc or Systemic Manifestations of Tumor: This category 
is used for noting certain types of evidence that cannot be cited in the 
morphologic categories of column 57. Among the entities are: 
(a) Hemoptysis in a patient who has not had it before zero 
time, or who has it after conclusion of the post-operative period that 
followed resection of the primary tumor. If the hemoptysis appears to 
have been associated with a pneumonia, code as ?-attribution; if the 
pneumonia occurs at a non-neoplastlc site, do not code the hemoptysis. 
(b) Appearance of HFO or of paraneoplastic s3mdromes that 
had not been present before zero time. If the only evidence of a new 
paraneoplastic s3mdrome is para-clinical, without clinical manifestations, 
do not code here; code as Special Note in column 73. 
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(c) Anatomic evidence of endopulmonlc recurrence on the same 
side as that of a surgically-removed tumor; or anatomic evidence of metastases 
to other parts of the ipsilateral lung. Evidence obtained from biopsy, 
surgical exploration, endoscopy, or unequivocal roentgenography is coded as 
attribution certain. Evidence from cytology is coded as ?-attrlbutlon. 
New Evld. of Thoracic Involvement; This category is used to denote 
new clinical manifestations that suggest the thoracic metastases described 
by the findings listed in columns 19 and 20, and in category ^ of column 
31. A new manifestation is not cited here if a previous manifestation had 
already occurred in the same general region. Thus, the new appearance of 
hoarseness [NMVC] would not be cited here for a patient who previously had 
SVC syndrome without hoarseness, because both manifestations are "mediastinal" 
on the other hand, the new appearance of a Homer's syndrome would be coded 
here for such a patient, because it is "regional". 
Development of a post-zero pleural effusion in the absence of a 
pre-zero effusion is coded with a ^ in column 55 if the effusion is large 
or massive on X-ray or physical examination and is bloody or pink and/or 
the cytology is positive. Code 2^ in column 56 if the effusion is massive 
or large on X-ray or physical examination, but is non-bloody and its 
cytology is negative. If the pleural fluid cytology is positive, also code 
3^ in column 57. The cytology may be coded in columns 58-59 if warranted. 
New Evld. of Ultrathoraclc Involvement; This category is used for 
new clinical manifestations that would be regarded as ultrathoraclc, according 
to the list of entitles cited in column 21 and in categories ^ and ^ of 
column 31. Each new manifestation coded here should be in an anatomic 
location in which such manifestations have not been previously coded. For 
example, if a patient with pre-zero headache and seizures, attributed to 
cerebral metastases, develops post-zero hemiparesis, also attributed to 
cerebral metastasis, the new event would not be coded here. 
(57): SUBSEQUENT NEW MORPHOLOGIC EVIDENCE 
This column is intended to cite positive post-zero morphologic evidence in 
locations where no positive evidence of cancer was found before zero time. 
Topographically, the locations are in sites other than the Ipsilateral endopulmonlc 
parenchyma. Anatomically, the evidence consists of biopsy, cytology, gross 
visualization of tumor at surgery, or an unequivocal roentgenographic reading. (A 
positive specimen in sputum bronchoscopic materal, lung biopsy or other ipsilateral 
parenchymal morphology could be coded, if warranted, in columns 58-59.) 
Isothoraclc; Refers to midline structures (mediastinal nodes, 
pericardium, esophagus, sternum, thoracic vertebra); or ipsilateral 
endothoraclc structures (pleura, chest wall, ribs); or ipsilateral 
perlthoraclc structures (scalene node, clavicle, etc.). 
Note; A pleural effusion by X-ray or physical examination is not 
positive morphologic evidence unless microscopically demonstrated to be 
neoplastic. 
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Contrathoracic: Refers to any neoplastlcally involved structure on 
the side of the chest opposite the primary. If a primary side has not been 
established, use category ^ for denoting Involvement of midline or lateral 
thoracic structures. 
Ultrathoraclc; Refers to any structure outside the thorax or its 
coverings. The topographic sites are listed In column 42 and Appendix B. 
(58) - (59); SUBSEQUENT MICROSCOPIC EVIDENCE 
This column Is Intended to denote the most convincing microscopic evidence 
of cancer that was found after zero time, but before necropsy. The order of 
preference for specimens and for sites Is listed In Appendix D. 
(60); MODE OF DEATH 
Circumstances Unknown; This category refers to a situation In which 
we do not have specific Information about the terminal events In a patient 
who did not seem moribund In the last known follow-up examination. If we 
do not know whether the patient Is dead or alive, do not code here; code 
as a ^ In column 69. In the criteria cited below, the word "advanced" 
refers to a situation In which the patient, when last examined, had evidence 
of disseminated cancer. 
Criteria for Coding "Unknown" In (60) 
PATIENT'S STATE 
WHEN LAST NOTED 
TIME BETWEEN LATEST 
FOLLOW-UP DATE AND 




"Advanced" > 6 mos. Unknown 
"Advanced" < 3 mos. Not Unknown 
"Advanced" > 3 but < 6 mos. Individual decisions 
Sudden or Unexpected; This category refers to a situation In which 
the patient was not specifically moribund at a particular moment, and then. 
In the next moment, the patient was either dead, or entered Into a 
continuous sequence of rapid, adverse events that ended In death. Examples; 
gunshot suicide; exsanguinating hemorrhage; "coronary"; "stroke"; "dropped 
dead"; sudden a8ph3rxla. In addition to the situations just cited, any 
Intra-operative death is coded here. A post-op. death may be also coded If 
the sequence was sudden and rapid. Because a patient Is so vulnerable 
during the post-op. period, the "suddeness" must be particularly distinctive 
to be recorded here, whereas a somewhat slower course may be acceptable as 
"sudden" for a patient who Is not In the post-operative period. 
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Definitely or Probably not Pue to CA Lung: This category Is based 
on clinical, not necropsy, evidence; and the necropsy data should not be 
used for this decision, even If the decision Is thereby erroneous. The 
most obvious kind of extraneous lethal cause Is suicide or externally 
Inflicted trauma. Other examples are an unequivocal myocardial Infarction 
or a stroke (with a rapid onset and rapidly fatal resolution). If no data 
are available to describe the terminal events, the diagnosis recorded on 
the death certificate suggests an extraneous lethal cause If the recorded 
diagnosis Indicates such a cause, while either omitting any mention of 
cancer, or citing the cancer In a minor position on the certificate. 
(61); ASSOCIATED DISEASES 
Coexistent Other Cancer; This category refers to any other primary 
cancer (Including another separate primary cancer of the lung), that was 
identified at any time In the clinical course. Including necropsy. 
Leukemia or other hematologic neoplasms are regarded as cancers, as are 
certain benign tumors so designated by the checker (e.g., neurofibroma), 
but basal cell cancer of the skin and Kaposi's sarcoma are not regarded 
as cancers. 
Coexistent Tuberculosis; This category refers to the occurrence 
of a clinical episode of pulmonary tuberculosis, regardless of when It 
appeared In the clinical course; before the "present illness", during 
the "present Illness", or In the post-zero interval. If evidence was 
obtained to demonstrate that the diagnosis of TBC was fallacious, do not 
code here. 
Necropsy Detection; This category refers to a situation In which 
the primary site of a lung cancer was first detected at necropsy. The 
detection could be a complete "surprise" (In which case a jO Is also entered 
in column 9); or an "Identification", In which disseminated cancer was 
demonstrated or suspected during life, although a primary site was never 
established. 
(62); NECROPSY FINDINGS 
A necropsy Is considered "unrestricted" If it includes the thorax and abdomen, 
regardless of whether or not the head Is examined. A "restricted" necropsy Is 
confined to the thorax alone, abdomen alone, or bead alone. 
The following definitions are used for the terms cited in the coding; 
"Tumor In thorax"; Anywhere Inside the chest. Including chest 
wall and upper surface of diaphragm. 
"Minimal amount of tumor elsewhere"; Scattered deposits here and 
there; not enough In any single location per se to have been a major 
cause of death. 
"Significant amount of tumor elsewhere"; Strategic location 
(e.g., brain, both adrenals replaced) or quantity (e.g., massive 
replacement of liver) to have been a major contribution to the cause 
of death. 
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0: Not applicable (no necropsy done or no data available) 
1: No tumor present 
2: Tumor present, confined to thorax 
3: Tumor in thorax; minimal amount of tumor elsewhere 
4: Tumor In thorax; algtilfleant amount of tumor elsewhere 
5: No tumor In thorax; minimal amount of tumor elsewhere 
6: No tumor In thorax; significant amount of tumor elsewhere 
7: Necropsy restricted to thorax; tumor present 
8: Necropsy restricted to thorax; no tumor found 
9: Necropsy restricted to non-thoraclc site (the findings are 
not coded) 
(63) - (64); NECROPSY TISSUE 
Use the Designation of Cell Types listed in Appendix D. 
If several different types of tissue are sientloned at different locations, 
code the discrepancy In column 73. To choose which specimen to code here, use 
the following order of preferential topographic sites: primary parenchymal site; 
any endothoraclc site; intra-abdomlnal sites; other. 
(65) - (72): INTERVALS 
A critical Issue In determining these Intervals Is the selection of zero time, 
which Is discussed In Appendix A. A problem arises when a patient has received 
thoracotomy as the second element of a pair or In a subsequent course of treatment. 
For the particular interests of our research In comparing the results of surgical 
therapy, we have taken the thoracotomy, whenever It occurred, as the date of zero 
time for coding the intervals In colinnns 65-72. This convention does not alter 
the chronological order In coding columns 47, 48 and 54. 
The two chronometrlc intervals cited In these 8 columns should be recorded 
in months, with the decimal point placed as shown in the form. Do not enter another 
decimal point. A conversion table for changing weeks or days to months Is contained 
in Appendix H. If there are two figures to the right of the decimal point, round 
off appropriately to one figure. (6.34 -► 6.3; 6.25 -*■ 6.3; 5.95 -► 6.0; 5.85 -*• 5.9). 
(65) - (68): PRE-TREATMENT INTERVAL (* TO ZT) 
The selection of the"*" event is described in Appendix A. 
When the interval can be exactly specified: code directly 
Examples 




If the interval is more than 199.9, code as 199.9 
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When the interval cannot be specified exactly, use the following conventions: 
Maximutps (<): For a single Interval code a ^ In column 65, and 
the value In columns 66-68. For example: 
<3.6 mos. Is coded as j 2 ^ 13 . 6 ; 
If the maxlmim Interval Is longer than 99.9 months, code as 299.9. If more 
than one interval la possible, use the convention below for coding uncertain 
intervals. 
Mlnlmums (>): For a single interval, code a "3" in column 65, and 
the value In columns 66-68. For example: 
>12.3 mos. is coded as 31 ^ 
If the minimum interval Is at least 99.9 months, code as 399.9. 
Uncertains: If the interval Is uncertain (l.e., two or more values 
are distinctly possible), code the largest value up to 99.9 months in 
columns 65-68. If larger than 99.9, code as 99.9. Note that a "metastatic" 
symptom of questionable attribution (coded in column 22) is eligible for 
coding in this column only If it Is the shorter of two candidate intervals. 
Then use the following code for column 65: 
Value of Smallest Interval Code Column 65 As: 
0 - <3 mos. 4 
3 - <6 mos. 5 
6 - <9 mos. 6 
9 - <12 mos. 7 
12 - <the other value In mos. 8 
Examples: 
Value of * to ZT 
40.6 or 2.4 mos. 
240.6 or 12.6 or 5.7 mos. 
5.8 or 1.2 mos. 
14.5 or 7.67 mos. 
58 or 11 mos. 
24 mos. or 48 mos. 
Code As: 
4 4 :0 , 
1 ■ ! 
T o' jT'i 
"T i' 4 
T~ ~5 8 







None: If patient had no "* to ZT" Interval, as will be the case for 
those with a ^ or ^ In column 9, code the duration of the to ZT" interval. 
(The to ZT" interval Is described In Arch. Intern. Med. 123: 571-590 
(May), 1969.) 
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Unknowns; If the interval le unknown, code as 999.9. (This situation 
will occur occasionally in patients diagnosed during life, and is the usual 
circumstance for the "necropsy discovery" group.) 
(69) - (72)! POST-TR£AT?ffiNT INTERVAL (ZT to END) 
Column 69 is used for two purposes: (a) to indicate whether a patient le 
alive, dead, or of unknown status; and (b) to indicate the time interval elapsed 
between first anti-neoplastic therapy and primary surgery (aero time) in the cases 
in which another form of therapy precedes primary surgery. By further convention, 
categories 3-9 in the colmnn take precedence over the entries ^2> Categories 0, 
or ^ may be used only in situations where primary surgery was not done, or was 
done without a preceding course of anti-neoplastic treatment. 
0: Patient is dead and his survival data are Imown 
1: Patient is a five-year survivor and still alive as of our last 
survey time 
2: We do not know the current state of a patient for whom the known 
post-zero Interval of life is less than five years. Code the 
known Interval in columns 70-72 
3: The Interval between the beginning of the first anti-neoplastic 
treatment and primary surgery is « 1 month 
4: The Interval is > 1 month but < 2 months 
5: The Interval is > 2 months but < 3 months 
6: The interval is > 3 months but < 6 months 
7: The Interval is > 6 months but < 9 months 
8: The interval is > 9 months but < 12 months 
9: The Interval is > 12 months 
Colums 70-72 are used to record survival in months from zero time. If 
survival time was longer than 99.9 months, record as 99.9. 
(73); SPECIAL COtPCENTS 
Special Note; This category is used for any special note, written 
on the extraction form during its clinical review, that comments on the 
various diagnostic, therapeutic, or other judgments encountered in the 
patient's course. A description of the diverse content of these notes is 
presented on pages 588-589 of Paper IV in "The Epidemiology of Cancer 
Therapy", Arch. Intern. Med. 123: 571-590 (May), 1969. Also Included in 
this category are post-zero para-clinical evidence of metastasis (e.g., 
abnormal LFT's) and systemic effects of the cancer (e.g., hypercalcemia) 
in the absence of clinical evidence. 
The next two categories incltide histologic inconsistencies based on locations 
(dlscrep^cy) or time of reading (disparity). The criteria for determining an 
"inconsistency" are presented in Appendix D. Cytology readings or negative readings 
are not Included among candidates for histologic disparities and discrepancies. If 
an "inconsistency" is present, code as follows: 
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Histology PlBcrepBDcy; Code here vhenever the histologic citation 
made in any histologic coding field is based on a choice hetveen different, 
but Isotemporal, readings that sire Inconsistent. For example, if pre-zero 
bronchial biopsy is read as epidermoid carcinoma, and pre-zero scalene node 
biopsy is read as adenocarclnopa, this disagreement constitutes a discrepancy 
for coding columns 34-35. 
Histology Disparity; Code vhen (a) an inconsistency occurs among the 
histologic diagnoses made at different readings of the same specimen, or 
(b) the histologic readings cited in columns 3^-35, 51-52, 55-59, or 63-64 
are Inconsistent. Situation (a) usiially occurs vhen the tissue specimens 
or slides are re-read at the index hospital after the patient vas transferred 
from a previous hospital irtiere specimens vere originally obtained and 
interpreted. 
(T4) - (75); CARD HUMBER 
For all formats in this coding series, this number is 02 , 
(76) ; ADDITIONAL DATA 
This column is used to denote additional data that could not be cited 
elsetd^ere in the single Hollerith card format described by these criteria. 
1: Beverslble Co-^orbid Weight Loss: Significant weight loss (>10? or 
>20 lbs. if % cannot be calculated) that is attributable only to a reversible 
co-fflorbid condition. Criteria for such weight loss are described in 
column 24. 
2: Additional Card: Further details for this patient are coded on an 
additional Hollerith card. 
4: Pre-Zero Morphologic Evidence of Brain Involvement: Code this category 
if the ultrathoracic morphologic evidence cited in category 4 of column 33 
refers to tumor involvenent of brain. 
(77) - (So); PATIEWT HUMBEB 
This is a four-digit coding number, arbitrarily assigned in seguence to each 
new patient in the series. 
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Appendix A: Chronometrlc Decisions 
Appendix B: Topographic Classifications 
Appendix C: Clinical Grouping 
Appendix D: Microscopic Classifications 
Appendix E: Examples of Coding of Radiographic Data 
Appendix F: Anatomic Grouping 
Appendix G: Therapeutic Classifications 
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Appendix J: Diagnostic Classifications 
/. ' t 
V. 
j'-M t '‘i >;, ( ■ A 
id- 
fUi'IVCt'- • '>‘'^> ^ it 
•« 
*J(rn k. \«f ,-,‘'VX' ■ o T 
... 'u -I il‘'*vqv^ . 
3rj'v;t|3ii>j • r - . x'^* •W'‘‘ 
£>L'''«I .J" '■• •.a ’i-- 
* ' rO . 1 j-'i .t •• 
. ' I'- 
- 106 - IV 
APPENDIX A: CHRONOMETRIC DECISIONS 
This coding system requires two critical decisions about chronometry In a 
patient's clinical course. 
Selection of Zero Time 
The first chronometrlc decision Is the selection of a temporal reference point 
for the events of a patient's clinical course. This datemark, which we call zero 
time, allows the course to be divided chronologically Into a pre-zero Interval, zero 
time, and post-zero Interval. The patient's condition at zero time then becomes the 
reference state at which diverse patients can be mutually compared. 
The choice of this temporal reference point will vary with the purpose of the 
coding system. If an Investigation Is concerned mainly with the effects of treatment 
on "natural history", the best choice of zero time would be the date of first antl- 
neoplastlc therapy, since this date would represent the first attempt to Intervene In 
the patient's natural course. In ordinary clinical circumstances, however, a type 
of zero time occurs whenever a clinician makes a decision about antl-neoplastlc 
treatment for a patient with cancer. At such times, the clinician would like to know 
the state and outcome of patients whose previous course had been comparable to that 
of the new patient. Since the new patient may or may not have received antecedent 
therapy, the appropriate comparative groups might not be found In data that have 
been coded according to a zero time and zero state based on the first therapy. 
If warranted by the data and the purposes of the coding system, arrangements 
could be made to code the full details of each patient's condition at the time of 
each antl-neoplastlc treatment. Such arrangements were not made here. The available 
data, although generally thorough for the patient's condition at the time of surgery 
or other types of first treatment, were not always equally detailed for the 
circumstances of subsequent therapy. Moreover, our Investigation was concerned 
mainly with the way "natural history" had been affected by surgery In operable 
patients or by other therapeutic agents In patients regarded as Inoperable. 
Accordingly, the following conventions were developed for the selection of zero time: 
If the primary site of the cancer Is surgically explored, with a pre-operative 
goal other than biopsy alone, the date of that surgery Is zero time, regardless of 
whether the cancer was removed, and regardless of whether the patient had received 
previous antl-neoplastlc therapy. If there was no primary surgery, zero time Is the 
date of whatever antl-neoplastlc treatment was given first. If "metastatic surgery" -- 
such procedures as craniotomy, laparotomy or laminectomy — was performed before 
other modes of antl-neoplastlc treatment, and If a significant amount of neoplastic 
tissue was removed, the metastatic surgery Is regarded as zero time treatment. The 
amount of removed metastatic tumor Is regarded as significant If reported In such 
phrases as "tumor enucleated" or "a large portion of tumor was excised". Alternatively 
the amount will be regarded as significant If the quantity of removed tissue cannot 
be determined from the record, and If there Is no statement that the excised specimen 
was a biopsy. If the amount of removed tissue Is not significant by these criteria, 
the metastatic surgery Is regarded as a pre-biopsy, and the choice of zero time 
depends on subsequent antl-neoplastlc therapy or therapeutic decisions. If no 
antl-neoplastlc treatment was given, zero time Is the date of the M.D.'s decision to 
give no treatment, or the date of the patient's refusal of offered treatment. If no 
therapeutic decision was made, zero time Is the date of acquisition of the most 
recent diagnostic evidence that could have been followed by a therapeutic decision. 
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The review of such diagnostic evidence should concentrate on Its role in therapeutic 
decisions. Thus, the date of a metastatic series or a scalene node biopsy, performed 
for pre-therapeutlc appraisal of the cancer’s extensiveness, would be a more cogent 
selection than the date of a repeated chest X-ray, performed to follow the progress 
of a pneumonia. 
An exception to these principles occurs in situations where the patient 
remained untreated for a long time after a decision not to give antl-neoplastlc 
treatment while the patient was in a relatively favorable stage of the cancer. This 
contra-therapy decision may have been made by an M.D. or by the patient, who refused 
an offer of thoracotomy, primary radiotherapy, or pre-therapeutic "work-up". 
Thereafter, the patient remained untreated until the development of new events, 
leading to an advanced or pre-terminal stage of the cancer, when usually the patient 
receives chemotherapy or metastatic therapy. In such circumstances, the initial 
decision against treatment can be regarded as zero time; and the later antl- 
neoplastlc treatment can be coded as "subsequent" therapy. The definition of an 
"advanced" or "pre-terminal" stage will vary with different situations, as will the 
definition of the "long time" in which the patient remained untreated. In general, 
the development of metastatic or of major "systemic" phenomena that did not exist 
previously can be regarded as "advanced", and an untreated Interval of 6 months or 
more can be regarded as a "long time". When alternative criteria are used for these 
decisions, an appropriate entry should be made in the running log, so that 
consistency can be maintained In later decisions for comparable cases. 
A detailed discussion of zero time appears in Arch. Intern. Med. 123: 323-344 
(March), 1969. A flow chart for the decisions, omitting the exception noted in the 
preceding paragraph. Is presented on page A-4. 
_2. Selection of Zero State 
The coding of columns 3-46 depends on the patient's zero state, which 
represents his condition at zero time, and Includes data of the clinical and para- 
clinical events that occurred during the "present Illness", as well as data about 
the diagnostic and prognostic co-morbidity present at zero time. The "present 
illness" begins with the inception event, described in section 3. 
In consolidating the available data for coding, the following conventions 
are used: 
"Greatest Extent" Convention 
For endoscopic and microscopic evidence (bronchoscopies, biopsies, and 
cytologies), code the greatest extent of positive findings noted during the present 
illness. Thus, if a mass was seen at one bronchoscopy but not seen at a later 
bronchoscopy, code the existence of a visible mass (unless there is reason to 
believe that the first bronchoscopy is unreliable). Similarly, if the cytology of 
a pleural effusion is positive at a first thoracentesis but negative later, code 
the positive finding. 
"Most Recent" Convention 
For radiographic evidence, code the results that were closest to zero time in 
conmiensurate examinations of the same region. Thus, if routine Chest X-ray showed 
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"hilar involvement" that later disappeared (on routine Chest X-ray), do not code the 
hilar Involvement. If the hilar Involvement was noted on routine Chest X-ray but 
not noted at lamlnography (or vice versa) the hilar Involvement should be coded. If 
the "disappearance" or "appearance" of a manifestation represents a disagreement in 
radiographic interpretations of films on a single date, rather than a change in films 
for two dates, code either the "greatest extent" of noted lesions, or the opinion of 
the radiologist selected for preferential consideration, or the ambiguity. 
This same convention applies to certain other t3rpes of data. For multiple 
values of weight, pre-transfusion hemoglobin or hematocrit, and para-cllnlcal 
laboratory tests, code the values closest to, but before, zero time. 
jc. "Symptom Disappearance" Convention 
Symptoms that appeared during the present Illness, and that are attributable 
or possibly attributable to the cancer, need not persist to zero time to be coded. 
Primary symptoms that have entirely disappeared before zero time can be recorded 
appropriately for their existence, regardless of whether they disappeared spontaneously 
or after treatment. The disappearance of such manifestations can be cited 
appropriately (if no systemic or metastatic symptoms can be coded) under "Transient 
Primary Symptoms". In patients whose zero time is at a thoracotomy that was preceded 
by anti-neoplastic therapy, antecedent systemic or metastatic symptoms can be coded, 
although absent at zero time, if their amelioration can be explained by the earlier 
therapy. Thus, HPO-type joint pain disappearing after radiotherapy or focal CNS 
symptoms alleviated after craniotomy, can be coded as part of the total events that 
had occurred during the present illness that Is "aummated" In the account of zero 
state. 
Precedence of Conventions 
If evidence of tumor involvement of a particular anatomic site is obtained 
from both radiographic and surgical procedures, then the "greatest extent" 
convention, takes precedence over the "most recent" convention for coding both 
types of data. For example, if a cranial metastasis demonstrated on X-ray by pineal 
shift is removed at pre-zero craniotomy and a subsequent pre-zero skull film is 
read as normal for pineal shift, the initial, positive X-ray finding should be coded, 
as well as the positive microscopic evidence obtained at craniotomy. 
Selection of the Inception Event 
The second main chronometrlc decision is the selection of the inception event. 
which is the earliest symptom or clinical event (such as pneumonia) that is 
diagnostically attributable or questionably attributable to the lung cancer. 
Hetastatlc symptoms of questionable attribution can only compete in the coding for 
the inception event if they are of a shorter duration than the other possible 
candidates. [A discussion of the attribution decisions appears in Arch. Intern. 
Med. 123: 448-461 (April), 1969 and in J. Chron. Pis. 23: 455-469 (Dec.), 1970.] 
The inception event, also known as the asterisk event ("*" event), thus denotes the 
onset of the "present illness" for the lung cancer. The choice of this event is 
further discussed in Arch. Intern. Med. 123: 448-461 (April), 1969 and Arch. Intern. 
Med. 123: 571-590 (May), 1969. 
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Flow Chart for Coding First Therapeutic Action 
and Zero-time Events 
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APPENDIX B; TOPOGRAPHIC CLASSIFICATIONS 
The nomenclature developed here la needed for several types of coding in 
which the location of a structure must be classified. The classifications occur 
during the coding of metastatic symptoms In columns 19-21; during Anatomic Grouping 
(see Appendix F); during the coding of radiographic data In columns 36-42; and during 
the coding of columns 31, 32, 33, and 55-57. 
Three different concepts are involved In these classifications: contiguity, 
lateralization, and location. 
_1. Categories of Contiguity 
Two lesions at two discretely different locations are said to be contiguous 
If they have a direct anatomic connection between them. For example. If a tumor 
grows outward from bone toward the surface. Invading muscle and skin, each of these 
three separate locations — bone, muscle, and skin — will contain tumor, but the 
tumor in muscle Is contiguous to bone; and the tumor In skin is contiguous to muscle. 
Similarly, when a tumor of the lower part of the upper lobe of a lung grows across 
the fissure lines Into the upper part of the lower lobe, the two locations — upper 
lobe and lower lobe — are Involved contiguously. On the other hand. If the upper 
part of the upper lobe and lower part of the lower lobe are each Involved separately, 
%d.thout any direct anatomic "bridge", the lesions at these two locations are non¬ 
contiguous. 
The Importance of contiguity Is Its role In Indicating how far a tumor has 
spread from the site of origin. Thus, In the two examples just cited of upper and 
lower lobe involvement, the tumor has spread more widely In the second case than In 
the first, even though the same lobes are involved In both Instances. As another 
example, consider a patient who has lung cancer in a rib; a primary tumor near the 
hllum has spread farther to reach the rib than a peripherally located primary tumor 
that has invaded the rib contiguously. 
The contiguity of anatomic Involvement can readily be determined when data are 
available from surgery or from necropsy. Such data are not available, however (or 
cannot be used) for the classifications performed at zero time and at many other 
"datemarks" of classification. In such circumstances, decisions about contiguity will 
depend on clinical evidence obtained by Inspection and palpation, and on para-cllnlcal 
evidence obtained from radiography, endoscopy, and microscopic examinations. Two 
lesions will be called contiguous If the available evidence suggests that they are 
anatomically connected. If the evidence of a direct connection Is dubious, 
unavailable, or negative — and If a positive Inference cannot be made — the two 
lesions will be called non-contlguous. 
In lung cancer, the questions of contiguity will usually arise for lesions 
within the lung and In perlpulmonlc tissues that are adjacent to the lunge 
(mediastinal structures, pleura, bones, chest wall, skin). 
a^. Intrapulmonarv Contiguity 
If two different lobes, segments, or discrete parts of the same Iting are 
Involved by tumor, they may be regarded as contiguous unless the X-ray report 
specifically Indicates that they are not. For example, such citations as "one lesion 
Is metastatic from the other" or "diffuse nodules" would Indicate non-contiguity; or. 
If one lesion Is clearly at the apex of the lung, any other lesion In a distal site of 
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the parenchyma td.ll be non-contiguous. 
Perlpulmonary Contiguity 
A tumor that Is centrally located, in or near the hlliHB can spread contiguously 
to the “Inner thoracic region" of hilar nodes and mediastinal structures. A tumor 
that Is peripherally located — at the apex or near the parietal pleura — can spread 
contiguously to the “outer thoracic region" of the pleura and structures of the 
thoracic vail and akin. 
The following conventions are used for coding "inner" and "outer" contiguity. 
1) . Inner Contiguity 
At zero time, involvement of hilar and mediastinal nodes is regarded as 
contiguous. At subsequent “datemarks", this involvement may be marked as 
non-contlguouB if direct anatomic evidence from surgery or necropsy has demonstrated 
the presence of a peripheral primary tumor. 
At zero time. Involvement of “mediastinal viscera" (as defined later In this 
appendix) Is regarded as non-contlguous. At subsequent "datemarks", this Involvement 
may be marked as contiguous if direct anatomic evidence has demonstrated that the 
source of the primary cancer Is adjacent to the involved "viscus" or "viscera". 
2) . Outer Contiguity 
An “outer" lesion may be considered contiguous If at least one of the three 
following criteria has been fulfilled: 
a) . The primary site of the tumor, as demonstrated on X-ray, is 
peripheral (or apical); and the Involved site (in bone, chest wall, or skin) is 
adjacent to the primary, as demonstrated by roentogenography and/or clinical 
examination. For example. X-ray may show the primary tumor near the chest vail, 
and palpation may show a hard mass in the adjacent chest wall. 
b) . The presumptive primary site of the tumor and the "outer" 
structure are involved together In a lesion whose topographic components cannot be 
distinguished. For example, an Infiltrate in the apex may destroy part of a rib, 
without clear definition of which part of the total lesion is the "primary". 
c) . A lesion develops in an “outer" structure that is the site of 
previous surgery. For example, tumor nodules may develop along the line of a 
thoracotomy scar, or in the track of a needle biopsy. 
2,. Categories of Laterality 
The term "laterality" is used for at least two different purposes in labelling 
thoracic structures: to denote the site of a single structure as being "central" or 
“lateral": and to denote the relationship of a given structure to the primary as 
either ipsllateral or contralateral. 
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Single Sites 
A structure Is laterallzed If It can be labelled as being on either the right 
or left aide of the chest. The follovd.ng structures are laterallzed: bronchi, 
pulmonary parenchyma, hllum, pleura, recurrent laryngeal nerve, ribs, chest wall, 
scapula, clavicle, diaphragm. The following structures are central (or non- 
laterallzed): sternum, thoracic vertebrae, Intrathoraclc spinal cord, mediastinal 
nodes, and all mediastinal "viscera" except the diaphragm and the recurrent laryngeal 
nerve. A central structure Is sometimes cited In a way that laterallzes It; thus, a 
radiologist may describe nodes In the "right mediastinum". 
b, Inter-Relationship to Primary Site of Tumor 
Any structure In the chest can be classified as Ipsllateral ("same side") or 
contralateral ("other side") in Its relationship to the side of the primary tumor. 
As an arbitrary convention, any central structure will be regarded as Ipsllateral, 
and so the question of classification arises only for laterallzed structures In 
relation to a laterallzed primary. 
The primary tumor is laterallzed If Its site of origin can be located on one 
side of the chest. Occasionally, the primary tumor cannot be laterallzed, as In 
these examples: no primary site Identified on the chest X-ray; primary site appears 
to be in central mediastinum; chest shows bilateral neoplastic involvement, with no 
primary side discernible. If no primary site has been identified, the side of an 
isolated unilateral abnormality believed due to the cancer may be regarded as the 
side of the primary. For example, the right pulmonary parenchyma may be obscured 
by a neoplastic pleural effusion, while the left lung Is clear; In this circumstance, 
the tumor may be regarded as laterallzed on the right side. 
3^. Categories of Location 
The use of these categories in the staging of Anatomic Croups (see Appendix F) 
will depend on features of laterality and of contiguity. 
B. Endothoraclc Structures 
1) . Endopulmonlc; bronchi and pulmonary parenchyma 
2) . Perlpulmonlc: 
a) . Outer zone: visceral or parietal pleura; chest wall (muscles, 
nerves, or "chest wall" without other specifications); 
endothoraclc bones (ribs, thoracic vertebrae, sternum, xiphoid, 
manubrium), intrathoraclc spinal cord. 
b) . Inner zone (mediastinum): 
(1) . Lymph nodes (hilar, mediastinal, carlnal, paratracheal, 
peri-aortic). 
(2) . Mediastinal "viscera" (trachea, esophagus, heart, major 
vessels [aorta, pulmonary artery, pulmonary vein, superior 
vena cava, inferior vena cava], recurrent laryngeal nerve, 
diaphragm, phrenic nerve. The carina is not considered to 
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Perlthoraclc Structures 
1) . Farathoraclc lymph nodes (scalene, supraclavicular, and/or axillary). 
2) . Parathoraclc bones (scapula, clavicle). 
3) . Skin and subcutaneous tissues covering the thorax. 
c. Dltrathoraclc 
Any structure beyond those cited In Sections a and b. This category Includes: 
1) . Cervical and other non-parathoraclc lymph nodes; skin and subcutaneous 
Structures. 
2) . Mon-thoraclc vertebrae and other bones. 
3) . Brain and skull. 
4) . Abdominal structures: liver, pancreas, etc. 
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APPENDIX C: CLINICAL GROUPING 
The codes here represent an arbitrary system developed during this research 
to classify "suspicious" symptoms that are either definitely or questionably 
attributed to the lung cancer. These categories are used for coding column 23. 
1: "Asymptomatic"; No "suspicious" symptoms. 
2: "Long Pulmonic"; The patient must have none of the symptoms of groups 
3 and 5 below, and one or more of the following "suspicious" symptoms: 
recent new cough or change In pattern of chronic cough; hemoptysis; 
subjectively noted wheeze; recent dyspnea; thoracic ache or pain; or 
a clinical manifestation of pulmonary Infection. At least one of these 
symptoms must have been present for 6 months or more. By convention, 
appropriately symptomatic patients with an ambiguous duration for the 
* to ZT Interval (l.e., one reported value Is less than 6 months, and 
another reported value Is at least 6 months) or patients whose 
duration Is uncertain (l.e., columns 65-68 are coded as 999.9) are 
also classified as "Long Pulmonic". 
3; "Short Pulmonic"; The same t3rpes of symptoms cited In group 2 above, 
except that all of the symptoms must have a pre-zero Interval of less 
than 6 months. No symptoms of groups 4 and 5 below. 
4: "Systemic"; The patient must have at least one of the symptoms cited 
In this category, and none of the symptoms of group 5. Symptoms of 
groups 2 and/or 3 may or may not be present. The appropriate symptoms 
for group 4 are: persistent anorexia, weight loss as a presenting 
complaint; persistence of weakness, fatigue, or significant malaise; 
clubbing noted by the patient; significant clubbing noted by M.D,; 
Joint pain due to HPO (hypertrophic pulmonary osteoarthropathy); or a 
special paraneoplastic syndrome due to "hormonal" secretion by the 
lung cancer. Among the syndromes Included In this last category are: 
Inappropriate secretion of vasopressin (ADH); neuromyopathy that has 
been specifically diagnosed as due to "hormonal" rather than anatomic 
metastatic causes; Cushing's 83mdrome; and carcinoid syndrome. The 
systemic symptoms are represented by any positive entry In columns 17 
or 18, or categories j4, or ^ In column 16. By convention, objective 
evidence of substantial weight loss, although not strictly a "symptom", 
is also Included In this clinical group. The appropriate categories 
are 2^, 3_, or ^ In column 24. 
5: "Metastatic"; The patient must have at least one of the entitles cited 
as a mediastinal, regional, or distant metastatic symptom definitely 
attributable to the spread of the cuicer. Symptoms from groups 2, 3, 
and 4 may or may not be present. 
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APPENDIX D; MICROSCOPIC CLASSIFICATIONS 
This appendix provides (1) a coding taxonomy for designating cellular types, 
(2) Instructions for making a choice among competing specimens, and (3) a classification 
of histologic inconsistencies. For the microscopic designations on this page, the 
negative code is used if a biopsy specimen is reported as "suggestive of cancer", 
without specification of a cellular t3rpe. 
Designation of Cell Types 
00: Not applicable (not done, unsatisfactory, or none available) 
01: Negative biopsy 
02: Negative pap smear or negative cell block 
03: Negative onkosponge 
04: Positive pap smear (other than sputum) 
05: Positive cell block 
06: Positive onkosponge 
07: Positive sputum cytology 
10: Epidermoid (Squamous-cell) Carcinoma [Use this Dx if the £p. CA is not further 
specified]; (WHO 1) 
11: Highly differentiated Ep. CA; Well dlff. Ep. CA; (WHO la) 
12: Moderately differentiated Ep. CA; Dlff. Ep. CA; (WHO lb) 
13: Slightly diff. Ep. CA; Poorly dlff. Ep. CA; Mod. Undiff. Ep. CA; (WHO Ic) 
14: Anaplastic Ep. CA; Pleomorphic Ep. CA; Polymorphous Ep. CA 
15: Undifferentiated Ep. CA; Dediff. Ep. CA; Undiff. epithelial CA 
17: Carcinoma in situ 
20: Small-cell CA (Undifferentiated Small-cell CA); (WHO 2) 
21: Oat cell CA; Oval-cell structure; (WHO 2a) 
22: Polygonal cell structure; (WHO 2b) 
30: Adenocarcinoma; Well differentiated Adenocarcinoma; Mucinous Adeno. CA; (WHO 3) 
31: Acinar; (WHO 3a) 
32: Bronchiolar CA; Papillary (alveolar cell); Papillary (mucous-producing) 
Adeno CA; (WHO 3b) 
33: Chiefly large cells; (WHO 3c) 
34: Anaplastic Adenocarcinoma 
35: Undifferentiated Adenocarcinoma; Poorly differentiated Adeno CA 
40: Large-cell undifferentiated carcinoma; (WHO 4) 
41: Giant-cell anaplastic 
42: Pleomorphic 
43: Plexlform 
50: Combined Epidermoid and Adenocarcinoma; (WHO 5) 
51: Combined Small-Cell and Adenocarcinoma 
55: Anaplastic Carcinoma; Poorly diff. CA; Undiff. CA; Anaplastic scirrhous CA 
56: Bronchogenic Carcinoma 
57: Carcinoma [Type unspecified]; Malignant tumor cells [Type unspecified] 
60: Bronchial Adenoma [Type unspecified] 
61: Carcinoid Type 
62: Cyllndrold Type 
70: Mesodermal Tumor [Type unspecified] (sarcoma) 
71: Fibroma 
72: Fibrosarcoma 
76: Cancer other than CA lung (includes mallg. melanoma) 
77: Metastatic Cancer 
80: Cancer groasly visualized at time of exploratory surgery 
81: Cancer grossly visualized at endoscopy [Description must say "cancer" or 
"neoplasm", not just "mass"] 
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In the list of codes on the preceding page, the numbers and letters in 
parentheses after the letters WHO represent the coding citations used In the original 
World Health Organization classification, as reported by Yesner, R., Gerstl, B., and 
Auerbach, 0. In Ann. Thorae. Surg. 1: 33-49 (January), 1965. 
2_. Choice of Competing Specimens 
The coding system contains four "datemarks" for recording microscopic evidence 
of cancer: columns 34-35, 51-52, 56-59, and 63-64. If several types of evidence, or 
evidence from several sites, are available as competitors for citation at a 
particular "datemark", a decision must be made about which evidence to code for that 
"datemark". 
If several types of evidence are available, use the following order of 
preference: positive histology (codes 10-57. 70; 72-77); positive cytology (codes 
04-07); positive gross visualization (codes 80. 81). The exception to this 
preferential order occurs when a thoracotomy patient has a negative pathology report. 
Since the information regarding gross visualization of tumor will already be coded 
In column 53, code the negative pathology finding In columns 51-52. 
If histologic evidence Is available from several sites, a specimen from lung 
or bronchus is preferred. Use Che following order of preference: lung biopsy; 
bronchoscopy; parathoraclc node; other. If more than one positive cytologic specimen 
exists; choose in the order of 04 first, descending to 07. If more than one gross 
visualization exists, choose the one at which an endopulmonlc or endothoracic site 
was Inspected. If all specimens are negative, code In the order of preference 
descending from ^ to If no evidence is available, code 00. 
Classification of Histologic Inconsistencies 
A histologic inconsistency exists when two histologic readings for the same 
cancer are not exactly the same. If the readings compete for coding In the same 
"datemark" position, the disagreement Is called a discrepancy. If the same slide 
has received several readings that do not agree, or If the histologic specimens at 
several datemarks do not agree, the situation Is called a disparity. 
Despite the Issues of location and timing that distinguish discrepancies from 
disparities, an "Inconsistency" in two readings must also be defined. The 
"disagreement scale" listed here is derived from the Investigation reported In Am. 
Rev. Resp. Dls. 101: 671-684, 1970. In this list, each pair of h3rphenated numbers 
represents the two available histologic readings. 
In the sections that follow three different grades of disagreement are cited. 
The non-ltallclzed pairs of numbers were assigned to one of the three grades of 
disagreement during the cited investigation. The italicized pairs were added by 
extrapolation from that study's basic principles to cover additional disagreements 
encountered In the present investigation. 
/ 
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Grade : Slight Dlaagreeinents 
20-27-, 11-12; 13-40; 23-55; 24-55; 25-55; 20-21; 20-22; 20-57; 21-22; 21-55; 
22-67; 22-55; 30-31; 30-32; 30-33; 31-32; 25-40; 40-42 
!: Definite Disagreements 
10-11; 10-12; 10-13; 20-25; 20-42; 20-50; 20-55; 11-13; 22-24; 22-55; 12-13; 
22-55; 23-20; 13-22; 13-33; 22-24; 22-25; 20-35; 20-55; 22-22; 22-55; 22-40; 
30-25; 30-50; 30-55; 31-33; 32-33; 32-35; 22-55; 22-60; 33-40; 33-50; 24-55; 
35-55; 40-55; 40-56; 40-60; 42-55; 50-55 
1: Maj or Disagreement s 
10-30; 10-31; 10-32; 10-33; 10-40; 10-60; 11-21; 11-31; 11-40; 11-60; 12-21; 
12-22; 12-30; 12-32; 12-33; 12-40; 12-60; 13-21; 13-30; 13-31; 13-32; 13-50; 
13-60; 20-40; 21-31; 21-40; 30-40; 31-40; 32-40; 40-50 
For practical purposes, differences that are only "slight disagreements" will 
not be coded as "Inconsistencies", and this term will be restricted to "definite" 
and "major" disagreements. If a particular pair of discordant readings Is not cited 
in the above list, an ad hoc decision Is required about the magnitude of disagreement. 








Order of Precedence for Competing Specimens 
1) Zero Time Thoracotomy 
2) Pre-Zero Time Bronchoscopy or Lung Biopsy 
3) Necropsy Tissue 
4) Other Zero Time Tissue 
5) Other Pre-Zero Time Biopsy 
6) Post-Zero Time Biopsy 
Well-differentiated Epidermoid Cancer 
Well-differentiated Adenocarcinoma 
Anaplastic 
Metastatic, not otherwise specified 
Cytology only 
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AfPBJDIX E: KAKPLES OF CODING OF RADIOGRAPHIC DATA 
The examples provided is this appendix are Intended to Illustrate the arbitrary 
conventions used for coding special situations In radiographic data. 
Jk» Primary Site Dnspeclfled 
0^1v one side of the chest Is Involved, primary parenchymal site not discerned 
Lung obscured by massive opacity 




_3 or ^ A 
3 or 4 5 
(40) (41) 
Laterallzed bony or chest vail lesion; 
no other distinct lesion visible 
Lung parenchyma Is bilaterally Involved; 
No extraparenchymal lesions 
lib Involved on one side 
Ribs involved on both sides 
Pleural effusion on one side 






"Atelectasis" Is an Interpretation given to an X-ray shadow. The interpretation 
generally Implies the radiologist's belief that the shadow Is not neoplastic, but a 
neoplasm may be Interpreted fallaciously as merely atelectasis, because (1) the tumor 
may be small, but big enough to block a bronchus, creating atelectasis beyond the 
site of the block; or (2) this neoplastic shadow may be the only abnormal shadow In 
the parenchyma. If another and more clearly neoplastic shadow has been described by 
the radiologist, an "atelectatic" area, reported in the same reading. Is probably not 
regarded as neoplastlcally involved. 
Situations Involving atelectasis are coded as follows: If the only evidence 
of Involvement is an atelectatic lobe, code the lobe In columns 37-38. If hilar or 
mediastinal nodes are involved In addition to the atelectatic lobe, code the lobe In 
columns 37-38 and the nodes appropriately in columns 39 or 41. If the only evidence 
of contralateral Involvement Is an atelectatic lobe, code 2 column 41 for 
"questionable Involvement". 
2* Haln Bronchus 
The radiographic coding of Involvement of a main bronchus should be based on 
radiographic evidence alone. Endoscopic evidence. If present, is coded separately 
in column 29, and should not be used here. The radiographic coding for main 
bronchus Is as follows: If only the right or left isaln bronchus Is involved, code 2 
or _4 ^ column 37, and 6, in column 36. If the right or left main bronchus Is 
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lavolved and a lobe is atelectatic, code only the main bronchus in columns 37-38. 
If a lobe is specified as involved on gross films, but the main bronchus (and 
not the lobe) is specified in the reports of lamlnography, code only the involved 
lobe in columns 37-36. If the gross film specifies main bronchus and only the lobe 
is reported at lamlnography, code only the lobe in columns 37-38. 
If an involved hllum is reported in gross films, but the main bronchus is 
reported in lamlnography, code ^ or ^ in column 37, ^ in column 38, and ^ in 
column 39. 
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APPENDIX F; ANATOMIC GROUTING 
The classification of anatomic groups depends on the type of evidence and the 
topographic site and contiguity of the Involvement. A discussion of topography and 
contiguity Is contained In Appendix B. 
A. TYPE OF EVIDENCE 
Anatomic grouping requires evidence of structural lesions regarded as showing 
neoplastic Involvement. A positive finding In any of the categories cited here will 
denote such Involvement. 
_1. Microscopic: pap smear, cell block, onkosponge, aspiration biopsy, needle 
biopsy, operative biopsy. 
_2. Radiographic; a density, mass, infiltrate or other abnormal radiographic 
shadow strongly suspected as neoplastic, or related to neoplasm. A pineal shift on 
skull X-ray denotes Intra-cranlal tumor unless otherwise Interpreted. 
_3. Gross Anatomic; tumor grossly visible at endoscopy or at surgical 
exploration regardless of whether or not tumor is excised or demonstrated 
microscopically. Since positive findings at bronchoscopy or tracheoscopy Identify 
the primary site of the tumor, but not its extra-pulmonic anatomic extensiveness, 
such findings will never be used in these groups. 
Clinical Examination; unequivocal visualization or palpation of tumor in 
superficially palpable masses (Including lymph nodes); or in liver or other 
palpable organs. 
_5. Para-Cllnlcal Examination; bloody, pink, or sero-sanguinous pleural fluid, 
In the absence of some other explanation for the blood. The blood must therefore 
be found In a "first tap" specimen, and should not be attributable to an Isolated 
pneumonia, infarction, or other non-neoplastlc lesion. 
B. ANATOMIC GROUPS 
Anatomic staging is Intended to indicate the topographic extensiveness of 
tiamor Involvement beyond the endopulmonic tracheo-bronchial tree. Bronchoscopy, 
which reveals central location and resectable marglnatlon of the tumor, is not 
used to classify topographic extensiveness. 
The anatomic groups are listed here In reverse order. These same numbers 
are used for coding in column A3. At any level of the grouping, a member of one 
of these groups must have none of the characteristics of the higher groups (except 
6), but may have many characteristics of the lower groups. 
6: 'Unknown"; Used for "necropsy surprise" cases. 
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5: "Ultrathoraclc”; Involvement of any structure cited topographically as 
ultrathoraclc. The perlthoraclc skin and/or subcutaneous tissues are coded as 
ultrathoraclc if they are not contiguously involved with an "outer-zone" 
perlpulmonlc or perlthoraclc structure. 
4: "Contrathoraclc"; Contralateral involvement of any endothoracic, 
perlpulmonlc, or perlthoraclc structure. Includes cases in which tumor crosses the 
mediastinum to Involve the hllum or other contralateral structures contiguously. 
3: "Isothoraclc"; Ipsllateral involvement, without contiguity of any one 
of the following structures: another part of the same lung; any perlpulmonlc 
"outer-zone" structure; any mediastinal "viscus"; or any perlthoraclc structure. 
(Skin and subcutaneous tissues may be classified as Isothoraclc only if contiguously 
Involved with chest wall. The chest wall would be classified as isothoraclc only 
if not contiguously Involved with underlying primary tumor.) Tracheal involvement 
on bronchoscopy is not considered Isothoraclc Involvement for anatomic grouping. 
2: "Vicinal"; Lymph nodes of the hilum or mediastinum, or ipsllateral 
contiguous involvement of any perlpulmonlc structure. 
Note: The perlthoraclc bones and lymph nodes are seldom contiguously attached 
to primary tumor; when they are, they may be coded in this category. 
1: "Endopulmonlc"; None of the above. This category may also be coded, in 
the absence of any other topographic evidence, when the zero-state chest X-ray 
is read as "negative". 
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APPENDIX G: THERAPEUTIC CLASSIFICATIONS 
1^. Coding of Metastatic Surgery 
If metastatic surgery was a therapeutic procedure (l.e., a significant amount 
of tumor was removed, as defined In Appendix A), its chronologic occurrence is coded 
appropriately as ^ in column 47 or 48, or as £ in column 54. If It was part of the 
"first therapeutic action". Its microscopy is recorded in columns 51-52, unless it 
was followed by thoracotomy. If followed by thoracotomy, metastatic surgery is still 
coded as 9^ in column 47 or 46, but its site is recorded in column 32 or 33, and its 
microscopy in columns 34-35. The description of the thoracotomy is coded in columns 
49-53, and its chronologic occurrence is coded, if a "paired" procedure, as ^ in 
column 48 or, if a "subsequent" procedure, as in column 54. Column 69 is used to 
code the Interval by which thoracotomy was preceded by metastatic surgery (or by any 
other first anti-neoplastic treatment coded in column 47). 
If metastatic surgery was "subsequent treatment", its general site is coded 
in column 57, and its microscopy in columns 58-59. 
_2. Retrieval of Codes for Zero Time and First Therapeutic Decision 
Because of the complexity of the codings for zero time and first therapy, the 
following outline is cited here for use in retrieval of therapeutic data during 
subsequent analyses. The contents of columns 47 and 48 are briefly summarized as 
follows; 
Column 47 
0: No decision 
1: No Rx: M.D. decision 
2; No Rx: Pt. refused 
3: No Rx: Other reason 
4: Thoracotomy 
5: Primary Radiation 
6: Cytotoxic 
7: Primary Rad. + Cytotoxic 
8: Rad. to Metastasis 
9: Surg. or Focal Cytotoxic 
to Metastasis 
a. The "Later Surgery" Group 
According to the conventions described elsewhere (Appendix A, Section 1^) surgery 
directed at the primary site is always regarded as zero time, no matter when it 
occurred In the therapeutic sequence. Consequently, patients who did not receive 
surgery as their very first treatment are first found via any of the codes _3-_9 in 
Column 69. This "later surgery" subgroup can then be divided into two parts: the 
patients who had thoracotomy as the second element of a paired first treatment (^ 
in Column 48); and those who had thoracotomy as "subsequent treatment" (1, 3^, 5^ or 
2, in Column 54). 
The first therapeutic action for both these "later surgery" groups can be 
retrieved as described in the section that follows. 
Column 48 
0: No action 
1: Pt. refusal of work-up 
2: Alternate accepted 
3: Planned paired Rx not given 
4: Thoracotomy 
5: Primary Radiation 
6: Cytotoxic 
7: Primary Rad. + Cytotoxic 
8: Rad. to Metastasis 
9: Surg. or Focal Cytotoxic 
to Metastasis 
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■k* Treatment 
For all patients other than those just described In Section zero time and 
the first therapeutic action are Identical. The codes for retrieval are as follows: 
Patients with first treatment to primary site: ^ through T_ In column 47. 
Patients with thoracotomy as first treatment: ^ In colusm 47. 
Patients with first treatment to metastasis: ^ or ^ In column 47. 
Patients with no treatment at zero time: 0^ through 3^ in column 47. (We 
can conclude that these patients never received anti-neoplastic therapy only if ^ 
Is also coded In column 54.) 
Patients with treatment planned but not given at zero time: 2^ or ^ in 
column 47. The planned treatment is then found as ^ through 9_ in column 48. 
Patients who were offered, but did not receive thoracotomy: ^ in column 49. 
J. * ' , ' \ . 
,r* '. Viifcij-v. HiJri W . 
.'■< .iJ ^ f-a ,« ))i j.*#*444(i fa *!■ 
' V / 
^'J‘, . T* iMtS’KilB -fS ^ U“4fc 7C 03 /*.*;-<• 
ii *M-' '■' . I tlivi'':%/v Cii'* o^vr'^ow 7».'if'i'^iil^ ■i'i ' "< • ■.\vr:-r v ‘•.M> 
f,W cai'i't^ -•«> 
lU £i-^ j|' itHtiJ.) oif4» Kt .'aa '>4rt4 • i. _ ■''*>■'3 
.i** 'IMPT^CM <<>T ■■43 »- <•* ■ -.UC^ fcSif > ». ... lii “ ■! vt'4 ' i l,'"i(Jf: '■ '•*>^33 '. 
- ' ’. .S» 
‘•o' ' » 
- 124 IV 
APPEMDIX J: DIAGNOSTIC CLASSIFICATIONS 
During the retrieval and coding of the medical records, certain conventions were 
adopted for the diagnostic classifications in which each patient would he cited. The 
categories and methods of maiing these decisions are described in this Appendix. 
Eligible Case: A patient "vdio has satisfactory evidence to warrant the 
diagnosis of lung cancer. For certain types of analyses, microscopic evidence of cancer 
is a pre-requisite to diagnosis. For other analyses, the timing and hospital location 
of zero time are other pre-requisite conditions. 
Apzer (Contraction of "Appropriate Zero”) Cases; Eligible patients ^ose 
zero time occurred during a specified calendar interval at one of the index hospitals 
under survey. In this siirvey, the index hospitals are the West Haven VA Hospital and 
the Yale-New Haven Hospital. An otherwise eligible patient may be an "inapzer" case 
because zero time occurred at a different setting or outside the specified calendar 
interval, or both. The group of apzer patients form an inception cohort, as further 
defined in Clin. Pharm. Therap. 12: 86^1-879 (Sept .-Oct.), 1971. 
3> Necropsy Specification Case; This type of patient, also called an "I-E" 
case in various places in this coder's manual, was known or suspected to have a cancer 
during life, but the exact source of the primary lesion was unknown or uncertain until 
demonstrated at necropsy. Necropsy specification cases are eligible for inclusion as 
apzers and many of the necropsy-specification cases were treated during life with an 
anti-neoplastic agent. 
Necropsy Surprise Case; This type of patient, also called a "l-^^" case in 
various places in this coder's manual, was found unexpectedly at necropsy to have a 
primary lung cancer that had not been diagnosed or seriously suspected during life. 
The pre-mortem clinical diagnosis may have contained no mention of a lung lesion; or a 
lesion, if noted, may have been attributed to inflammation, benign neoplasia, metastasis 
from an exopulmonic source, or some other disease that was definitely cited as something 
other than primary lung cancer. Anti-neoplastic therapy, if given, was begun with the 
diagnostic belief that the patient's disease was definitely not primary lung cancer. 
Although eligible for certain analyses, a necropsy-surprise patient cannot be an 
apzer case. 
% Para-Diagnostic Case; This diagnostic category is used for several different 
kinds of patients whose records were examined but not coded in the format described 
in this coder's manual. 
a^. Wrong Diagnosis; Lung cancer was initially diagnosed but later shown to 
be erroneous. The contradictory evidence may have been found at surgery, necropsy, or 
some other time in the clinical course. In the absence of surgery or necropsy, the 
contradictory evidence may have been total disappearance of the roentgenographic lesion(s) 
or other evidence suggesting false positive cytologic smears. 
b. Equivocal Diagnosis; In the absence of surgery, necropsy, or 
contradictory evidence, the existing evidence of lung cancer was too equivocal for the 
patient's eligibility. Kiere may have been uncertainty as to whether the pulmonary 
lesion was a carcinoma or uncertainty about whether a presumptive pulmonary carcinoma 
was primary in the lung or elseirtiere. 
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£. ParamorpholoRic Case; This category consists of patients with diseases 
that may resemble lung cancer. Such cases can be divided into two groups. 
1) . Para-topographic; Cancer or benign tvunor of the trachea, 
pleura or mediastinum. 
2) . Para-histologic: Benign or malignant lesions of ineligible 
histology. The malignant lesions include various sarcomas as well as Hodgkin's disease. 
The benign tumors include bronchial adenoma, hamartoma, mesothelioma, fibroma, neuro¬ 
fibroma, dermoid cyst, and teratoma. Other benign lesions are tuberculoma, granuloma, 
lipoid pneumonia, and "organizing pneumonia". 
During this research, the records of patients with paramorphologic diagnoses 
were deliberately solicited and examined in order to find cases of lung cancer that 
may have received an erroneous citation in the SNDO or ICDA diagnostic codes used for 
the indexing of medical records. Such patients were also sought to obtain data about 
the epidemiologic spectrum of the "paramorphology" of lung cancer. 
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CRITERIA FOR CODING 
Cancer of the Lung 





( 2 ) - ( 9 ); nm CLASSIFICATION ^ 
(2 ) - (9): Pre-Zero TNM Classification 
Code In these colums the totality of anatomic evidence available 
at zero-time, prior to thoracotonQr. 
( 2 ) - ( 3 ) : Evidence for T3 
Code any evidence that allows a classification of T3. 
(2): Pleural Effusion 
0 * None 
1 ■ trace; e.g., "small amount of fluid In costophrenlc sulcus" 
2 ~ moderate; fluid was visualized at X-ray but does not qualify as category 
1 or 3; or, unco]q>llcated thoracentesis yielded less than 1000 cc fluid; 
or, chest was tapped only for diagnostic reasons«Tn the absence of 
specification of the size of the effusion. Code the effusion as of 
moderate size, by default. 
■^e TNM (TuDor-Node-Metastasls) classification system enployed here 
Is a replica of that devised and used by the American Joint Committee (AJC). 
For a description of the TNM classification of malignant tumors of the lung, 
see the Amer. Joint Coanlttee for Cancer Staging & End Results Reporting 
of Sept, 1973. Clinical Staging System for Care, of the Lung. 
These criteria for TNM classification were compiled by Dr. Feinstein 
and his clinimetric research group for the lung cancer cohort of 1953-1964 
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(2) [continued] 
3 ■ ■asslve; as coded on Card 02, where the effusion Is of magnitude 
great enough to obscure the lung roentgenographically, or to 
create respiratory distress, or to evoke a therapeutic thora¬ 
centesis, or fluid volume that Is cited as "large" or "mod¬ 
erately large". (Code here If on Card 02: Col. 40 > 1, 3, 5, 
or 7 and Col. 27 >0 and Col. 21 ^ 8.) 
(3) : Other T3 Evidence 
0 ■■ None 
r 
1 > "Juxtacarlnal"; tumor was shown bronchoscoplcally to be 
less than 2.0 cm distal to the carlna; l.e., coded on 
Card 02 as Col. 29 * 1,2, or 3; which Is a mass seen 
on bronchoscopy In or above the carlna, or In the carlna 
and at least one main bronchus, or In main bronchus close 
to the carlna. 
2 B Whole lung Involvement; e.g., "lung obscured by suisslve 
opacity", "atelectasis of all three lobes'" or primary 
tumor In main bronchus with total collapse of lung 
parenchyma dlstally. 
Additive/ 
4 > Adjacent structures; direct contlguotis extension, as 
coded on Card 02, to one or more of the following: 
mediastinal viscera (category 4 In Col. 39 or any category 
In Col. 20), Isothoraclc atructures on X-ray, other than 
multiple nodules (category 4 In Col. 40), microscopic 
proof of node (category 1 In Col. 32), pleura, pleural 
fluid, chest wall, or thoracic bone (category 2 In Col. 
32), or palpable thoracic node (category 1 In Col. 31). 
If the Involvement of these structures Is non-contlguous, 
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(3)[continued] 
^4 > [continued] the lesion Is regarded as aetastatlc and is 
coded as to. In Col. 51, not here. Non-contlguous Ipsllateral 
lesions in the lung parenchyma (multiple nodules) are coded 
only in Col. 49 as category 4. If information re: contiguity 
of other involvement is lacking, code adjacent structures 
here, and not metastatic Involvement (Col.51): that is, assume 
contiguity when in doubt. 
8 Non-specific; no statement of T3 evidence was made, but the 
tumor was judged to be of T3 extent. If coded here, a code of 
6 may not be used in either Col. 47 or 48. 
Additive/ 
(4); Evidence for T2 
Code evidence for asslgolng a classification of T2, regardless of ezl8t«^ 
Ing evidence for T3 (Col, 45-46), 
0 • None 
1 Specific statement by radiologist of tumor size >3 cm, 
2 > Coder's assuiqptlon, from radiographic description, that tumor 
size is >3 cm. ‘(e.g. described as a "mass", a "huge mass",) In 
the absence of a modifying phrase to Indicate that a tumor is 
small enough for a citation in Col, 48, the tumor will be coded 
Additive/ 
In Col. 47 as 2. A log will be kept of such codes to ensure 
consistency, 
4 ■ Spread to or toward the hilar region. This category refers to 
the extent of the primary, and does not include metastasis to 
hilar nodes (which are coded in Col, 50 as 1), An exception to 
this principle occurs when a hilar mass is described aa present, 
without any further description. Such a circumstance is coded 
T2N1 (Col, 47 * 4, Col, 50 ■ 1), Some exas^les of phrases 
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( 4)[continued] 
Additive 
'' indicating spread to ox toward the hilar region are "supra- 
hllar", "parahllar", "tumor extends toward the hllum". When 
In doubt, the coder will refer the case to A.R.F. for decision, 
^ and record the case in the log, to CASMU-e-later coding 
consistency. 
7 ■ mediastinal mass; no other evidence of primary tumor exists. 
8 ~ Non-specific; no statement of T2 evidence was made, but the 
tumor was judged to be of T2 extent (e.g. atelectasis of less 
than the whole lung). If coded here, a code of 8 may not be 
used In either Col. 46 or 48. 
NOTE: In the case of the 1* tumor being located In the hllum 
or In the mediastinum, no assumption of size of the 1^ Is coded 
here, as there Is no way to distinguish between mass size 
caused by the 1^ tumor and that caused by nodal involvement. 
(5): Evidence for T1 
This column is \ised to code evidence for the T1 category, regardless 
of evidence for T3 (Col. 45-46) or T2 (Col. 47). 
0 > None 
'"l m Tumor stated to be ^ 3 cm In greatest diameter (presumably 
surrounded by lung parenchyma) 
Additive/ 2 Tumor seen dlstally at bronchoscopy. Card 02, Col. 29 - 5,6; 
or tumor visualized at X-ray but bronchoscoplc report refers 
to all bronchi being clear. 
sA * Tumor visualized peripherally at X-ray or described as a 
'coin lesion" 
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( 3 ) [continued] 
6 > Non-specific; no statement of T1 evidence vas made, but the 
tumor vas judged to be of T1 extent, e.g. "parenchymal ab¬ 
normality of an infiltrative type". If coded here, a code 
of 8 may not be used in either Col. 46 or 47. 
(6): Pre-Zero T Classification of Primary Extent 
Only one T class may be coded for each patient, as follows: If the 
tumor is classified as T3 (Col. 45 > 1 or Col. 46 > 0), Col. 49 « 3; 
if the tumor is classified as T2 in Col. 47, Col. 49-2; etc. 
0 ~ Tumor proven only by bronchopulmonary secretions 
1 - T1 
2 - T2 
3 - T3 
4 * Multiple lesions in the same lung 
7 ■ Ho evidence of 1* irtiere clinical data (radiographic, bronchoscopic) 
are absent or Inconclusive 
8 ■ "TIS" (AJC); tumor in situ (must be described as such in the extraction 
form) 
9 * No evidence of primary tumor, where clinical data form the basis of this 
conclusion 
Coding Preference is given to the various T classifications as follows: 




•• ,,’^i.y. .1 If I ■ ■■ “i' 
• ,- 1 ,i ■' Mf* ' '«nn# 
..t ,1^ ..iL'--» ■ ■■■* '''^' «AVi'<J 
. "S' ■..S'V'-M'l E 
I' ,©- . , 'i ^ .i' 
4:t .« 
■:K' ‘ ^ '4-'' ,',iia„"5,e'.♦ .''' 
y^..' ’» 
. *!' 
• a .iv''-' it** fJttV' ' t?, ^ 1. ,v,')' ^ *<' ■''■ 
J .1 ■'. '' : ..; ; - ".V 
■' ■* <• 
.IX^.r 
* :-t 
■ t I . ■■ A 
- 131 V 
(7) : Pre-Zero H Classification of Hodal InvolveiBent 
Only the hipest H class is coded (if both hilar and aedlastlnal nodes 
are involved, code as 2). Most of the elenents Included here are already 
directly coded on Card 02. 
0 ■ NO: no nodes seen on X-ray 
1 ~ Nl; X-ray visualization of ipailateral hllum or hilar nodes (Card 02; 
Col. 39 ■ 1); or X-ray report of spread to "peribronchial nodes" at a 
distance from the hllum (such nodes are not coded on Card 02). Spread 
to nodes in the contralateral hilar region is not cited here. Such 
involvement is regarded as evidence of metastasis and is Included in 
the Ml code (Col. 51) below. 
2 - N2; X-ray visualization of aedlastlnal node Involvement regardless of 
laterality ( Card 02 category 2 in either column 39 or 41); or mani¬ 
festations of mediastinal Involvement which permit a clinical Inference 
that mediastinal nodes are involved. (The candidates are the signs and 
symptoms listed for column 19 of Card 02. Hoarseness is regarded as 
sufficient evidence for coding N2 only if a) vocal cord paralysis was 
demonstrated on laryngoscopy, or b) this sys^jtom was cited as a contra¬ 
indication for thortcfbon^), or c)' vocal cord not examined, but there was 
a substantial history of hoarseness (one month or more).) 
(8) : Pre-Zero M Classification of Metastasis 
The elements included here are already directly coded on Card 02. 
0 B MO; no evidence of metastasis 
1 •• MI; evidence of distant metastasis Including ultrathoraclc (Col. 42 >0); 
or non-contiguous Isothoraclc other than multiple nodules (Col. 40 ■ 4,5), 
or regional nodes (category 1 in Col. 32), or pleura, chest wall or 
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( 8 ) [1 > m, coBtlnued] 
thoracic bone (category 2 In Col< 32), or palpable thoracic, aurface, 
or liver and other aetaatases (Col. 31); or pericardial efftislon 
(category 1 In Col. 33); or contralateral pleural effusion (Col. 27 
<■ 9 or Col. 41 ■ 1) or contralateral thoracic Involvement (Col. 41 > 1) 
excluding mediastinal nodes (which are coded In Col, 50 a^); or non¬ 
contiguous thoracic symptoms (Col. 20); or syiq>toas of distant 
metastasis ( Col. 21 > 0). 
( 9); Pre-Zero TNM Stage 
The codes In Col, 49-51 are combined Into a Pre-Zero TNM composite 
stage as follows: 
1 - Stage 1; T1 NO MO, T1 HI MO, T8 NO MO , NO fAO 
2 Stage 2; T2 N1 MO 
3 ' Stage 3; T3 with any N or M 
N2 iwlth any T or M 
MI with any T or N 
9 * Dnlcnown Stage; TO NO MO 
T7 NO MO 
T9 NO MO 
T4 NO MO 
T4 N1 MO 
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(10) - (23): NEW DIAGNOSTIC TECHNIQUES 
New diagnostic techniques refer to methods of diagnostic imaging 
available to define tumor extent in the 1977 cohort but not available 
to the 1953-64 cohort. In particular, these techniques were nuclear 
imaging, computerized tomography, and ultrasonic imaging. 
For each test on the coding form, code the Result and Associated 
Clinical Evidence as follows: 
(10) , (12),(14),(16),(18),(20),(22): Result 
0 = Negative result; This may be a reading of "negative", 
"within-normal-limits", or a similar reading denoting the 
absence of abnormal findings. A negative result may be 
coded if the study noted an abnormality which was clearly 
attributable to another disease, (examples: a bone scan 
positive in areas of known degenerative joint disease; a 
liver-spleen scan with abnormal uptake consistent with 
parenchymal disease in a patient with a history of cirrhosis) 
1 = Positive result; Positive study showing an abnormality at 
a site other than the primary tumor, if the site of the 
primary is known 
8 = Equivocal result; Refers to readings which are unable to 
clearly define an abnormality but are not felt to be normal. 
Readings may be "equivocal", or "possibly abnormal". This 
category may also be coded for instances when the official 
reading denotes a positive result without clear documentation 
of another reason for the abnormal study, but, the study is 
treated as if negative in the following work-up and therapy. 
Code 8 if the positivity of result is questionable. 
X = Not done 
(11) ,(13),(15),(17),(19),(21),(23): Associated Clinical Evidence 
Associated clinical evidence refers to clinical or paraclinical 
data which might act as an impetus for performance of one of the 
new techniques, or which supports the result of the study when 
positive. The purpose of this category is to distinguish patients 
who were discovered to have more extensive disease as a result of 
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(11),(13),(15),(17),(19),(21),(23): Associated Clinical Evidence - cont. 
0 = None; or, no study performed 
1 = Yes; but questionably attributable to the cancer 
(l.e. another potential cause of the evidence is present) 
2 = Yes; clearly attributable to the cancer 
8 = Yes; but evidence is of questionable existence 
9 = UNK 
(22) - (23) : Other 
When a study is performed which was not available in the 1953-64 
study, and which is not listed on card 3, "other" will be coded 
if the study is performed to define tumor extent, and the type of 
study will be specified on the coding form. 
(24) - (33): IMPACT OF NEW DIAGNOSTIC TECHNIQUES ON STAGING 
Without Result of New Techniques: refers to the application of staging 
criteria with all pre-zero time infonnation except that provided by 
the new techniques described in (10) - (23). If a positive result 
from a new study prompted the performance of a previously available 
study which was also positive, then the information provided by the 
"old" technique can be included in the staging for this category. 
With Equivocal Results from New Techniques: refers to the application 
of staging criteria with all available pre-zero time information 
including results from new techniques which were positive and with 
results which were coded as equivocal now counted as positive. 
(24) - (25): Toponymic Stage 
(24) : Toponymic stage without results of new diagnostic techniques; 
coded as per (35) 
(25) : Toponymic stage with equivocal results from new techniques; 
coded as per (35) 
(26) - (33): ™ Stage 
(26) - (29): TNM stage without results from new techniques; 
(26) : ^ ; coded as per (6) 
(27) : N ; coded as per (7) 
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(26) - (29): TNM stage without results from new techniques - cont. 
(28) : M ; coded as per (8) 
(29) : Stage ; coded as per (9) 
(30) - (33) : TNM stage with equivocal results from new techniques 
(30) : ^ ; coded as per (6) 
(31) : N ; coded as per (7) 
(32) ; M ; coded as per (8) 
(33) : Stage ; coded as per (9) 
(34): FUNCTIONAL SEVERITY 
This is a composite stage of symptom severity and prognostic co-morbidity. 
Code in descending order of precedence: 
4 = IV = Severe prognostic co-morbidity 
(code as per card 2 criteria for column 44 ; code here 
if column 44 = 2,3,4,5,6, or 7) 
and/or Severe tumor effects 
(as per card 2 criteria for column 44 ; code here if 
column 44 = 1,3,5, or 7) 
and/or "Super Weight Loss" 
(as per card 2 criteria for column 24 ; code here if 
column 24 = 1, or 2) 
3 = III = Quasimetastatic 
(as per card 2 criteria for column 22 ; code here if 
column 22 = 4,5,6, or 7) 
2 = II = Severe dyspnea 
(as per card 2 criteria for column 28 ; code here if 
column 28 = 4,5,6, or 7) 
and/or Recent dyspnea 
(as per card 2 criteria for column 14 ; code here if 
column 14 = 1,3,5, or 7) 
and/or Systemic symptoms 
(as per card 2 criteria for columns 16, 17, and 18 ; 
code here if column 16 is greater than 4 ; and/or 
column 17 or 18 are greater than zero) 
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(35): TOPONYMIC STAGE 
This is a combination of morphologic and symptomatic evidence for tumor 
extensiveness. The composite contains 7 topographic strata. In 
descending order these are; 
7 = Liver/Other - evidence of metastasis to deep, vital organs other 
than brain or bone, and beyond the thorax (see card 2 criteria 
for column 31, category 4) 
6 = All Other Ultrathoracic Sites - evidence of metastasis to CNS, 
bone, surface nodules all beyond the thorax 
5 = Intrathoracic - Implies massive spread within the thorax; 
includes massive pleural effusion, spread to contralateral 
lung or chest wall, or involvement of all three lobes on one 
side 
4 = Isothoracic - non-contiguous spread within the thorax on the 
ipsilateral side. 
3 = Vicinal - spread limited to contiguous sites; includes chest 
wall if a peripheral tumor, or hilar and mediastinal involvement 
if central. There must be no evidence of non-contiguity. 
(see card 2 coding criteria Appendix B for examples of 
contiguity) 
2 = Symptomatic or Central - symptoms are bronchial, parietal, or 
parenchymal (other than dyspnea); central Includes gross 
visualization near carlna or involvement of 2 lobes on 
chest x-ray. 
1 = Asymptomatic and Peripheral 
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(36): COMPOSITE STAGE 
This is a combination of Functional Severity Stage and Toponymic Stage 
to form 5 strata as follows: 
Toponymic 
Stage 
Functional Severity Stage 
I II III IV 
As3nnptomatic 
& Peripheral (1) 
A A C D 
S3rmptomatic 
or Central 
(2) A B C D 
Vicinal (3) B B C D 
Isothoracic (4) C C C D 
Intrathoracic (5) C C D D 
CNS, Surface, 
Bone 
(6) C C D E 
Liver/Other (7) D D D E 
Code Composite Stage 
1 = A 
2 = B 
3 = C 
4 = D 
5 = E 
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